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ABSTRACT 
 
Monitoring patient health in low and middle-income country HIV care programmes is 
challenging, as, without evidence, measurement tools derived from high-income 
country studies have been adapted and paper-based monitoring systems quickly 
developed.  An accurate understanding of the population in care may be 
compromised.  This thesis examines aspects of HIV care: access to Cotrimoxazole 
preventive therapy (CPT), prevalence of common mental disorders (CMD), and tools 
used to measure outcomes on antiretroviral therapy (ART).    
 
CPT access is frequently cited as being as low as 4% with few studies estimating 
long-term access.  Estimated prevalence of CMD varies widely as little 
standardisation in measurement tools exists.  And, while international ART 
programme monitoring recommendations exist, no study has compared the 
concordance, or otherwise, between information collected in different countries.   
 
The first study in this thesis, in Ugandan and Tanzanian patients, estimates time 
from HIV diagnosis to CPT initiation, time spent on CPT and associated factors.  
These estimates are compared to reported data.  CPT coverage and time on CPT 
were poor.  The absence of unique patient identifiers means monitoring data cannot 
distinguish patients who were diagnosed and initiate CPT in different reporting 
periods.  Furthermore, no long-term data are officially reported.     
 
The second study estimates CMD prevalence and associated factors among HIV-
positive Ugandans, and validates measurement tools for this.  Prevalence was 
around 10% but no routinely-collected data identified at-risk patients.  
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Measurement tool validity was poor, and their use substantially overestimates 
prevalence.  
 
The third study compares ART programme monitoring systems in Malawi, Uganda, 
Ukraine and Tanzania.  There was little concordance with international 
recommendations, and discordance in additional data-items and paediatric age-
groupings.  This signalled a lack of understanding of how best to monitor the health 
of treated populations.   
 
Finally, a fourth study is proposed with the aim of assessing the validity and 
predictive value of existing programmatic monitoring systems. 
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Chapter 1 Introduction 
 
This chapter presents an overview of my thesis describing the rationale, aim and 
objectives and context of my work.  In more detail I present a background to this 
thesis and I provide a summary of the work I undertook.   
1.1    Overview 
The Human Immunodeficiency Virus (HIV) is the cause of one of the most 
destructive disease pandemics in recorded history having killed over 25 million 
people in less than 30 years.  Globally, an estimated 33 million people were living 
with HIV at the end of 2008 when I embarked upon the work included in this thesis 
[4].  The greatest burden of HIV is experienced in low and middle-income countries 
(LMIC), particularly in sub-Saharan Africa, which is home to more than two-thirds of 
all people living with HIV worldwide [4].   
 
As HIV treatment becomes more accessible in LMIC and patient life-expectancy is 
increased, the number of patients requiring long-term management in care and 
treatment programmes increases exponentially.  Having accurate epidemiological 
data on patients accessing HIV care and treatment programmes in LMIC is crucial to 
monitoring and controlling HIV.  Furthermore, if reported data lack validity, their use 
to inform patient and programme management is limited.  However, in LMIC, in the 
rush to keep pace with expanding access to HIV care, in the absence of scientific 
evidence, many measurement tools have been translated from versions developed 
based on high-income country studies and monitoring systems have been quickly 
developed which rely, for the most part, on paper-based records.   Generating 
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accurate HIV-related data from resource-limited care programmes is challenging.   
Our resultant understanding of the treatment and health of populations in HIV care 
in LMIC may be compromised.   
 
The overarching theme of this thesis is to examine how the treatment and health 
outcomes of people accessing HIV care are being measured in Low and Middle 
Income Countries (LMIC), and to provide recommendations for evaluating such 
measurements.  Chapter 2 contributes to this theme by reviewing published 
literature primarily to identify which measures are used, and at which common 
time-points, to report on the health of populations in care, and to summarise 
retention and attrition in care, and immunological and virological response to 
therapy.  Chapters 3 - 5 focus on two specific aspects of care: use of Cotrimoxazole 
Preventive Therapy (CPT) and screening for Common Mental Disorders (CMD). 
Access and retention on CPT, an intervention identified by the WHO as a key 
element of HIV care, by individuals newly diagnosed with HIV in Uganda and 
Tanzania is assessed, and compared to data reported in monitoring and evaluation 
reports.  The prevalence and risk factors of CMD of patients attending HIV clinics in 
Uganda, an area identified by the WHO as under-researched, is estimated and 
simple screening tools, which are often used to measure and report prevalence of 
CMD among HIV-infected populations, are validated.  Chapter 6 compares 
monitoring indicators used to assess the treatment and health outcomes of people 
accessing ART programmes collected by the Ministries of Health in four LMIC and 
discusses epidemiological challenges associated with the use of such indicators to 
measure the health of populations in care.  Chapter 7 highlights the lack of evidence 
for current monitoring indicators used to assess the treatment and health outcomes 
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of people accessing HIV care and proposes a study to validate such indicators 
against longer-term outcomes.   
 
The aim of my thesis is to contribute to our understanding of key aspects of the 
treatment and health of patients accessing HIV-care programmes in LMIC, to 
evaluate the ways in which this is measured, and to identify ways in which the 
health of populations in HIV care can be better monitored.  The objectives are: 
 
i) to review the health of the adult HIV-treated population in LMIC in 
published literature based on the most commonly reported outcome 
measures used to assess the health of treated populations, 
ii) to examine two specific aspects of HIV care: 
a. use of Cotrimoxazole Preventive Therapy (CPT) as prophylaxis 
against opportunistic infections in Uganda and Tanzania, and 
compare clinic data with reported monitoring data, 
b. the burden of, and risk factors for, mental health disorders 
among patients accessing HIV care in Uganda, and to validate 
simple tools for their diagnosis,  
iii) to compare tools and indicators used to monitor the health of 
populations on HIV treatment in Malawi, Tanzania, Uganda and 
Ukraine, to discuss challenges arising from monitoring the health of 
treated populations in the current way, and 
iv) to design a study to evaluate the validity and predictive value of 
indicators used to monitor outcomes in HIV treatment and care 
programmes in LMIC. 
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1.2 Background 
 
1.2.1 HIV and its pathogenesis  
Acquired Immune Deficiency Syndrome, and its causative agent, HIV, were 
relatively recently discovered.  In 1981, cases of an aggressive form of the usually 
benign  skin  cancer,  Kaposi’s  Sarcoma  (KS)  and  Pneumocystis Carinii Pneumonia 
/pneumocystis jeroveci (henceforth referred in this thesis as PCP) were documented 
in the United States [5, 6].   Around the same time in Zambia and the Democratic 
Republic of Congo (DRC, Zaire at the time), cases were emerging of aggressive KS 
which responded poorly to treatment, and in Uganda, cases of a new fatal disease 
called locally ‘Slim’,  marked  by  severe  diarrhoea  and  weight  loss, were being 
documented [7-9].  By 1982, an apparently common immunologic deficit, linked to 
an alteration in the ratio of helper T lymphocyte cells to suppressor T cells, had 
been reported in gay men, injecting drug users, heterosexuals and haemophiliacs in 
high and low-income countries [10-12].  The name Acquired Immune Deficiency 
Syndrome (AIDS) was proposed [13, 14].  In 1983, researchers at the Institute 
Pasteur, France isolated a novel retrovirus, similar to the human T-cell leukemia 
virus (HTLV) and apparently belonging to a family of T-lymphotropic retroviruses 
[15, 16].   One year later, researchers at the National Cancer Institute named an 
association between a further member of the HTLV family, HTLV-III, and AIDS [17].   
At the time, Slim disease in Africa was found to be associated with HTLV-III 
infection and the symptoms were known to be similar to AIDS symptoms seen in 
the neighbouring DRC [9].   In 1986, the International Committee on the Taxonomy 
of viruses proposed to name the commonly seen virus the Human 
Immunodeficiency Virus (HIV) [18]. 
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HIV causes systemic disease.  HIV infects the cells in the body normally responsible 
for mediating immunity.  The HIV virus breaks down the T cells of the white blood 
cells that bear the CD4 receptor (CD4+).  As the amount of virus in the host 
increases, the level of healthy CD4 T-cells,  the  body’s  natural  defence  against  
disease and infection, is depleted.  This loss of cell-mediated immunity increases the 
infected  individual’s  vulnerability  to  life-threatening illness [19].  In the absence of 
treatment, life expectancy with HIV is severely reduced.  Untreated, it is estimated 
that the median survival time after HIV infection for adults in LMIC is 11 years [20-
22].  For untreated infants in LMIC, disease progression is particularly rapid:  the 
risk of dying in the first two to six months of life is particularly high and one third of 
HIV-infected infants are estimated to die before their first birthday with 30% - 50% 
dying before the age of two [23-26].    For untreated HIV-infected children in Africa, 
median life expectancy is two years and most are estimated to die before their fifth 
birthday [27, 28].   
 
HIV-related immune suppression increases the opportunity for microbes and 
pathogens in the environment to find a host, resulting in so-called  ‘opportunistic  
infections’  (OI) and malignancies developing in HIV-positive individuals.  HIV-related 
OI have multiple patterns through which they affect the immune system including 
bacterial (e.g. Mycobacterium tuberculosis), protozoal (e.g. PCP), viral (e.g. 
cytomegalovirus), and fungal (e.g. cryptococcosis), together with HIV-related 
malignancies (e.g. KS, non-Hodgkin’s  lymphoma) [29] [30] [31].  Potentially 
preventable OI are the cause of more than half of all HIV-related infections and 
deaths in sub-Saharan Africa [32].  In adults in LMIC, tuberculosis (TB) is the most 
common OI and is among the leading causes of HIV-related mortality [33].  In 
2012, the estimated global incidence rate ratio of TB disease for an HIV-infected 
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person was 29.6 (interval 27.1 – 32.1) greater than for a non-HIV-infected person 
[34].  .  After TB, other bacterial pathogens account for considerable amounts of 
HIV-related disease in Africa [31].  In adults, preventing and treating bacterial-
related OI is vital to improving survival.  For HIV-infected children in Africa, lung 
infections (e.g. pneumonia) and blood infections (e.g. septicaemia) caused by 
bacteria (e.g. Pneumococcus, Haemophilus influenzae, Staphylococcus aureus) are 
the most common OI leading to HIV-related mortality [35].  In early infancy, PCP is 
the most common OI and is highly associated with mortality [36] [37].   Preventing 
PCP in infants could eliminate one third to one half of all HIV-related deaths in 
African infants [38].   
 
Further clinical features of HIV include depression, anxiety and issues of quality of 
life which arise as individuals adjust to being diagnosed with a chronic life-
threatening illness [39].  As early as 1983, soon after HIV had been identified, 
observations were reported among individuals diagnosed with AIDS of mental 
disorders including depression, a perception of isolation and anxiety about 
transmitting HIV to intimate contacts [40].  For individuals living with HIV, 
consequences of untreated mental disorders have been reported to include impaired 
quality of life, increased rates of HIV transmission, increased need and use of health 
services, poor adherence to treatment regimens, weakened immune function, and 
faster disease progression and mortality [41-53].  Some mental disorders are 
recognised as indicating late stage 3 or stage 4 HIV disease (new onset psychosis 
and mania) and signal the need to start anti HIV medication even if other clinical 
features are above the threshold for treatment initiation [54].  Identifying and 
addressing the needs of patients with mental disorders at an early stage is thus 
important. 
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1.2.2 The growing burden of HIV in low and middle income countries  
By 2008, HIV had become a pandemic and an important cause of global mortality.   
An estimated 33.2 (30.6 – 36.1) million adults and children were living with HIV, 
and in 2007 alone, 2.7 (2.2 - 3.2) million people were newly infected and an 
estimated 2.0 (1.8 -2.3) million HIV-infected persons died [4].  Global adult (age 15 
- 49 years) prevalence in 2007 was estimated at 0.8 (0.7 - 0.9)%.  However, HIV 
disproportionately affects individuals in LMIC.  In 2007, 67% of all people and 90% 
of the estimated 2.0 (1.9 – 2.3) million children living with HIV lived in sub-Saharan 
Africa.  Adult prevalence in sub-Saharan Africa was estimated to be 5 (4.6  - 5.4)% 
[4].  The continent accounted for an estimated 75% (1.5 million) of all AIDS deaths.  
Table 1.1 shows the global burden of HIV disease by WHO-defined geographical 
region as estimated at the end of 2007, by descending order of adult prevalence [4, 
20].  Malawi, Tanzania and Uganda have an estimated adult prevalence above the 
average of sub-Saharan Africa (nearly 12%, >6% and >5%, respectively) and are 
classified as LMIC with generalised HIV epidemics [4] [20].  In Eastern Europe and 
Central Asia, 1.5 million persons were living with HIV in 2007, 90% of whom were 
living in the Russian Federation (69%) or the Ukraine (29%).  In the Ukraine, adult 
prevalence is 1.6%, double the global adult prevalence of HIV [20].   Data from 
Malawi, Uganda, the Ukraine and Tanzania form the basis of the work in my thesis.  
They provide examples of countries with limited resources facing the challenge of 
responding to a high burden of HIV.   
 
1.2.3 HIV care and healthcare systems in low and middle income 
countries 
The introduction of potent anti-HIV treatment, also known as Highly Active 
Antiretroviral Therapy (HAART), has led to a greatly reduced rate of HIV disease  
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Table 1.1 Regional HIV burden, 2007: number living with HIV, adult prevalence 
(15 - 49 years), and number of AIDS deaths (in descending order of prevalence) 
Region Adults and children 
living with HIV in 
(1000s) (range) 
Adult  (15 - 49 
years) 
prevalence %  
AIDS deaths in 
adults and children 
in (1000s) (range) 
Sub-Saharan Africa 22,000 
(20,500– 23,600) 
5.0 
(4.6 - 5.4) 
1,500 
(1,300 – 1,700) 
Malawi 930  
(860-1,000) 
11.9  
(11.0 - 12.9) 
68  
(59– 77) 
Tanzania 1,400  
(1,300– 1,500) 
6.2  
(5.8 - 6.6) 
96  
(86– 110) 
Uganda 940  
(870-1,000) 
5.4  
(5.0 - 6.1) 
77  
(68– 89) 
Ukraine 440  
(340– 540) 
1.6  
(1.2 - 2.0) 
19  
(14– 25) 
Caribbean 230 
(210– 270) 
1.1 
(1.0 – 1.2) 
14 
(11 – 16) 
Eastern Europe & 
central Asia 
1,500 
(1,100 – 1,900) 
0.8 
(0.6% - 1.1) 
58 
(41– 88) 
North America 1,200 
(760– 2,000) 
0.6  
(0.4 – 1.0) 
23 
(9.1 -55) 
Latin America 1,700 
(1,500– 2,100) 
0.5 
(0.4 – 0.6) 
63 
(49– 98) 
Oceania 74 
(66– 93) 
0.4 
(0.3 – 0.5) 
1 
(<1– 1.4) 
South & South East 
Asia 
4,200 
(3,500-5,300) 
0.3 
(0.2 – 0.4) 
340 
(230- 450) 
Western & central 
Europe 
730 
(580– 1,000) 
0.3 
(0.2 – 0.4) 
8 
(4.8 – 17) 
North Africa & middle 
east 
380 
(280– 510) 
0.3 
(0.2 – 0.4) 
27 
(20– 35) 
East Asia 740 
(480– 1,100) 
0.1  
(<0.1 – 0.2) 
40 
(24– 63) 
Global Total 33,000 
(30,000– 36,000) 
0.8 
(0.7 - 0.9) 
2,000 
(1,800– 2,300) 
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progression, changes in the clinical course of HIV infection and increases in life 
expectancy [55-57].  From this point in my thesis, I use the term Antiretroviral  
Therapy (ART) when referring to current HIV treatment.  For individuals accessing 
care, HIV can be managed as a chronic disease requiring life-long health-status 
monitoring and appropriate disease management.   
 
The scale-up of providing access to ART in LMIC has been unprecedented.  While, 
globally, sub-Saharan Africa has the highest HIV burden, in 2004 it was estimated 
that in the sub-continent, just over 1% of people in need had access to life-saving 
ART [4].  Since then, significant political and financial commitments have been 
made to make life-saving ART accessible to those most affected by HIV.  These 
commitments resulted in over four million people accessing ART in 2007, a ten-fold 
increase over a 5-year period, with access growing by 42% in 2007 alone [20]. 
Within sub-Saharan Africa, during the four years from 2004 to 2008, ART coverage 
increased from an estimated 1% to 44% [4].   Multinational HIV treatment 
programmes have been hailed among the greatest public health successes of the 
twenty-first century [58].   
 
The pathway to accessing HIV care in many LMIC is similar (Figure 1.1).  Patients 
receive an HIV test at, for example, an HIV specialist care centre, a TB or antenatal 
care clinic or by health-care teams visiting communities throughout a country.  If 
the test is positive, the patient is assessed to determine the stage of disease 
progression, on which the decision is made on whether they should be commenced 
on ART or they enter pre-ART care.  This decision is based on an immunological or 
clinical assessment, depending on resources available.  All HIV-infected patients are 
invited to attend follow-up appointments.   
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Fiure   
1. HIV diagnosis & referral 
i. HIV Counselling and Testing within a health care setting or in the community 
 
ii. referral to clinical team to assess disease stage 
2. Staging and determining treatment plan  
i. disease staged based on CD4 count and/or clinical symptoms 
 
ii. ART eligibility determined 
 
iii. registration into HIV care as either pre-ART or ART-eligible patient (name added to 
the  clinic’s  pre-ART HIV care register until ART commenced) 
 
Pre-ART care 
Regular outpatient visits (usually 2-monthly 
but sometimes monthly) to 
 
i. monitor disease progression based on 
clinical symptoms, and (6 monthly, if 
available) based on immunological signs  
 
ii. prescribe prophylaxis against OI 
(Cotrimoxazole) and treatment of OI  
 
iii. if available, provide other services (e.g. 
nutritional supplements, prophylaxis against 
tuberculosis, mental health services) 
 
 
 
ART care 
Regular outpatient visits (monthly for first 6 
months, then generally 2-monthly) to 
 
i. as per all pre-ART care, and 
 
ii. initiate patients on ART, if no adverse 
reactions and good adherence  to CPT 
demonstrated  
 
iii. monitor ART adherence and outcomes on 
ART and, if not contraindicated, routinely 
prescribe ART  
 
 
 
* In some settings, testing, staging and follow-up appointments are conducted in the 
same clinic.  In others, HIV-positive patients are referred to a specialised ART clinic 
for care 
 
 
 
Figure 1.1 HIV diagnosis, treatment and care pathway in low and middle-income countries 
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If a patient is not yet eligible for ART, at the follow-up appointments they will 
receive prophylaxis against OI and disease monitoring to assess when treatment 
initiation becomes necessary.  Prophylaxis against OI is given as a fixed dose 
combination of the generic drugs Trimethoprim and Sulphamethoxazole (TMP-SMZ).   
TMP-SMZ is produced under brand names including Bactrim, Bactrim DS, Bethaprim, 
Cotrimoxazole, Cotrim, Cotrim DS, Septra, Septra DS and Sulfatrim and is available 
in high quality generics.  I refer throughout this thesis to TMP-SMZ as Cotrimoxazole 
(CTX).  Given as a daily preventive therapy, it is referred to as Cotrimoxazole 
Preventive Therapy, Cotrimoxazole Preventative Treatment or Cotrimoxazole 
Prophylaxis.  In my thesis, I use the term Cotrimoxazole Preventive Therapy (CPT).   
Providing prophylaxis against OI is vital for patients who are not yet eligible to 
initiate ART and the WHO recommends that it should be provided as key element of 
the chronic care package [59].  Various other services form part of the HIV-chronic 
care package.   These may include, if available, advice on how to reduce the 
onward transmission of HIV, the provision of Isoniazid Preventive Therapy as 
prophylaxis against tuberculosis, the treatment of tuberculosis and other OI, 
nutritional support, and mental health services.   
 
ART-eligible patients are initiated on ART and their response to ART is monitored 
continuously throughout their time in care.  In 2008, the recommended first-line 
regimen combinations for adults were: Stavudine (d4T), Lamivudine (3TC) and 
Nevirapine  (NVP)  (in  one  tablet  called  “Triomune”)  in  Malawi;;  Zidovudine  (known  as  
AZT or ZDV), 3TC and Efavirenz (EFV) in Tanzania; ZDV and 3TC and either NVP or 
EFV in Uganda; and ZDV, 3TC and either EFV/NVP or Nelfinavir in the Ukraine [60-
63].  For patients receiving and responding to ART, although the rates of disease 
 35 
caused by major opportunistic pathogens decrease enormously, preventing OI is still 
important [64].   Therefore, in addition to receiving ART, patients receive the same  
care as that provided to pre-ART patients, including the provision of CPT.   
 
At routine HIV care appointments, disease monitoring for patients accessing and not 
accessing ART includes assessing adherence to CPT and to ART regimens (if 
appropriate), monitoring the incidence of OI, the presence of drug toxicities, 
changes in weight and other clinical symptoms, as determined by the national MoH. 
 
In LMIC, HIV care is coordinated by the national MoH, though care is often provided 
through a combination of the national health services, non-governmental 
organisations (NGOs) and private sector foundations.  Because health centres vary 
in size and resources, there are often patient transfers between health centres, 
depending on individual requirements.  Small clinics, health posts and outreach 
teams provide general care to patients with HIV, but often there are no specialist 
doctors in the care teams.  In some small health clinics, HIV testing is provided but 
follow-up care has to be accessed in a health centre with more resources.  More 
specialised care can be provided within peri-urban health centres and district 
hospitals, which are more likely to have specialist doctors.  Regional and national 
hospitals can provide highly specialised care.   Cases which cannot be managed in 
the original health centre will be referred up to the next appropriate level of care.  
Patients may also elect to transfer between health centres for logistical reasons 
(e.g. walking time to clinic) or reasons of stigma.  
 
Our understanding of the health of populations accessing ART in LMIC is based 
largely on chronic disease monitoring systems that have been quickly adapted to 
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match the pace of expanding ART roll-out.   Staff in health care centres aggregate 
data on individual patients in their care into summary reports for donors and the 
MoH.  However, the accuracy of these monitoring systems, and in turn, our 
knowledge about the health of patient populations accessing HIV and ART care in 
LMIC, may be questioned. 
 
1.3 Overview of chapters 
My thesis evaluates key aspects of the treatment and health of HIV-infected 
patients accessing HIV care in Malawi, Uganda, the Ukraine and Tanzania and 
evaluates methods used to monitor this.   
 
In Chapter 2, I present the results of a literature review on the health of adult 
patients treated within ART programmes in LMIC.  The primary objective of the 
review was to synthesis evidence from cohort reports relating to i) survival and 
retention in care, ii) virological, iii) immunological and iv) other clinical outcomes of 
adult patients in HIV care.  A secondary objective was to compare the outcome 
measures used to assess the health of treated populations. 
 
In Chapters 3 and 4, I present a study I undertook to assess access to 
Cotrimoxazole Preventive Therapy (CPT) in Uganda and Tanzania.  The aim of the 
study was to examine the extent to which the provision of CPT was being 
implemented in health centres on the ground.  I estimated the probability of 
initiating CPT after HIV diagnosis among newly diagnosed patients or birth to an 
HIV-positive mother, examined time from HIV diagnosis/birth to CPT initiation and 
differences by age, sex and diagnostic clinic type.  I also examined access to CPT 
for patients during their time in care and compared clinic data with reported CPT 
monitoring data.   
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In Chapter 5, I present a cross-sectional study I undertook to assess the burden of  
mental health disorders among patients in HIV clinics in Uganda, to identify whether 
routinely collected HIV-care data can identify at-risk patients, and to assess the 
validity of simple assessment tools which can be used by HIV health care workers to 
screen patients in care for mental health disorders.  
 
In Chapter 6, I present a cross-sectional study I undertook to compare the degree 
to which internationally-recommended tools and indicators used to assess the health 
of populations in ART care have been incorporated into national monitoring systems 
in Malawi, Tanzania, Uganda and the Ukraine.  The chapter also reviews challenges 
associated with using the current monitoring systems to assess the health of 
populations treated within ART programmes in LMIC.  
 
In Chapter 7, I present the main recommendation from my thesis, that further work 
is necessary to determine how the health of populations treated within ART 
programmes can be better monitored.  I describe the aim and design of a study to 
evaluate the ability of currently-used ART programme monitoring indicators to 
represent the health of the treated population by assessing the validity and 
predictive value of population-level monitoring indicators. 
 
Chapter 8 discusses the contribution of this thesis to the wider context of the health 
of patients treated within HIV treatment and care programmes in LMIC.  This final 
chapter outlines my recommendations and suggests further work that is needed to 
improve our understanding of the health of patients accessing HIV care in LMIC.
Figure 1.21.2  HIV diagnosis, treatment and care pathway in LMIC *, based on [1] 
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    Literature Review Chapter 2
 
2.1 Background 
Programme managers and health professionals, entrusted with the care of the HIV-
affected population, and donors accountable for their funds, have a responsibility to 
monitor and understand the health of the patient population within HIV 
programmes.  HIV care can be viewed along a continuum, starting with prevention, 
HIV counselling, testing and diagnosis, disease staging/ART eligibility assessments, 
pre-ART care and ART care.  Losses from HIV care along the continuum have been 
documented in two systematic reviews among adults and one among children [65] 
[66, 67].  This chapter focuses on outcomes of patients in ART care.  With the 
advent of ART and the extensions to life-expectancy afforded by it, it has become 
possible to consider HIV a chronic disease [68].    Good chronic disease 
management is based on reliable information systems and a longitudinal record 
tracking a patient’s  clinically-relevant data and health outcomes [69] [53] [70].  
Aggregated data from such systems can be used to monitor the welfare of groups 
of patients in care programmes and to measure and benchmark the performance of 
a programme [71] [72].   
 
There is a growing body of literature on the welfare of ART-treated patients in 
LMIC.  Systematic reviews to date have summarised information published before 
the end of 2009 relating to retention in ART programmes, immunological and 
virological outcomes on ART and rates of IRIS among patients in care in sub-
Saharan Africa [73-77].  However, little is known about the health of patients 
treated within other LMIC geographical regions.   Furthermore, most studies 
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included in reviews to date have presented information on short-term outcomes of 
ART programmes with the median duration of time on ART in one review being 10 
months [75].   As HIV is now managed as a chronic condition and ART programmes 
expand globally, there is a need to understand the longer-term health of patients 
treated within ART programmes in LMIC.   Moreover, as tracking the health status 
of patients in chronic care programmes over the long-term can be challenging, with 
few long-term outcome data reported, it would be useful to know if any early 
reported outcomes can predict later retention in ART programmes.    
 
The aim of this chapter, therefore, is to review literature relating to the health of 
the adult population treated within ART programmes in LMIC and to explore 
whether any outcome reported at an intermediate time-point is related to later 
reported retention in care. 
2.2 Methods 
2.2.1 Search strategy 
My search strategy involved multiple stages.  Firstly, I used broad search criteria to 
identify studies published since the advent of ART in 1996 which reported on the 
outcome of patients treated within ART programmes in LMIC.   I searched Medline 
through PubMed.  The search was last updated on 22nd July 2013.  I used the 
following search terms (MeSH and Text) resulting in the respective number of 
references: 
i) HIV or AIDS or HIV/AIDS (290,763 references) 
ii) combined with antiretroviral therapy (15,027 references) 
iii) combined with LMIC regional names: developing countries or low-income  
countries or Africa, Asia, Pacific Islands, Europe Eastern, Russia, Latin 
America, Central America, Caribbean Region (1,914 references) 
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iv) were English language and reported the outcomes of humans (1,823 
references) 
Secondly, having read 1,823 titles, I excluded titles that described the basic science 
of ART or referred to the use of ART as a method for the prevention of HIV 
transmission (Figure 2.1).  Thirdly, therefore, I reviewed 874 abstracts and excluded 
studies which: did not report information on outcomes of ART, considered 
adherence an outcome of ART, only reported on resistance mutations, only reported 
on paediatric cohorts, or described outcomes for participants who were HIV-
exposed or treated within PMTCT programmes.  After these exclusions, 180 articles 
remained.  Fourthly, as not all abstracts contained adequate information on study 
design or cohort inclusion criteria, I read the full manuscripts of these 180 articles 
and excluded studies that did not meet all of the following criteria: 
 
a. prospective or retrospective observational cohorts (not randomised-
control-trials, case-controlled-studies, cross-sectional, modelling 
studies or economic evaluations) 
b. cohort patients were adults 
c. patients were ART naïve at entry into the cohort 
d. outcomes of more than 100 patients on ART were reported 
e. cohort was followed-up for at least 6 months after ART initiation 
f. cohort was not set up to study outcomes of a specifically co-infected 
population  
g. cohort was derived at ART initiation and was not restricted to 
individuals who returned for follow-up visits  
  
41 
 
 
  
1,823 titles reviewed 
873 abstracts reviewed 
180 full articles read 
83 studies included in final review 
Excluded 949 
- described basic science of ART 
- described ART as prevention 
Excluded 694 
- with no information on outcomes 
- considered adherence an outcome 
 - reported on resistance mutations 
- were paediatric cohorts 
- were among HIV-exposed infants or 
patients only in PMCTC programmes 
- full article not available 
 
 
Excluded 97 
- RCTs, case-controlled, cross-
sectional, modelling or economic 
studies 
- cohort was ART experienced 
- n=<100 participants 
- cohort was followed for < 6 months 
- cohort was among specific co-
infected population (e.g. HIV and 
hepatitis B positive) 
- cohort was restricted to patients who 
returned for follow-up 
- previously reviewed studies 
- published by ART-LINC collaboration 
Figure 2.1 Flowchart depicting articles included in final literature review 
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I was unable to access the journals and retrieve the full manuscripts of three 
abstracts and I therefore did not include these data in this review. 
In addition to the above inclusion and exclusion criteria, I excluded articles 
published by the Antiretroviral Therapy in Low Income Countries (ART-LINC) 
collaboration.  ART-LINC was an international collaborative network of ART cohorts, 
some of whom participate in regional International Epidemiological Databases to 
Evaluate AIDS (IeDEA), TREAT Asia or CCASANet (Caribbean, Central and South 
America) collaborations.  Some of these cohorts may have reported information 
independently and may already be included in my review.  To avoid duplication, 
therefore, findings from ART-LINC cohorts, which met the above criteria, are 
summarised separately.   
 
Finally, I excluded individual studies which had been reviewed in previous 
systematic reviews or meta-analyses, unless the study provided additional 
information not already reviewed (e.g. retention reviewed but immunological 
response not previously reviewed).  I discuss the outcomes of my current review in 
the context of these reviews.   
 
In addition to the above search strategy, I reviewed the latest global report 
published by UNAIDS which reports on the outcomes of country cohorts treated 
worldwide.  
2.2.2 Data-extraction and summarising 
I extracted and summarised information from the included articles relating to health 
status at ART-initiation and throughout follow-up using separate tables created in 
Microsoft Excel.  I summarise the health status of patients initiating ART and 
throughout time in care using the most frequently reported outcomes.  I summarise 
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the proportion of the treated patient cohorts retained in care as this is the closest 
proxy to survival on ART reported in most LMIC ART programmes.  If outcomes 
were reported on the same cohort at different follow-up times in different 
manuscripts, data were combined.   I do not summarise outcomes for sub-groups  
(e.g. sex, age groups, CD4 counts).  When exploring the links between outcomes 
reported at intermediate time-points and retention in care at later dates, I did not 
include attrition outcomes (reasons for losses from care) as they directly influence 
retention.  
2.3 Results 
Eighty-three studies were included in this review (Table 2.1).  The studies were 
from the following regions and countries: 
Africa (61) : Botswana, Burkina Faso, Côte  d’Ivoire,  Democratic  Republic  of  
Congo, Ethiopia,  Lesotho, Malawi, Mozambique, Nigeria, Rwanda, Senegal, 
South Africa, Tanzania, Uganda, Zambia and Zimbabwe 
Asia (11): Burma, Cambodia, China, India, Indonesia, Lao 
Eastern and Central Europe (3): Poland, Serbia 
Latin America and Caribbean (3): Barbados, Jamaica, Curacao 
Multi-country combined cohorts (5): including 2 from sub-Saharan Africa, 1 
from Latin America and the Caribbean, 1 from Cambodia, Thailand, Kenya, 
Malawi and Cameroon, and 1 from 2 countries in Asia, 2 in Africa and Brazil.   
 
The median number of patients included per cohort was 1,672 (range 100 – 
829,640).   Data were available from 5 systematic reviews and 16 studies from the 
ART-LINC collaboration [73-94].   Data on outcomes on ART from the latest UNAIDS 
report were available on 92 cohorts in LMIC [95].  UNAIDS data were provided for 
the following number of regional country cohorts: the Caribbean (10), Latin America 
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Table 2.1 Cohort characteristics at ART initiation, length of cohort follow-up, median length of time on ART, and retention in care (studies 
are ordered by publication date, with the most recent data first) 
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Uganda  [96] 
2004-
2011 
 
peri-urban 
hospital 6970 66% 36  - 
82% 
<250  -   - 36 86% 36 
Mozambique  
[97] 
2004-
2007 
 
 
30 clinics 2596 62% 34 153  - 63%   - 18  -    - 
Lao [98] 
2003-
2009 
 
provincial 
hospital 913 44% 32 49 86% 87%   -  22 73% 24 
Zimbabwe [99] 
2005-
2008 
 
25 rural clinics 898 71%   - 119 66%  - 36 15 81% 36 
Malawi [100] 2010 
 
2 district 
hospitals 370 58%  -  -  -   - 6 6 76% 6 
South Africa 
[101] 
2006-
2007 
 
 
2 urban clinics 498 75% 35 106   69% 6 5 95% 6 
Uganda [102] 
2005-
2007 
 
ART 
programme in 
mental 773 64% 35 118  -  - 15   - 
 
65%, 47% 
(mentally 
well, ill) 12 
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hospital 
Nigeria [103] 2007 
 
10 hospitals 4785 59% 34 152  - 45% 36 28 57% 36 
Democratic 
Republic of 
Congo [104] 
2005-
2009 
 
6 ambulatory 
treatment 
centres 1450 66% 40 150 24% 67%   19 57% 36 
South Africa 
[105] 
2004-
2009 
 
urban clinic 5996  -  -   -  -  -   - 28  -    - 
Zambia [106, 
107] 
2006-
2007 
 
urban clinic 142 61% 32 34   -  -  3 3 59% 3 
Ethiopia [108] 
2005-
2009 
 
urban hospital 4210 59% 35 113 87% 75% 60 31 76% 60 
Burma [109] 
2003-
2007 
 
10 country-
wide clinics 5963 61% 33 71 85% 94% 85 36 76% 60 
Cambodia 
[110] 
2003-
2010 
 
urban hospital 2581 52% 35 87   - 80%   -   -  -   - 
Tanzania [111] 
2005-
2010 
 
101 clinics with 
electronic data 88875 66% (36-37)   -  -  -  54 10 
56% (m) 
60% (f) 60 
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Tanzania [112] 
2007-
2010 
 
 
2 urban 
hospitals 486   -  -   -  100% 
5% 
stage IV 11   - 
63% (ART) 
55%(&TB 
treatment) 12  
South Africa 
[113] 
2002-
2009 
 
peri-urban 
clinics 818 87%  (20-28)  116    -   -   - 31   -   -   
Tanzania[114] 
2004-
2009 
 
 
urban clinics 18965 67% 36 124 55% 85%   -   -  -     - 
Burkina Faso 
[115] 
2003-
2009 
 
24 country-
wide clinics 5608 70% 35 124 83% 82%   - 23 77% 24 
Rwanda [116]   - 
 
urban 
women’s  clinic 490   - 36 185   
most 
stage IV 15  -  79% 12 
Uganda [117] 
2004-
2010 
 
11 regional & 
35 rural clinics 22315 69%  -   - 
84% 
<250 42%   -  -   -   -  
South Africa 
[118] 
2004-
2007 
 
urban hospital 9040 66%  -   81   -  -    -  19 71% 24 
South Africa 
[119] 
2003-
2008 
 
279 
community & 15060 36% 38 127 -   61%   - 22 40% 24 
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workplace-
clinics 
China [120] 2006 
 
multiple clinics 
in 31 provinces 3457 41% 38 109 78%  -  24 21 84% 24 
Tanzania [121] 
2004-
2009 
 
urban clinic 18271 65% 36 112 78% 85% 36 12  -    - 
India[122] 
2002-
2004 
 
urban hospitals 
& non-
hospitals 141  -    - 218  -    -  -  15  -    - 
Jamaica[123] 
2004-
2009 
 
urban hospital 165 56% 37 186  -    -  -    -  -    - 
Nigeria [124] -  
 
urban clinic 130 69%  -    -  -    - 12  -   -    - 
Uganda [125] 
2004-
2005 
 
urban clinic 559 69% 38 98 - 88% 36 - 71% 36 
Uganda [126] -  
 
urban clinic 219 70% 36 130 
 - 
49%  -    - 83% 12 
Lesotho [127] 2008 
 
decentralised 
clinics 1124 68% 39  -  
 - 
 -  24 16   -    - 
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Curacao  [128] 
2005-
2008 
 
urban hospital 123 38% 44 141 63% - 12 - 80% 12 
South Africa 
[129] -  
 
multi-site 
workplace 
programme 3270 7% 45 155  _ 45% 12  _  -   _ 
South Africa  
[130] 
2002-
2008 
 
peri-urban 
clinics 3162 67% 34  _ 89% 75% 84 29 63% 60 
Lesotho [131] 
2006-
2010 
 
14 clinics, 1 
hospital 1177 67% 38 212 46%  _ _  17  -   _ 
South Africa 
[132] 
2004-
2008 
 
urban hospital 7536 67% 36  _ 88%  _  _ 21 79% 24 
Uganda [133] 
2004-
2005 
 
urban clinic 559 70% 38 98  _  _ 36 33 74% 36 
South Africa 
[134] 
2004-
2009 
 
peri-urban 
clinic 1154 65% 32 122   - 76% -  17  -    - 
South Africa 
[135] 
2004-
2006 
 
32 clinics 28835 67% 34   -   -   -   - 22 78% 24 
Senegal [136] 
1998-
2002 
 
urban clinic 404 55% 37 128   - 56%   -   - 73% 42 
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Nigeria [137] 
2005-
2006 
 
5 hospitals 5760 59% 35 121 76%   -   - 7  -    - 
South Africa 
[138] 
2004-
2006 
 
urban hospital 1719 82% 38 79   -   -   -   -  -    - 
Uganda [139] 
2003-
2009 
 
urban clinic 5982 66% 37 117   -   -   - 20 69% 24 
Malawi [140] 2005 
 
urban hospital 300 61% 36 157   - 29% 12   - 72% 12 
Indonesia [141] 
1996-
2008 
 
urban hospital 
626   -   - 99   -   -  -  
12 (IDU) 
8 (non IDU) 67% 6 
South Africa 
[142] 
2001-
2006 
 
3 rural clinics 7322 68% 
31 (f), 
36 (m) 43   -   - 60   - 65% 60 
Serbia [143] 
1998-
2007 
 
urban clinic 563 31%   -   - 78%   -   - 72  -    - 
China [144] 
2001-
2007 
 
multiple-clinics 
1 province 512   -   - 123   -  -    - 27 81% 60 
Uganda [145] 
2004-
2007 
 
peri-urban 
clinic 3628 61% 35 95   -   - 45   -  -    - 
China [146] 
2002 - 
2008 
 
multiple clinics 48785 42% 38 118   -   - 60 17 76% 60 
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Côte d'Ivoire 
[147]   - 
 
 
urban hospital 303 75% 35 150 70% 21%   -   - 95% 6 
Rwanda [148] 
2004-
2005 
 
71 clinics 3194 65% 37 141   -   -   -   -   -   - 
South Africa 
[149]   - 
 
multiple clinics 1480 70% 34 97 
73% 
<150 80%   - 25 72% 54 
Latin America 
& Caribbean  
[150] 
1996-
2007 
 
 
7 urban clinics 
5152 35% 37 107 63-85%   -  -   -  86% 12 
sub-Saharan 
Africa   [151] 
2001-
2006 
 
workplace 
programme 249 41% 39 170   - 24% 67 32 89% 48 
Malawi [152] 
2006-
2007 
 
1 hospital & 9 
clinics 4074 
61%-
72%  32   -   - 96%   - 5 83% 12 
South Africa 
[153] 
2004-
2007 
 
 
urban clinic 7512 66% 35 
58(TB) 
94(no TB) 88% 10%   - 14  -   - 
Ethiopia [154] 
2004-
2006 
 
rural hospital 
1002 57% 34 89   -  -   -   -   -    - 
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Botswana [155] 2002 
 
urban hospital 349 59% 35 22   - 90%  -  14 78% 12 
Uganda [156]   
 
peri-urban 
hospital & 
home-based 
care 1625 72% 39 157 68%   -  -  13  -    - 
India [157] 2005 
 
urban hospital 142 36% 38   -  -   -  6   69% 6 
Botswana [158] 2002 
 
32 clinics 633 60% 35 67   - 81%   - 42  -    - 
South Africa 
[159] 
2001-
2006 
 
 
 
3 rural clinics 3970 68% 
31 (f), 
36 (m)   -  -   -  72   -  -     - 
South Africa 
[160] 
2003-
2006 
 
 
rural clinic 609 71% 35 67   -   - 12   - 67% 12 
South Africa 
[80] 
since 
2001 
 
 
10 clinics 2348 71% 33 80   - 91% 24 11  -    - 
Côte d'Ivoire 
[161] 
2004-
2007 
 
 
19 clinics 10211 70% 36 123   - 81%   - 18  -    - 
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Mozambique, 
Tanzania, 
Malawi [162] 
2003-
2005 
 
 
 
12 clinics 3456 60% 37 166  62% 72% 12   -   -   - 
Senegal [163] 
1998-
2002 
 
multiple clinics 
404 55% 37 128   - 56%   - 46  -    - 
Abidjan [164] 
1998-
2003 
 
urban clinic 187 69%   - 174   -   -   - 19 89% 24 
South Africa 
[165] 
2004-
2005 
 
urban hospital 1735 63%   -   -   -   - 48   -  -    - 
Cambodia 
[166] 
2001-
2005 
 
urban hospital 1735 42% 
32 (f), 
35 (m) 20 99%   - 24 13 87% 24 
Zambia [167] 
2004-
2005 
 
18 clinics 16198 61% 35 143   - 73%  -   -   -    - 
Cambodia, 
Thailand, 
Keyna, Malawi, 
Cameroon 
[168] 
2001-
2003 
 
 
 
 
5 multi-site 
programmes 3151 57% 33-35   - 90% 
13% - 
47%   - 7  -    - 
Barbados [169] 
2002-
2003 
 
urban clinic 158 42% 39 74 82%   - 12   - 94% 12 
Côte  d’Ivoire   1996-
 
129 63% 32 125   - 87%   - 26 88% 2 
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[170] 2003 multiple clinics 
South Africa 
[171] 
2005-
2009 
 
 multiple 
clinics  829640   -  -    -  -   -   -  - 76% 51 
Studies 
reviewed 
with no 
aggregated 
baseline or 
retention 
data  
 
          
Poland [172] 
2000 -
2002 
 
10 clinics  -   -   -    -  -   -   -   -   -   -  
India  [173] 
2006-
2007 
 
urban hospital  100  -   -    -  -   -   -   -   -   - 
6 African, 2 
Caribbean 
countries [174] 
2004-
2005 
 
 
 
27 clinics 13391  -   -    -  -   -  12   -  -    - 
Malawi [175] 
2008-
2009 
 
rural hospital 555  -   -    -  -   -    - 6 90% 6 
Zambia [176] 
2007-
2009 
 
multiple urban 10485  -   -    -  -   -    - 8  -    - 
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clinics 
Serbia & 
Montenegro 
[177] 
1998 - 
2005 
 
 
urban clinic 481  -   -    -  -   -    - 72  -    - 
Malawi [178] 2005 
 
- 4347  -   -    -  -   -  12   - 65% 12 
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(15), East Asia (2), South and South East Asia (12), Eastern Europe and Central Asia 
(10), Middle East and North Africa (12) and sub-Saharan Africa (31).  The median 
size of the cohorts was 714 patients (range 5 – 144,854).   
 
Studies reviewed were of heterogeneous study design (including retrospective 
reviews of routinely-collected records, prospective studies and research-specific data 
gathering), size and geographical origin which may influence the ability to compare 
cohort outcomes.  The results from studies whose cohorts form part of existing 
research groups or which were set-up to ask a specific research question may be 
biased towards higher retention rates as the quality of care in such sites may be 
better as a result of additional resources.  Furthermore, key outcomes such as 
deaths, losses to follow-up (LTFU) and transfers-out may have been better captured 
in prospective studies if staff understood the importance of accurately capturing 
these outcomes compared to retrospective data-collection. Conversely, data-
completeness on key outcomes for cohorts with larger number of patients may have 
been less accurate than for smaller cohorts, due to overburdened staff in large 
health centres.  Although I do not show these data, the age-definitions used for 
adults varied between studies, with some cohorts including patients as young as 14 
years  while  others  only  included  adults  aged  ≥18  years.  Adolescents experience 
lower rates of virological suppression and immune recovery and higher rates of 
rebound, therefore, comparing aggregated results from cohorts with varying 
proportions of adolescents must be done with caution [179].   
 
Previous systematic reviews and meta-analyses of the health of the treated adult 
population in LMIC have focused on sub-Saharan Africa [73-76].  This review adds 
to our knowledge by expanding to countries in Latin America, Asia and Eastern 
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Europe.  Nevertheless, the majority (63, 76%) of included studies were based in 
sub-Saharan Africa.  In fact, of the single-country African studies, nearly half (29, 
48%) were based on cohorts in South Africa or Uganda.  This distribution of 
literature somewhat reflects the global HIV disease burden at the time of the 
literature search in 2013, as sub-Saharan Africa continues to have the highest adult 
prevalence of HIV (4.7%, CI 4.4 – 5.0%) compared to Latin America (0.4%, 0.3 – 
0.5%), the Caribbean (1.0%, 0.9 – 1.1%), East Asia (0.1%, 0.1 – 0.1%), South and 
South East Asia (0.4%, 0.2 – 0.4%) or Eastern Europe and Central Asia (0.7% (0.6 
– 0.9%) [95].  If HIV prevalence were an explanation for the dominance of 
literature from Africa, countries with high prevalence should be represented here.  
However, some countries with extremely high prevalence (e.g. Swaziland at 26.5% 
(24.6 – 28.3%), Botswana 23% (21.8 – 24.4%) or Lesotho 23.1% (21.7 – 24.7%)) 
are either poorly represented here, or not represented at all [95].  It is possible that 
researchers from such countries elect not, or do not have resources, to publish in 
international journals, despite information most likely being available in unpublished 
government documents.  However, it is also possible that international journals 
prioritise data from certain geographical regions, resulting in a lack of published 
literature from studies assessing the health of the treated population in areas other 
than sub-Saharan Africa.   
 
In LMIC geographical regions outside of sub-Saharan Africa, the number of patients 
living with HIV and accessing ART programmes continues to grow [95].  Most ART 
programmes, globally, are required by programme funders and MoH to collate data 
and compile reports to monitor the health of patients in their care.  Given the 
availability of these pre-generated data, it is surprising that more ART programmes 
do not publish articles using these data.  There is an obligation to monitor, publish 
57 
 
and understand the outcomes of patients treated in ART programmes throughout 
the world.   
 
2.3.1 Health of patients at ART initiation 
The most commonly reported cohort characteristics were proportion female, median  
age, median CD4 cell count, proportion with CD4 <200 cells/mm³, and proportion in 
WHO stage III or IV or CDC stage C or D (i.e. those with more advanced clinical 
disease).  Less commonly reported characteristics at ART initiation included viral 
load (VL), Body Mass Index (BMI), and proportion with tuberculosis (TB).   
 
Patients initiated ART at a median age of 36 (range 32 – 45) years.  The majority 
(median 65%, range 7 – 87%) of patients were female.  The median weight was 51 
(range 46 – 57) kg (n=7) and the median BMI was 19.9 kg/m² (IQR 19 – 22.3) 
(n=18), higher than the BMI used to classify patients as underweight (18.5kg/m²).  
The majority of patients (median 75%, range 10 - 96%) initiated ART at late stage 
HIV (WHO stage III/IV or CDC stage C/D) with the median CD4 count being 119 
(IQR 95 – 143) cells/mm³.  A median of 80% (range 24 – 100%) of participants 
initiated ART with a CD4 < 200 cells/mm³ and the median viral load was 5.1 (IQR 
4.9 – 5.3) log copies/mL (n=18).  The median proportion with TB was 16% (range 
2 – 54%) (n=15).   
 
This demographic and clinical profile of patients initiating ART in LMIC is similar to 
that described in earlier systematic reviews of ART-treated patients in sub-Saharan 
Africa [75] [76].  This emphasises the need for continued efforts to encourage 
males and older adults into care and to encourage all to seek HIV testing and to 
initiate ART at lower levels of immune suppression. 
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2.3.2 Health of patients over time on ART 
The median length of cohort follow-up was 24 (range 3 – 85) months and the 
median length of time on ART was 19 (range 3 – 72) months.  Such short median 
times on ART before stopping have huge implications for universal access to ART.  
If patients, on average, spend less than two years on ART, consequences for their 
own health (in terms of viral rebound) and for the health of others (in terms of 
onward transmission of HIV when viraemia is not controlled) are vast.   
 
The most commonly reported outcomes were retention in care, attrition from care 
(deaths, losses to follow-up, transfers-out, stopping ART), immunological response, 
virological response, and other important clinical outcomes (TB, Immune 
Reconstitution Inflamatory Syndrome (IRIS), AIDS defining illnesses (ADI) and 
hospitalisations).  Other less commonly reported outcomes were virological failure, 
weight changes, adherence, haemoglobin changes and total lymphocyte (TLC) 
changes.  
2.3.3 Retention in care and losses from ART programmes 
Of the 83 studies included in this review, 47 (57%) reported information on 
retention in care, at between 1 - 72 months of cohort follow-up (Figure 2.2).  The 
majority (33, 70%) of these 47 studies reported retention  in  care  at  ≤ 24 months, 
while few (7  at  36  months,  7  at  ≥ 48months) reported longer-term retention of 
patients in care.  The change in retention in care was greatest early after ART 
initiation. The median proportion retained in care at 6, 12, 24, 36 and ≥ 48 months 
was 81% (range 67 – 95%), 80% (63 – 94%), 77% (40 – 89%), 74% (53 – 89%), 
and 76% (60 – 81%). 
 
For patients treated within ART-LINC programme cohorts, between 4 - 6% never 
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Figure 2.2 Proportion retained in care from time since ART initiation, as reported by 47 studies 
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returned for a single follow-up appointment [84] [82].  Retention at 12 months was 
80% and dropped to 64% by 36 months after ART initiation [84] [82].    For cohorts 
reporting to UNAIDS, the median proportion known to be alive and on ART 12 
months after initiation was 82% (range 33 – 100%) [95].    
 
The wide range in proportions retained in care at each time-point can partly be 
explained by the different geographical origins of the cohorts.   Of the 10 cohorts 
reporting the highest proportion retained in care at 6, 12, 24, 36, and 48 months 
(highest 2 cohorts per time-point), 40% were based in Africa, compared to 90% of 
the 10 cohorts reporting the lowest proportion retained.  No other cohort 
characteristics at ART initiation (cohort size, date of ART initiation, proportion 
female, age, WHO stage, CD4 cell count) appeared to account for the differences in 
proportions retained in care.  This geographical explanation, however, should be 
interpreted with caution as the number of non-African cohorts in this review was 
small.  Yet, this explanation also seems to account for the variation in retention in 
care reported by cohorts reporting to UNAIDS.  UNAIDS reported retention in care 
at 12 months varying by nearly 10% depending on geographical origin of the 
cohort, with cohorts in sub-Saharan African reporting amongst the lowest: 
Caribbean 78%, sub-Saharan Africa 79%, Latin America 82%, Eastern Europe and 
Central Asia 82%, South and South East Asia 86%, East Asia 87% and the Middle 
East and North Africa 87% [95]. 
 
The difference in proportions retained in care may also be explained by differences 
in methods of defining the original cohort.  Failure to distinguish between patients 
newly initiating ART and entering a reporting cohort and experienced-patients 
transferring in for care will mean that data in the reporting cohort are included on 
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patients who have already survived past the first few months of treatment.  This will 
bias all outcome data in favour of a healthier population and increased retention in 
care.  It is likely that some reporting cohorts include transfers-in (and thus healthier 
patients) while others do not, thus making comparisons between programmes 
problematic.  Whether there is any geographical propensity to account for transfer-
ins, originating perhaps from some governments but not all requiring nationally 
reported data to be disaggregated in such a way, should be examined.  
 
Twelve-month (80%) and 24-month (77%) retention is higher than retention 
estimates from earlier systematic reviews which suggested that  75% - 77% of 
patients remained in care at 12 months, and 62% - 75% at 24 months, the lower 
proportions being reported in the earlier reviews [75] [76].   This suggests a 
calendar time effect, with newer ART programmes retaining more patients in care.  
Such an accomplishment should be commended, however, more information on 
longer-term retention is urgently needed as the available data, though few, suggest 
that retention dramatically decreases as length of time on ART increases.  
Furthermore, as fewer studies report over the longer-term, this may represent a 
reporting bias with studies with worse longer-term retention only electing to report 
over the short-term, or not reporting at all.   
 
Although the included studies had different durations of reporting, I did not attempt 
to account for missing data if not reported at certain time-points through measures 
such as imputation, or scenario projections.   This meant that the number of studies 
reporting retention in care and other outcomes at the same time-points, particularly 
after 24 months, was small and interpretation of the summary estimates should be 
done with caution.   Both previously published systematic reviews on retention in 
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care attempted to account for missing data.  The first review projected retention to 
24 months for studies reporting short follow-up periods and assumed best (no 
further attrition) and worse (linear continuation of attrition) scenarios.  This resulted 
in a mid-point retention estimate of 50% (range 24% - 77%) retention in care at 
24-months [75].   The second review, projected retention over time using the same 
methods as the first study and, additionally, interpolated missing retention rates 
using later reported data and used a pooled-random-effects-meta-analysis.   Using 
the first method, retention was 70% and 65% at 24 and 36 months and, using the 
second method, was 86%, 80%, 77% and 72%  at 6, 12, 24 and 36 months [76].  
These data, which estimate 24-month retention at 50, 70% or a maximum of 77%, 
compared to a median of 77% in the individual studies included in this review, 
suggest that summarising the proportion retained in care from only the few studies 
with available long-term data may considerably overestimate retention in care.   
True retention of patients in ART care, where data are few, may actually be lower 
than that summarised here.   
 
Even assuming that the consistent reports of 80% retained in care at 12 months are 
not overestimates, this represents, in routine care in LMIC, that every fifth patient 
initiated on ART is lost from care within the first year of therapy.  In ART-Cohort 
Collaboration (ART-CC) cohorts in HIC, after nearly 12 months on ART, a higher 
proportion of ART initiators (up to 88%) remained alive and in care [180].  
Retaining greater numbers of patients in ART care is feasible in LMIC settings, when 
adequate resources are available.  Within the DART randomised clinical trial, which 
compared patient monitoring in ART programmes in Uganda and Zimbabwe using 
routine laboratory tests versus clinical monitoring alone, survival on ART in routine 
health centres was 90% and 87%, respectively, after 5 years  [181].   Establishing 
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and addressing reasons for losses from care in routine ART programmes in LMIC is 
essential if improvements in retention are to be made.  
2.3.4 Attrition from care 
While retention in care was reported in 47 studies, 33 studies reported reasons for 
patients leaving the original treatment cohort, while the remainder (30%) did not 
(Table 2.2).  Reasons for leaving the original ART cohort can include deaths, 
electing to stop ART, transferring officially to another ART clinic, or leaving ART care 
and providing no further information on vital status to the ART clinic (known as 
becoming lost to follow-up, LTFU).  Overall, median attrition from care due to 
deaths (11%) and LTFU (11%) was equal, with a median of 5% of patients 
transferring-out and a median of 3% stopping ART.  At 6, 12, 36, >42 months, a 
cumulative median of 5%, 11%, 13%, 14% of patients had died, 8%, 11%, 9%, 
12% were LTFU, and 3 - 7%, 5%, 5% and 7% had transferred elsewhere for care, 
respectively.  The proportion stopping ART increased from 1% in the first few 
months to a maximum of 18% after 56 months of cohort follow-up.    
 
For ART-LINC cohorts, the majority of cohort losses were due to deaths and LTFU.  
As per the individual studies reviewed, most deaths occurred in the first year on 
ART with cumulative deaths at  6, 12, 18, 22, 24 and 36 months of 3 – 9%, 6 - 8%, 
5%, 8%, 7 – 12% and 13%, respectively [79, 80, 82-87].  LTFU increased over 
time, accounting for 3 – 16%, 13%, 9%, 31%, 7 - 32% and 25 - 29%, respectively 
at 6, 12, 18, 22, 24 and 36 months [79, 80, 82-87]. 
 
Table 2.2 demonstrates the challenges arising from comparing retention in one 
cohort against another without considering reasons for losses from care, even when 
reported retention rates are similar.  For example, at 12 months one study reports  
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Table 2.2 Cohort follow-up period, median time in follow-up and retention and 
attrition at end of follow-up/median follow-up (ordered by maximum length of 
cohort follow-up, with shortest follow-up time shown first) 
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Zambia [106, 
107] 
 
142 3 3 18% 23% - - 59% 
Malawi [100] 
 
370 6 6 9% - - - 76% 
South Africa 
[101] 
 
498 6 6 5% - - - 95% 
India [157] 
 
142 6 -  4% 27% - - 69% 
Malawi [175] 
 
555 6 1 2% 6% - 3% 90% 
Malawi [178] 
 
4347 6 6 13% 8% 1% 7% 71% 
Malawi [178] 
 
4347 12 12 13% 11% 1% 10% 65% 
Tanzania 
[112] 
 
 
486 12 12 11% 12% - 14% 
63%(ART) 
55%(&TB) 
Barbados 
[169] 
 
158 12 12 1% - 1% - 94% 
Curacao [128] 
 
123 12 12 10% 10% - - 80% 
Malawi [140] 
 
300 12 12 14% 3% 5% 5% 72% 
South Africa 
[160] 
 
609 12 12 19% 15% - - 67% 
Botswana 
[155] 
 
349 12 - 20% 13% - 1% 78% 
Uganda [126] 
 
219 12 - 4% 3% - 4% 83% 
Latin America 
& Caribbean 
[150] 
 
 
5152 12 - 8% 6% - - 86% 
Malawi [152] 
 
4074 14 - 9% 6% <1% 2% 83% 
Rwanda [116] 
 
490 15 12 1% 3% 4% - - 
 
Uganda (no 
mental illness, 
mentally ill) 
[102] 
 
 
 
 
773 15 15 1%, 2% - - - 65%,47% 
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Cambodia 
[166] 
 
1735 24 13 11% 2% - - 87% 
China [120] 
 
3457 24 21.3 13% 4% 3% 0% 84% 
Zimbabwe 
[99] 
 
898 36 15 8% 11% - - 81% 
Nigeria [103] 
 
4785 36 28 3% 21% 8% 5% 53% 
Uganda [133] 
 
559 36 33 18% 4% - 2% 74% 
Uganda [125] 
 
559 36 36 18% 6% - 5% 71% 
Senegal [136] 
 
404 42 42 26% - - - 73% 
South Africa 
[171] 
 
 
829640 51 - 5% 8% 1% 8% 76% 
South Africa 
[149] 
 
1480 54 25 11% 11% - 6% 72% 
Tanzania 
[111] 
 
88875 54 10 12% 36% - 11% 
56% (m),  
60% (f) 
China [144] 
 
512 56 27 22% - 18% - 81% 
China [146] 
 
48785 60 17 13% 10% - - 70% 
South Africa 
[142] 
 
7322 60 60 16% 23% - - 65% 
Ethiopia [108] 
 
4210 60 31 7% 13% 0% 3% 76% 
Burma [109] 
 
5963 82 36 14% 7% - 4% 76% 
South Africa 
[130] 
 
3162 84 29 10% 19% - 10% 63% 
Cote  d’Ivoire  
[170] 
 
129 - 2 12% - - - 88% 
Indonesia 
[141] 
 
 
626 
 
12(IDU), 
8.4(non 
IDU) 16% 13% - 4% 67% 
South Africa 
[118] 
 
- 19 5% 24% - - 71% 
DRC [104] 
 
1450 - 19 6% 18% - 1% 57% 
Cote  d’Ivoire  
[164] 
 
187 
 
19 9% 2% - - 89% 
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Uganda [139] 
 
5982 - 20 6% 15% - 10% 69% 
South Africa 
[132] 
 
7536 - 21 7% 14% - - 79% 
South Africa 
[119] 
 
15060 - 22 18% 23% 4% 15% 40% 
Lao [98] 
 
913 - 22 12% 4% - 11% 73% 
Burkina Faso 
[115] 
 
5608 - 23 12% 7% - 4% 77% 
sub-Saharan 
Africa [151] 
 
249 - 32 10% 3% - 3% 84% 
Uganda [96] 
 
6970 
 
36 - - 11% 3% 86% 
Uganda [117] 
 
22315 - 36 7% 
8%(m), 
6%(f) - - 
85%(m), 
87%(f) 
South Africa 
[153] 
 
 
7512 - - 
6%(TB),  
4%(no TB) 
20%(TB), 
19%(no TB) - - 
74%(TB), 
77%(no 
TB) 
 
  
67 
 
retention of 65% while another reports retention of 67% [160, 178].  However, for 
the second study, all of the reported losses are due to deaths (19%) and LTFU 
(15%), while for the first study, 10% of patients have transferred-out and are 
receiving ART elsewhere.  Further challenges arise when interpreting widely-varying 
proportions retained in care.  For example, at 36 months, one cohort reports 
retention in care of 53% while another reports 74% of the cohort retained in care 
[103, 133].  It would be understandable to assume that the ART programme 
reporting the lowest proportion retained was doing less well.  However, only 3% of 
that cohort’s  patients  had died compared with 18% of patients in the other cohort.   
Neither study reported whether patients LTFU were traced to ascertain vital status 
which may have inflated the proportion of deaths and reduced the proportion LTFU.  
For example, one reviewed study traced a sub-sample of patients LTFU and 
ascertained that 29% of those traced had died [145].  Without adequate 
information, comparing these cohorts is challenging.   
 
Cohorts appear to report consistently that at 12 months post ART-initiation, nearly 
half of the 20% of losses from care are due to deaths.  Continued efforts are 
needed, therefore, to encourage people to seek HIV testing and access care earlier 
in disease to reduce early morbidity and mortality.  The remaining half of losses 
from care is due, in the main, to LTFU with the vital status of lost patients unknown.  
Official transfers-out of care or patients electing to stop ART make up a smaller 
proportion throughout time on ART.  LTFU by 12 months in LMIC is double that 
seen in HIC, where it has been reported to be 5% among ART-Cohort Collaboration 
(ART CC) cohorts [182].  It is, therefore, essential to encourage patients attending 
clinics to remain in care and to ascertain and address reasons for LTFU in LMIC.   
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Being able to understand and report reasons accurately for patients dropping out of  
ART care is complex as it can be hard to ascertain the vital status of patients who 
have become LTFU.  Some sites invest vast resources into tracing patients LTFU to 
ascertain if patients have died, transferred unofficially elsewhere for care or whether 
they have defaulted from ART completely.  Some patients, in fact, may default from 
care but resume after some time.  One study reported that the probability of 
resuming ART within 3 years of default can reach more than 40% [134].  
Comparing cohorts who trace patients with cohorts without resources to do so will 
lead to inaccurate conclusions about the relative performance of the programmes.  
 
Collating data on observable-outcomes such as the proportion retained, died, LTFU 
or transferring-out appears feasible and data are reported by more than half of 
cohorts in this review.  It is surprising, in fact, that UNAIDS only present the 
proportion alive and on ART 12 months after initiation, not collecting or publishing 
data on reasons for attrition from ART programmes.  However, interpreting 
retention and attrition must be done with caution, particularly when comparisons 
between programmes are made.   
2.3.5 Immunological response 
Thirty-two studies reported the median increase in CD4 cell count since ART 
initiation, the median absolute CD4 cell count or the proportion with poor immune 
response [80, 98, 101, 103, 113, 116, 118, 123, 128, 130, 131, 136, 139, 143, 144, 
147-149, 151, 155, 157-162, 164, 166, 168, 169].  For all cohorts reporting CD4 cell 
count changes, the median CD4 cell count at ART initiation was low at 123 (IQR 80 
– 152) cells/mm³.   
 
The greatest increase in CD4 cell counts (Figure 2.3) was observed early after ART  
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Figure 2.3 Median increases in CD4 cell count over time 
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initiation, as expected.  At 6 and 12 months, the median increase in CD4 cell count 
from ART initiation was 108 (IQR 100 – 136) cells/mm³ and 168 (IQR 124 – 178) 
cells/mm³, respectively.  Fewer studies reported at other time-points though these 
demonstrated a positive trend over time: 191 and 202 cells/mm³ (18 months), 168 
– 302 (n=4, 24 months), 196 and 337 cells/mm³ (36 months), 238 – 430 cells/mm³ 
(n=3, 36 months) and 474 cells/mm³ (60 months).  The median absolute CD4 cell 
counts at 6, 12, 18 and 24 months were, respectively, 222, 264 - 312, 354 - 355, 
and 348 - 372 cells/mm³ (n=10).  The proportions with poor immune response at 6 
and 12 months were 19% - 43% and 25% - 42%, respectively (n=10).  However, 
the threshold for definition of poor immune response varied across the studies from 
< 50 to <500 cells/mm³.   
 
Of two ART-LINC studies, increases in median CD4 cell counts at 12 and 24 months 
were 166 and 292 cells/mm³, respectively [81] [80].    
 
Cohorts initiating ART at lower CD4 cell counts reported greater increases in CD4 
cell counts.  At 6, 12 and 24 months, for study cohorts initiating ART with CD4 <120 
cells/mm³ (median of all studies), the median increase was 156, 178 - 292, and 302 
cells/mm³. This compares to increases at the same time-points of 100, 136 - 168, 
and 248 cells/mm³ among cohorts whose participants initiated ART with CD4 count 
≥ 120 cells/mm³.  No other baseline factor (geographical origin of cohort, cohort 
size, date of initiation, proportion female, WHO stage, age) appeared to explain the 
ranges observed in increases in CD4 cell counts.  These results are similar to 
significantly greater CD4 cell count gains among patients starting ART with lower 
CD4 cell counts, compared to higher counts reported by UK CHIC and CASCADE HIC 
cohorts [180, 183].  These earlier gains, however, do not appear to continue and  
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stabilise over time [180]. 
 
There appears consistency in reported increases in CD4 cells at 6 (around 110  
cells/mm³), 12 (around 170 cells/mm³) and 24 (just under 300 cells/mm³) months.  
These gains are similar to gains reported among ART-CC cohorts in HIC at 6 months 
and similar to gains among the UK CHIC cohort [182, 184].  The median absolute 
CD4 counts at 6 and 12 months were also similar to median absolute values 
reported in a previous systematic review of LMIC cohorts at 3, 6, 12, 18, 24 and 
>24 months of 244, 249, 277, 274, 298 and 374 cells/mm³ [74].   Most data, 
however, relating to CD4 increases or absolute counts were reported at 6 and 12 
months after ART initiation and while the studies included here suggest a continued 
increase in CD4 count gain over time, more data are needed to examine the longer-
term effect on CD4 counts among patients who remain in care.    
 
However, interpreting cross-sectional medians over time must be done with caution.  
As individuals who are most sick are likely to drop out of care or die, the risk-set 
used to calculate median increases will decrease over time.  At each reporting time-
point, the median CD4 is, therefore, likely to appear to have increased as those left 
in the risk-set will be the healthiest proportion of the population. 
2.3.6 Virological response 
Sixteen studies reported the proportion of patients achieving undetectable viral load 
over time (Figure 2.4) [80, 101, 113, 128, 130, 136, 140, 142, 144, 151, 155, 159, 
160, 162, 169, 170].  Among these, median viral load at ART initiation was 5.1 (IQR 
5.0 – 5.2) log copies/mL, though this was only reported by 4 of these cohorts. 
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Figure 2.4 Proportion with undetectable viral load 
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At all time-points, wide-ranges in the proportions achieving undetectable viral load 
were reported.  Only two studies reported at 3 months, and at least half of these  
participants who remained in care and had a viral load measured achieved 
virological suppression (49% and 88%).  By 6 and 12 months, the median 
proportion with undetectable virus was 78% (range 62 - 93%) and 83% (range 
63% - 96%), respectively.  An increasing trend in the proportion achieving 
undetectable viral load was reported over time: 77% and 88% (24 months), 84% 
and 88% (36 months), 56% and 89% (48 months) and 84% (60 months) (n=7 
studies).   
 
Of the cohorts reporting the greatest proportion with undetectable viral load at 6 
and 12 months, however, median viral load at ART initiation was 4.9 and 5.1 log 
copies/mL respectively, compared, somewhat counter-intuitively, to slightly lower 
levels of viremia at ART initiation (4.8 and 5.0 log copies/mL) among the cohorts 
reporting the lowest proportions undetectable at 6 and 12 months. These 
observations of greater proportions undetectable being linked to higher viral load at 
baseline have previously been observed among ART-CC cohorts in HIC: 79% of 
patients with viral loads >100,000 copies/mL at ART initiation were suppressed 
(<500 copies/mL) at 12 months, compared to 78% among patients with 10,000 – 
1000,000 copies/mL, and 72% among patients with <10,000 copies/mL at ART 
initiation [185].  However, it is worth noting that the main aim of the analysis of the 
ART-CC cohorts was to estimate probability of death after 36 months, therefore 
analyses were limited to patients who survived to a minimum of 36 months, thus 
the sicker patients who were likely to be those with higher viremia at ART initiation 
are not captured here.   
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There appeared to be no other baseline factors (cohort country of origin, cohort 
size, year of ART initiation of patients in the cohort, proportion female, median age, 
proportion initiating ART at WHO stage III/IV, or CD4 count at ART initiation) which 
were related to virological outcomes.  The threshold for detection, however, varied 
widely across the cohorts from < 50 - < 1,000 copies/mL which may explain much 
of the variability in response rates reported.  Viral load assays have differing lower 
limits of detection.  However, given their cost and limited availability within LMIC, 
every effort should be made to ensure maximum information is gained when viral 
load tests are employed.  If they are to be used as a reporting measure within ART 
programmes, standard threshold levels based around the highest viral load 
threshold to classify undetectable viremia need to be agreed upon. 
 
The proportions with undetectable viral load at 6 months (78%), 12 months (83%) 
and 24 months (77% - 88%) are  higher than proportions reported in an earlier 
systematic review at 3, 6, 12, 18, 24 and >24 months of 73%, 75%, 67%, 68%, 
65% and 74% [74].  They are also higher than another review which reported 78%, 
76% and 67% with undetectable viral load at 6, 12 and 24 months [73].  These 
differences across reviews may be explained by a calendar time effect, with the 
more recent studies in this review reporting on cohorts in more experienced ART 
programmes.  The differences, however, may also be explained, in part, by the high 
threshold level employed by some of the studies in this current review, which 
accepted limits of <1,000 copies/mL to meet definitions for undetectable viremia, 
compared to thresholds of below 400 copies/mL in the first review and between 
200-500 copies/mL in the latter [74] [73].    
 
The proportion of cohorts in LMIC with suppressed viremia appears similar to  
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proportions suppressed among cohorts in HIC, however HIC cohorts tend to use 
stricter thresholds to define levels of undetectable viremia [182] [180, 184].    
As viral load tests are costly, many cohorts in LMIC did not report HIV RNA changes.  
It is likely that programmes which were able to conduct viral load tests have greater 
resources than other cohorts.  Improved resources may lead to improvements in 
care and it is feasible that cohorts reporting viral load changes have better overall 
outcomes.  Reports of high proportions with undetectable viremia may not, in fact, 
be representative of controlled viremia in ART programmes in LMIC.   
 
Furthermore, comparing any reported immunological or virological changes should 
be interpreted with caution. Firstly, the baseline health status of the treated 
population should be considered.  Here, cohorts with low CD4 at initiation appeared 
to have greater increases in CD4 counts and cohorts with higher viral loads 
appeared to have greater proportions with undetectable viremia over time.  This is 
because the less healthy a cohort at initiation, the greater scope for early viral 
suppression and immune recovery.  A cohort, therefore which reports smaller 
increases in CD4, may indeed reflect a population which was healthier at initiation.  
Secondly, care must be taken when interpreting gains to ensure knowledge is 
available on who is included in the risk set at all time-points.  Measures reported at 
ART initiation (baseline measures against which increases are compared) are often 
only given for those who also have an immunological or virological measure at 
follow-up.  The baseline values will likely be higher for these patients than if the 
value also included patients who go on to die or drop out of care, and were likely 
more sick, before there is an opportunity for a follow-up immunological or 
virological assessment.  When using this information to assess the health of a 
treated cohort, or to compare treated cohorts, even if a remarkable response is 
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noted, this should only be interpreted alongside information on other key outcomes 
for individuals from the original treatment cohort (e.g. number of deaths, number 
transferred elsewhere, and number of losses to follow-up).   
2.3.7 Other clinical responses: TB, AIDS-defining illnesses, IRIS and 
Hospitalisations 
Eleven studies reported the overall proportion of patients with TB throughout time 
on ART, though the maximum number of studies reporting at any one time-point 
was 4 [97, 100, 108, 112, 126, 132, 139, 149, 157, 168, 170].  After the original 
increase in cases, the cumulative proportion experiencing active TB did not change 
greatly over time: at 6, 12, 24, 36, 48 and 60 months, 14%, 6%, 8%, 9%, 8 - 10%, 
and 21% had TB.  Seven studies reported the overall incidence rate of TB while on 
ART, ranging from 3.1 – 7.3/100 person years (py).  TB incidence rates increased 
sharply in the first 3 months on ART (11.3 and 13.9/100py) and then slowed over 
time, dropping to 2.5 – 12.5/100py between 6 - 12 months, 1.0 – 4.5/100py 
between 12- 24 months, 1.6 – 3.2 between 24 – 36 months and reached 0.4 – 
2.2/100py by 60 months.  Reducing rates of TB as time on ART increases have been 
shown previously in LMIC [186].  The high early rates may be due to IRIS as the 
risk of TB-associated IRIS has been shown to be very high, particularly for patients 
with low baseline CD4 cell counts initiating ART early in the course of anti-TB 
treatment [187].  However, early TB may be due to unmasking of asymptomatic or 
minimally symptomatic disease pre ART initiation [188, 189]. 
 
Among ART-LINC cohorts, by 12 and 18 months on ART, 6% of patients had 
developed TB, with an overall incidence rate of 7.4/100py in the first 12 months, 
and 8.2/100py over the first 18 months [88] [86].  The highest incidence rate of TB 
was reported early after ART initiation, dropping from 10.7/100py during months 1- 
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3, to 7.4 - 7.5/100py during months 4 – 6, to 5.2/100 py during months 7 – 12 
months [88].   
 
Eight studies reported information about other AIDS defining illness (ADI), including 
IRIS or hospitalisations, though only three provided details about the time-point at 
which the estimates were made  [101, 126, 128, 131, 136, 140, 154, 172]. The 
median overall proportion hospitalised, with IRIS or with an ADI was 13% (range 
1% - 38%), with incidence rates ranging from 1.6 – 20.5/100py.    This is similar to 
the range of estimates (9 – 39%) found in a recent systematic review of IRIS 
among HIV-infected persons [77].     
 
One ART-LINC cohort reported the proportion with ADI.  At 12 months, incidence 
rates of cryptococcal meningitis, PCP, KS and non-Hodgkin lymphoma were 0.48, 
0.35, 0.31 and 0.02/100py, respectively [87].  After a median of 22 months of 
follow-up, the following proportions had developed ADI: cryptococcal disease 
(0.4%), KS (0.4%), and PCP (0.3%).   
2.3.8 Other outcomes 
Ten studies report on patients failing ART, though some reported proportions 
failing, others failure rates, and few reported at the same time-points [80, 130, 139, 
142, 143, 146, 159].  The proportion failing ranged from 7% at 6 months, to 
between 23% - 26% around 24 months, and between 14% - 50% at 5-years, with 
failure rates ranging widely from 5.0 – 31/100py.  Immunological and virological 
threshold levels used to determine the proportions failing varied between the 
studies.  One ART-LINC study reported that 26% of patients experienced viral 
rebound within two years, despite 96% being suppressed (<500 copies/mL) at 12 
months [80]. 
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Adverse events (AE) were reported by 10 studies, though only two studies reported 
at the same time-point [110, 118, 120, 138, 140, 144, 157, 164, 165, 173].  The 
proportion with an AE varied considerably in the reports: at 6, 12, 24, 36 and 72 
months, 38%, 3% -7%, 28%, 17 - 56%, and 19 – 72% had an AE.  The most 
commonly reported AE were: peripheral neuropathy (11 – 17%), headache (12%), 
lipoatrophy (5% – 7%), symptomatic hyperlactataemia (3% - 6%, rate 3.2/100py), 
hepatoxicity (3%), lactic acidosis (1% - 3%, rate 1.4/100py) and others 
(percentages not given) fever, cough, diarrhoea, lymphadenectasis, weight loss, 
tetter, weakness and fungal infections.  The difference in proportions with AE is 
likely due, in part, to the different diseases considered clinically-important enough 
to report.  Some cohorts may have included only serious AE and report a low 
proportion, while others may have included all AE and report a high proportion.   
Moreover, a number of these adverse events (e.g. neuropathy, raised lactate and 
lactic acidosis) are related to treatments such as d4T (stavudine) which are being 
phased out.  Comparing the proportion of patients with AE in different cohorts 
should be done alongside a knowledge of which regimen was in use.   
 
Eight studies reported changes in weight or BMI over time, though few reported the 
same measure at the same time-points and two studies reported no aggregated 
measure (only disaggregated by sex or weight at ART initiation) [114, 118, 121, 
124, 148, 155, 160, 166].  At 3, 6 and 12 months, median weight increased by 2.5 
and 2.6kg, 3kg and 10kg.  At 6 and 12 months, median BMI increased by 0 – 
2.4kg/m² and 1.6 – 4.8/m², respectively.   
 
While 21 studies reported the overall proportion of patients interrupting, switching 
or substituting ART combinations, terminology was used interchangeably and it was  
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unclear if all switches truly represented changes between drug classes or were 
substitutions within the same drug class [80, 101, 110, 112, 123, 127, 128, 133, 
140-143, 148, 151, 158, 159, 161, 166, 167, 173, 176].  I, therefore, did not 
summarise this information. One ART-LINC study reported that 22% of patients 
changed their first-line regimen in the first two years [80].  
 
Though this review excluded studies specifically reporting on adherence as an 
outcome on ART, 3 studies included for other outcomes also reported on adherence 
[116, 137, 147].  Good adherence was reported among 26% of participants at 3 
months and among 62% - 100% of participants at 12 months.  However, different 
methods were used to measure and different definitions  were  used  to  define  ‘good’  
adherence making comparing reported adherence challenging.   
 
Other outcomes reported included changes in renal function, TLC, lipid changes and 
changes in haemoglobin but were reported by too few studies to summarise [124, 
147, 166, 173, 176]. 
 
2.3.9 Outcomes as predictors of retention in care 
Very few studies reported an immunological, virological, clinical (TB, IRIS, ADI, 
hospitalisations) or other (AE, weight changes, switches, adherence) outcome at an 
intermediate time-point together with the proportion retained in care at a later point 
in time.   It was, thus, only possible to examine the potential relationship between 
immunological and virological indicators and retention in care.   
 
Plotting increases in CD4 cell count at 6 and 12 months against the proportion  
retained in care up to 24 months suggests that the greater the increase in CD4, the  
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lower the proportion retained in care (Figure 2.5).  Similarly, plotting the proportion 
achieving virological suppression at 3, 6 and 12 months against up to 60-month 
retention in care appeared to suggest a similar, though less clear, negative 
relationship between increasing proportions suppressed and lower proportions 
retained in care (Figure 2.6).   While this may seem counter-intuitive, it is possible 
that as patients regain their health and feel they need less health services, retention 
in care may fall.  However, this component of the review was limited by the small 
number of studies reporting intermediate outcomes and future retention making 
assessing potential relationships between intermediate outcomes and longer-term 
retention nearly impossible.   
2.4 Discussion 
The median length of cohort follow-up has increased to 24 months, from the 10-
months observed in reviews of studies published before this work as more data are 
emerging on the longer-term health of treated populations [75] [76].  However, this 
review has highlighted the lack of commonality of outcomes reported and the large 
discrepancy in time-points at which outcomes are reported.  Monitoring the health 
of patients in ART programmes using clinic-measurable data, such as retention, 
losses from care, transfers-out, patients stopping ART, incidence of TB, other ADI, 
and hospitalisations appears feasible for a number of ART programmes, while the 
use of routine immunological and virological measures remains limited to health 
centres with adequate resources.  For a life-long condition and for ART programmes 
in LMIC which have been funded widely since around 2004, more information is 
urgently needed on outcomes on ART after two, three and five years in treatment 
programmes.  Indeed, for patients who initiated ART in 2004, it would be of value 
to know how they are doing after nearly 10 years on ART.   There remains a need  
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Figure 2.5 Median CD4 increase at 6 and 12 month and up to 24 month retention 
in care 
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Figure 2.6 Proportion with undetectable viral load and up to 60 month retention 
in care 
60%
65%
70%
75%
80%
85%
90%
95%
100%
40% 50% 60% 70% 80% 90% 100%
Pr
op
or
tio
n 
re
ta
in
ed
 in
 c
ar
e 
(%
) 
 
Proportion with undetectable viral load (%) 
3mth proportion
undetectable VL
6mth proportion
undetectable VL
12 month proportion
undetectable
83 
 
for data from more studies from outside of Africa.  There is also a need for 
increased reporting at intermediate time-points rather than just the end of cohort 
follow-up.  Moreover, there is a clear need for better descriptions of how 
numerators and denominators are derived to enable cross-programme comparisons. 
 
Monitoring outcomes for the increasing number of patients accessing ART is 
challenging.  It may be that random, systematic or consecutive sampling 
techniques, which have demonstrated similar proportions retained in care as full-
cohort data analyses, could provide a feasible method to monitor the health of 
increasing numbers of patients in care in LMIC  [94].  A less resource-intense 
monitoring method, such as this, may provide increased scope for greater accuracy 
and more detailed descriptions of reported data.  
 
The lack of common reporting outcomes and time-points shown in this review has 
highlighted a lack of knowledge of which outcomes, reported at which time-points 
provide the best insight into the progress of the treated population.  Non-
standardised data make comparisons across geographical areas, programmes and 
time challenging [190].   Furthermore, gaps in monitoring the treatment and health 
of patients in care remain.   
 
Notably, tools do not exist to monitor long-term access to Cotrimoxazole 
preventative therapy (CPT) and a review of access to CPT is needed.  I undertook 
this work and present the results in Chapters 3 and 4.  Furthermore, a set of 
outcome measures to monitor depression in the context of HIV does not exist [191].  
Given the implications on adherence to treatment and faster disease progression for 
HIV-positive patients with comorbid mental health disorders, an evaluation of the 
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burden of mental health disorders among HIV-positive patients is needed.  I 
undertook this work and present the results in Chapter 5.  Furthermore, while most 
funders and MoH require reports on the health of the treated population, a 
comparison of which outcomes are currently used by ART programmes in LMIC is 
needed to identify which outcomes are perceived by national MoH as most relevant.  
I undertook this work and present the results in Chapter 6.  Moreover, as it is not 
known how accurately currently reported outcomes reflect the welfare of the 
population in care, an evaluation of the validity and predictive value of such 
measures is needed [20] [68] [56].  I present the design of such a study in Chapter 
7 of this thesis.  These studies will provide the evidence-base to determine which 
data should be collected by programme managers to monitor the health of the 
population in their care, enabling them to respond to predictors of failure early.  
This is crucial to provide a clearer understanding of the health of the treated 
population and to enable best practice in ART roll-out in LMIC.    
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 Reported access and barriers to Chapter 3
Cotrimoxazole Preventive Therapy 
 
This chapter describes a study I undertook to evaluate access to Cotrimoxazole 
Preventive Therapy (CPT).  The study aimed to estimate time to CPT initiation 
following HIV diagnosis or birth to an HIV-infected mother and time on CPT.  The 
study also aimed to compare these derived estimates with data reported in 
monitoring reports.  I designed and conducted the study in Uganda and Tanzania 
between May 2009 and December 2011.  In this chapter, I present the results of 
pilot work which influenced the design of the study and describe differences in 
health care worker prescribing practices and barriers which may impede regular 
access to CPT.  The main findings of the study are presented in the following 
chapter.  
3.1 Background 
The drug Cotrimoxazole (CTX) acts as a broad-spectrum antimicrobial agent that 
targets a range of aerobic gram-positive and gram-negative organisms, fungi and 
protozoa [59].  Today, CTX is used widely in LMIC to treat infections including acute 
respiratory infections, diarrhoea and Pneumocystis pneumonia (PCP) [192].  As a 
prophylaxis, CTX is used for the prevention (primary prophylaxis) and against the 
recurrence (secondary prophylaxis) of opportunistic infections (OI).  It has been 
used in high income countries (HIC) since the early 1980s to prevent bacterial 
infections in HIV-negative people with granulocytopenia [193].  In HIV, 
Trimethoprim-Sulphamethoxaole (TMP-SMZ) was recommended as the drug of 
choice for the treatment of AIDS-related PCP as early as in 1983 and prophylaxis 
with CTX, the official generic name for the co-formulation of TMP-SMZ, was first 
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used to prevent PCP in HIC in 1985 [40] [194].  Prophylaxis with CTX is known as 
Cotrimoxazole Preventive Therapy (CPT).  
 
Evidence for the use of CPT to prevent OI in HIV-positive individuals in LMIC first 
emerged in 1999 in the Côte   d’Ivoire   [195] [196].  Further retrospective and 
prospective cohort studies, randomised controlled trials and cost-effectiveness 
studies have added to this evidence [195-205].  In 2006, the WHO updated earlier 
guidelines and issued revised ones stating that CPT should be used as a key 
element in the HIV chronic care package [59].   
 
The 2006 WHO guidelines state that CPT should be provided to:  
x all HIV-exposed children under 18 months until HIV infection has been 
excluded, 
x children aged more than 1 year who are asymptomatic (WHO stage 1) but 
have a CD4 cell of less than 25%, 
x children aged more than 1 year who are symptomatic (WHO stage 2, 3 and 
4) regardless of CD4 count or percentage, 
x adults with advanced disease (WHO stage 3 and 4) regardless of CD4 count 
or with less severe disease (WHO stage 2) and a CD4 cell count less than 
350 cells/mm³.  
WHO  also  recommends  a  ‘universal  option’  in  countries  with  high  prevalence  of  HIV  
and limited health infrastructure whereby CPT is recommended for all patients living 
with HIV [59].   
 
Furthermore, WHO guidelines recommend that CPT should be continued throughout 
care, because patients living with HIV are at high risk of bacterial infections in LMIC.  
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However, patients who are stable on ART, with good adherence, secure access to 
ART and with a CD4 and clinical evidence of immune recovery can be reassessed 
and consideration given to discontinuing CPT [59].   
 
Despite the 2006 WHO guidelines for the use of CPT as a key element of the HIV 
care package, the process of creating national level policies on CPT has varied 
between African countries, with some countries still not advocating the use of CPT 
in 2008 when I embarked upon the work included in this thesis [193].   For 
example, in Zambia, there were no national CPT guidelines.  This was despite the 
country having been host to a large clinical trial (the CHAP trial) of CPT in HIV-
infected children which had led directly to the formulation of the WHO 2006 
guidelines [198].   Moreover, in 2008, concerns had been raised that the routine use 
of CPT had only partially been translated into practice and was only partially 
implemented in LMIC health centres [38, 193, 206, 207]. These concerns had been 
particularly voiced in relation to CPT access for children in sub-Saharan Africa [208] 
[209].   In 2006, UNAIDS estimated that, globally, only 4% of adults and 1% of 
children living with HIV had access to this key element of HIV care [210].   
 
Therefore, firstly, I reviewed published literature to summarise the proportion of 
eligible patients initiating CPT in LMIC and their time spent on CPT after initiation.  
Secondly, I designed the current study to describe how well, following national CPT 
policy formulation, CPT was being accessed in Uganda and Tanzania.  I examined 
existing records to assess access to CPT in routine HIV care in the two countries.    
 
3.2 Literature review 
The aim was to evaluate access to CPT in LMIC as reported in published literature  
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by synthesising estimates of the proportion of patients initiating CPT, and 
summarising information relating to retention on it.  A secondary aim was to 
synthesise from commentary pieces information relating to perceived barriers to 
CPT scale-up and recommendations on ways to improve the implementation of CPT.  
 
My search strategy involved multiple stages.  Firstly, I used broad search criteria to 
identify English language studies which assessed access to CPT in HIV care in LMIC 
published since 1999, when the first evidence emerged supporting the use of CPT 
as prophylaxis in HIV care [195].   I searched Medline through PubMed.  The search 
was last updated on 29-01-2014.  I used both Mesh terms and Text fields to capture 
HIV care and Cotrimoxazole (TMP-SMZ).  This resulted in 880 titles.   Secondly, 
having read the 880 titles, I excluded titles which described the following: 
a. Efficacy studies (e.g. randomised controlled trials and systematic 
reviews) 
b. Safety studies or adverse reactions to CPT 
c. Case-series 
d. Cost-effectiveness studies 
e. Mechanism of action of CPT (e.g. role of CTX in prevention of 
bacteraemia, PCP, anaemia) 
f. Treatment outcomes for patients on CPT 
After the above exclusions, 50 titles remained.  Where abstracts were available 
(n=44), I read the abstracts and where abstracts were not available via the 
literature search, if available I accessed the full texts of the articles and reviewed 
the abstracts (n=4).  Two titles had no abstract available and I was unable to 
retrieve the full text.  These titles, however, suggested that the articles described 
efficacy of CPT and no further attempts were made to find these articles.  
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Therefore, having read the 48 abstracts, I selected 36 texts that met at least one of 
the following criteria: 
a. Described proportions of patients in need of CPT initiating it 
b. Described access to HIV care services (including CPT) 
c. Provided a commentary of CPT scale-up or barriers to the 
implementation of CPT 
Having read the full texts of 34 of these articles (2 articles were not found), I 
further excluded 4 which: described access to CPT in an American cohort, 
systematically reviewed the effectiveness of CPT, reviewed the efficacy of CPT in 
pregnant women, and described the efficacy of CPT in HIV-infected children.   I was 
unable to retrieve the full text of 2 of the selected abstracts but as they met the 
above inclusion criteria, I included their data directly from the abstracts.  This 
review, therefore, includes 32 papers.   
Twenty-three studies reported quantitative data on the proportion of patients 
initiating and retained on CPT or the proportion of sites providing CPT (Tables 3.1 – 
3.5).  CPT is recommended for different population groups: HIV-infected patients, 
HIV-TB co-infected patients and HIV-exposed infants.   The articles are tabulated 
accordingly.  Eight articles were commentary pieces describing challenges 
associated with scaling-up access to CPT, and one article described the number of 
patients in need of CPT (Table 3.6).  From the quantitative studies, I extracted 
information on study country, year and design, study population and sample size, 
the proportion initiating CPT and the proportion still on CPT after initiation.  From 
the commentary pieces, I extracted reasons given that might explain slow scale-up 
of CPT and recommendations to improve the implementation of CPT.  I present the 
quantitative data first, followed by a summary of the key points from the 
commentary pieces. 
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Table 3.1 Proportion of HIV positive adults and children initiating CPT (ordered by year of study data-collection) 
Authors Country Data-
collection 
year 
Sample Design Proportion initiating CPT 
Desmonde 
[211] 
Côte 
d'Ivoire 
04 - 09 405 children, 
median age 
4.5yrs 
prospective cohort in 2 urban 
facilities 
67% of all HIV positive 
children  
90% of eligible children 
(WHO guidelines) 
36% of infants < 12 months 
Khoza [212]* Zimbabwe 04 234 adults retrospective record review 19% 
Nakigozi 
[213] 
Uganda 05 - 06 1145 adults review of surveillance records 
of a community cohort 
69%  
Ong'ech 
[214] 
Kenya 08 - 10 363 mothers  prospective cohort in HIV care 
& Mother and Child Health 
clinics (MCH) in 2 hospitals 
81% in MCH clinic 
97% in HIV clinic 
      
*Full text not available 
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Table 3.2 Proportion of HIV-exposed infants initiating CPT (ordered by year of study data-collection, firstly for studies reporting patient 
data, then programmatic data) 
Authors Country Data-
collection year 
Sample Design Proportion initiating CPT 
Steel-Duncan 
[215]* 
Jamaica 04 132 prospective cohort 90%  
Ong'ech [214] Kenya 08 - 10 363 prospective cohort in HIV 
care & mother child health 
clinics in 2 hospitals 
98% of mothers in HIV care & 100% of mothers in 
MCH clinics  
 
Moodley [216] South 
Africa 
09 - 10 400 record review & mother 
interviews in 1 child 
immunisation clinic 
67% of all HIV-exposed 
93% of HIV-exposed infants discovered HIV positive  
64% of HIV-exposed infants discovered HIV negative  
71% of HIV-exposed infants of unknown HIV status  
Luo [217] LMIC 04 - 05 71  
countries 
review national programme 
data 
4% globally; ≥15% in only 5 countries: 
        Ukraine 88%,  Botswana 58% 
        South Africa 26%, Guyana 18% 
        Georgia 15%.   
14% Laos (highest in Asia)  
10% Benin (highest in W Africa) 
Ginsburg [218] LMIC 05 - 06 52,342 PMTCT indicators review  9% across 18 countries 
*Full text not available  
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Table 3.3  Proportion of TB-HIV co-infected patients initiating CPT (ordered by year of study data-collection) 
Authors Country Data-
collection 
year 
Sample Design Proportion initiating CPT 
Maher [219] LMIC 00 25 countries  national indicators review 38% in 1 country (Zimbabwe) 
<10% in 7 countries 
0% in 8 countries 
9 countries provided no data  
Chimzizi 
[220] 
Malawi 03 956 descriptive study of patients in 
15 hospitals being scaled up to 
deliver CPT 
77% - 100% (average 97%) 
91% within 7 days of starting TB 
treatment 
Chakaya 
[221] 
Kenya 05 - 08 25,558 national TB case notifications 
review across 1605 facilities 
85% 
Pevzner 
[222] 
Rwanda 05 - 09 122 retrospective data review in 23 
TB clinics 
2.5% in 04 
15% in 05 
92% in 09  
93 
 
Authors Country Data-
collection 
year 
Sample Design Proportion initiating CPT 
CDC [223] Kenya 06 - 09 36,136 in 06 
43,954 in 07 
41,174 in 08  
42,210 in 09 
review TB surveillance data from 
approximately 2,200 TB clinics 
87% in 06  
86% in 07  
92% in 08 
92% in 09 
Raizada 
[224] 
India 07 734 retrospective record review 
across 154 primary health care 
facilities 
97% overall 
44% within 1 week of starting TB 
treatment 
62% within 1 month 
70% within 4 months 
Louwagie 
[225] 
South 
Africa 
08 - 09 1283 retrospective cohort from 46 TB 
treatment centres 
65% in semi-integrated & 69% in separate 
facilities 
Kapata [226] Zambia 06 - 10 33, 748 record review & surveillance 
data across multiple sites 
31% in 06 
70% in 10 
Harries [227] Malawi 10 by 2010 
250,987 ART 
patients 
13,677 TB-HIV co-
record review from multiple sites 
in 2 districts 
86% in 03 
97% in 04  
96% in 05 
93% in 06 
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Authors Country Data-
collection 
year 
Sample Design Proportion initiating CPT 
infected  89% in 07 
96% in 08 
Lawn [188] sub-
Saharan 
Africa 
12  - descriptive study 76% in 10 (cited from WHO Global report) 
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Table 3.4 Availability of CPT (ordered by year of data-collection) 
Authors Country Data-
collection 
year 
Sample Design Provision of CPT 
Filler [228] sub-Saharan 
Africa 
06 - 07 45 PEPFAR-
supported 
sites 
interviews & 
record review 
98% of sites provided CPT 
Date [229] multi-country 07 41 countries WHO officer 
survey 
93% of all countries have policy for CPT provision & 66% 
cite nationwide implementation  
   Africa 94% (policy) & 69% (implementation) 
   Americas 100% & 67% 
   Eastern Mediterranean 100% & 67% 
   Europe 86% & 50%  
   SE Asia 100% & 50% 
   W Pacific 75% & 100%;  
90% & 75% of ART & HIV care facilities provided CPT  
70% of staff report erratic supply 
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Table 3.5 Retention on CPT (ordered by year of data-collection) 
Authors Country Data-
collection 
year 
Sample Design Retention on CPT 
Zachariah 
[230] 
Malawi 01 87 HIV 
positive/TB 
co-infected 
adults 
cross-sectional study to 
assess CPT compliance 
while on TB treatment in 4 
centres in 1 district 
94% had CTX in urine at 4 – 6 months 
 
Alkatout [231] Zimbabwe 01 - 04 908 HIV 
positive 
adults 
prospective study in 1 rural 
hospital 
Mean time 32 weeks  
34% <1 month 
67% < 6months   
    (47% at 4 months) 
    (18% at 8 months) 
Kohler [232] Kenya 05 - 07 1024 HIV 
positive 
adults 
retrospective cohort from 1 
urban health centre 
63% at 12 months before free CTX    
84% at 12 months after free CTX 
Ong'ech [214] Kenya 08 - 10 363 HIV-
exposed 
infants 
prospective cohort in 2 
hospitals 
56% in HIV care & 75% in MCH clinic at 6 
months 
40% lost to follow-up at 12 months 
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Table 3.6 Commentary pieces describing barriers to scaling up widespread access to CPT and recommendations (ordered by publication 
year) 
Authors Country Year 
published 
Study 
population 
Barriers Recommendations 
Bortolotti 
[32] 
sub-
Saharan 
Africa 
02 HIV positive 
adults and 
children 
-Questionable efficacy of CPT & concerns 
about increased resistance  and duration on 
CPT if efficacy diminishes over time 
-identify HIV positive patients  
-ensure life-long adherence 
-monitor adverse events 
-understand cost-effectiveness  
-increase capacity of health care staff 
-ensure adequate drug supply 
-enhance monitoring & follow-up 
Boerma 
[233] 
LMIC 05 HIV-
exposed & 
HIV positive 
children 
-4 million children & infants in need of CPT 
   sub-Saharan Africa 3.5million,  
   Asia 309,000,  
   Latin America 99,000,  
   N Africa/Middle East 59,000,  
   Eastern Europe/Central Asia 18,000 
-greater monitoring will lead to more 
accurate data which will lead to more 
accurate understanding of numbers in need 
of treatment & better resource allocation 
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Authors Country Year 
published 
Study 
population 
Barriers Recommendations 
Harries 
[234] 
sub-
Saharan 
Africa 
06 HIV-TB co-
infected 
-Malawi - 23% of hospitals had complete 
stock-outs, remainder of clinics had 
insufficient supplies 
-add columns to TB registers for CPT start 
date 
-provide CPT asap to HIV positive/TB co-
infected patients 
-test all TB patients & initiate on CPT all HIV 
positive 
-provide easy dispensing of 1-2mth supplies 
(e.g. in 120 tablet packs) 
-pharmacy CTX register to aid forecasting; 
-integrate TB-HIV services to aid dispensing 
of TB, CPT & ART drugs 
Zachariah 
[207] 
LMIC 06 HIV-TB co-
infected 
 -supply CPT through existing TB clinics free 
of charge 
-implement CPT register to monitor follow-
up, side-effects & drug requirements 
-train TB counsellors & staff  
-increase patient education 
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Authors Country Year 
published 
Study 
population 
Barriers Recommendations 
Zachariah 
[38] 
LMIC 07 HIV-
exposed 
infants & 
HIV positive 
children 
-original objections to the evidence 
(particularly in areas of high resistance) 
-lack of policy of CPT in infants & children 
-inability to diagnose infants <18 months & 
lack of available testing for children 
-need to visit hospital to pick up CPT (not 
MCH clinic) 
-insufficient patient knowledge re CPT 
-drug supply/stock-outs: 55% of facilities 
out of stock in Malawi, 2007 
-lack of implementation plans & funding 
-develop national drug procurement systems 
-develop registers of CPT use & monitoring 
systems to aid drug forecasting 
- develop surveillance systems to monitor 
resistance 
- develop guidelines on when to stop CPT 
- develop accessible diagnostic tests for < 18 
months & increase compulsory HIV testing 
-provide CPT at lower level health centres 
-provide 3-mth supply not 1-mth 
(particularly when journey distances are 
long) 
-educate patients on CPT 
Callens 
[235] 
LMIC 08 HIV-
exposed 
infants & 
HIV positive 
children 
-lack of guidelines  
-limited drug availability 
-cites the estimate that 4 million children 
are in need of CTX but only 4% are on it 
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Authors Country Year 
published 
Study 
population 
Barriers Recommendations 
Msellati 
[208] 
Africa 08 HIV positive 
children 
-inadequate policy guidance 
-limited availability of CTX due to public 
health authorities not considering it a 
rationale choice of resource allocation 
-lack of HIV testing, particularly in children 
-cites the estimate that 4 million children 
are in need of CPT but only 4% are on it 
 
Coutsoudis 
[236] 
LMIC 10 HIV-
exposed 
infants 
 -advocates breastfeeding over CPT as 
benefits of breastfeeding outweigh risks of 
CPT 
-rationale: as PMTCT services increase & 
transmission decreases & option B+ aims to 
get infection to <2%, risks of mass 
prophylaxis with CPT become more relevant 
(skin reactions, gastro, resistance) 
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3.2.1 Study populations and study designs 
The studies providing quantitative data were conducted in Côte  d’Ivoire,  India,  
Jamaica, Kenya, Malawi, Rwanda, South Africa, Uganda, Zambia and Zimbabwe, 1 
multi-country study in sub-Saharan Africa and four studies conducted in multiple-
LMIC.  Commentary pieces referred to the use of CPT generally in LMIC.  CPT is 
recommended for different populations groups, namely HIV-infected patients, HIV-
TB co-infected patients and HIV-exposed infants.  As such, the study populations 
for the quantitative and qualitative data were heterogeneous, but covered the key 
groups of patients eligible for CPT: HIV-infected adults (8 articles) and children (1 
article), HIV-exposed infants (10 articles) and HIV-TB co-infected patients (13 
articles).  The smallest study estimated CPT initiation among 87 patients and the 
largest study among 250,987 patients.   
 
Study designs were heterogeneous and included retrospective cohorts reviewing 
patient records, prospective cohort studies, reviews of clinic programmatic data, 
reviews of national programme data or surveillance data, cross-sectional interviews 
and surveys with programme staff or staff at international organisations.  One study 
estimated the number of HIV-infected children and HIV-exposed infants in need of 
CPT (4 million) in 2005, the majority of whom were seen in sub-Saharan Africa 
(3.5million) [233].  
 
3.2.2 Proportions of patients initiating CPT and availability of CPT 
Three studies estimated the proportion of HIV-infected adults initiating CPT: two 
examined adults within HIV clinics and one described initiation among mothers in 
antenatal care.  The earliest study was from 2004 and reported coverage among 
adults at 19% [212].  The two other studies reported that the proportion of adult 
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patients initiated on CPT was 69% in 2005 - 2006, and 81% of mothers (within 
Mother and Child Health clinics, (MCH)) and 97% of mothers (within HIV care 
clinics) between 2008 - 2010 [213, 214].    
 
One study estimated coverage among HIV-infected children.  This estimated that 
67% of all HIV-infected children in care and 90% of all CPT-eligible children in care, 
when using the WHO guidelines for initiation eligibility, initiated CPT between the 
period from 2004 - 2009.  However, the same study estimated that among infants 
< 12 months only 36% initiated CPT [211].   
 
Five studies estimated the proportion of HIV-exposed infants initiated on CPT, with 
the earlier studies tending to report lower proportions initiating CPT.  The earliest 
study, however, was conducted in 2004 and estimated access to CPT in Jamaica at 
90% [215].  While this estimate appears high, the full text of this article was not 
available and a complete understanding of the study population or definitions was 
not therefore possible, precluding any interpretation of this high estimate.  One 
study, reviewing national programme data in 71 countries in 2005, reported that, 
globally, only 4% of HIV-exposed infants accessed CPT and that only in 5 countries 
out of those surveyed did ≥  15% of HIV-exposed infants initiate CPT [217].  This 
study has been widely cited as evidence of CPT scale-up being slow, notably in the 
commentary articles included in this review [208, 235].  One further study, 
examining data from 2005 - 2006, reported similarly low proportions of HIV-
exposed infants accessing CPT (9%) [218].  This study also reported that in 2005 
and 2007 only 11% and 17% of sites, respectively, reported any data on CPT use.  
The two most recently published studies examined data collected between 2008 -
2010 and between 2009 - 2010, respectively. The earlier of these, estimated the 
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proportion of HIV-exposed infants initiated on CPT within MCH clinics in Kenya to be 
100% and within HIV clinics to be 98% [214].  The most recent study estimated 
that 67% of all HIV-exposed infants in clinics in South Africa initiated CPT [216].  
 
Ten studies estimated the proportion of TB-HIV co-infected patients in TB clinics 
who were initiated on CPT.  The studies examined data from 2000 – 2010, with 
some studies reporting at multiple time-points to provide assessments of changes in 
coverage over time.  The earliest report of access to CPT among TB-HIV co-infected 
patients was a global survey conducted in 2000.  This cited one country 
(Zimbabwe) with 38% of patients initiating CPT, seven countries with <10% 
nationwide coverage and 8 countries with 0% national coverage [219].  Reports in 
2004 and 2006 estimated similarly low levels of initiation of CPT, at 2.5% and 31%, 
respectively [222, 226].   One study estimated 97% of patients initiating CPT in 
2003, however this study described the initial period of an MoH-supported CPT 
scale-up programme in 15 hospitals in Malawi [220].  It is likely that this high 
coverage reflected the resources for CPT which were being invested into specific 
health centres and the additional monitoring at the time.   The most recent reports 
(2009 and 2010) among TB-HIV co-infected patients estimate access between 65% 
- 92%, of which three studies reported <80% and two reported >90%  [188, 222, 
223, 225, 226] .  The lowest estimate was extracted from a study examining 
retrospective data and the authors suggested that the low coverage may reflect 
poor record keeping, or challenges during their analyses when trying to match 
records in the absence of unique patient identifiers.   
 
The relative increases in the proportion of patients initiating CPT among TB-HIV co-
infected patients reported by four studies demonstrate the achievements in scaling 
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up CPT access within TB clinics: one study reports access at 86% in 2003 and 96% 
in 2008; one estimated access at 2.5% in 2004 increasing to 15% in 2005 and 
reaching 92% by 2009; a further study estimated access at 31% in 2006 increasing 
to 70% in 2010, while another reports an increase from 86% in 2006 to 92% in 
2009 [222, 223, 226, 227]. 
 
The proportion of clinics at which CPT was available was reported by two studies, 
both at the end of 2007: one described PEPFAR-supported sites in one-country 
(98% providing CPT) and the other was a global WHO survey describing the 
proportion of ART facilities (90%) and the proportion of HIV-care facilities (75%) 
dispensing CPT [228, 229].  The WHO survey also reported that in 2007, 66% of 
countries  had  achieved  ‘nationwide’  implementation  of CPT. 
 
3.2.3 Retention on CPT after initiation and risk factors for non-initiation 
Retention on CPT was estimated among HIV-infected adults in two studies, one 
reporting 18% of those initiated still on CPT after 8 months, with the other 
reporting that 84% of patients were still on CPT after 12 months [231, 232].  
Retention on CPT was estimated in one study among HIV-exposed infants (60% at 
12 months), but differed depending on whether infants were seen in MCH clinics 
(75% at 6 months) or HIV-care clinics (56% at 6 months) [214].  No study 
described retention on CPT among HIV-infected children.   
 
Adherence to CPT was estimated among HIV-TB co-infected patients in three 
studies: 29% of patients collected > 80% of CPT prescriptions in one study; 65% of 
staff reported that CPT was routinely prescribed to patients in another study; and a 
further study reported 94% of patients with laboratory detectable CTX after 4 - 6 
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months on CPT [222, 224, 230].  One study conducted among HIV-exposed infants 
reported that 47% of carers did not provide CPT to infants on weekends [216].    
 
Three studies reported on factors associated with non-initiation of CPT or with 
retention on CPT.  One study reported that non-initiation of CPT was higher among 
men than among women (38% vs 29%) and that younger individuals (15 - 24yrs vs 
> 24yrs) were more likely not to initiate (RR 2.22) [213].  A second study similarly 
found that being female was positively associated with initiating CPT, as was being 
on ART (RR not given) [212].  A third study reported that being aged < 15yrs or > 
30yrs or having a deceased partner were associated with longer time on CPT [231]. 
 
3.2.4 Barriers to scaling up CPT and recommendations  
Two studies described health-care worker knowledge or national policies relating to 
CPT. The first study, reporting on a survey conducted in 1999 - 2000, estimated 
that 6% of clinicians and 50% of health care workers had never heard of CPT, and 
that only 13% of clinicians had accurate knowledge of the correct dosing and 
prescribing practices for CPT [237].   The second study estimated that by 2007, 
93% of countries globally had a policy relating to CPT [229].  
 
Three studies provided quantitative data on stock-outs or inadequate supplies of 
CTX and all were conducted in 2006 or 2007.  Reasons for stock-outs of CTX 
include its prescribing for prophylactic and therapeutic use, poor drug forecasting 
and interrupted drug supply chains.   One study in Malawi reported that 23% of 
hospitals had complete stock-outs and the remainder of clinics had insufficient 
supplies on the day of the study visit, while another Malawian study reported that 
55% of facilities were experiencing stock-outs of CTX on the day of the study visit 
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[38, 234].  The third study was a 41-country survey, which reported that 70% of 
health centres experienced erratic supplies and stock-outs of CTX [229].   
 
The commentary pieces discussed barriers and recommendations to scaling up CPT 
among HIV-infected adults (1), HIV-exposed or infected children (5), and TB-HIV 
co-infected patients (2) and were published between 2002 and 2010.  
 
Early barriers to CPT scale-up related to lack of national policies due to concerns 
about the efficacy of CPT, particularly in areas of high bacterial resistance, and 
concerns about the development of resistance to CTX given the requirement for life-
long adherence to CPT [32, 207].  Early recommendations, therefore, included the 
need to monitor adverse events and to understand cost-effectiveness [32]. 
 
Existing barriers to increased access to CPT or retention on CPT include: limited 
ability to diagnose infants <18 months easily and challenges ensuring regular 
testing for children and adults; a continued perceived low priority of CPT among 
health care workers due to lack of adequate and accurate monitoring; inadequate 
guidance for health care workers on its use; inadequate patient education relating 
to the reasons for taking it and correct dosing, particularly among mothers; lack of 
implementation plans and funding for CPT, due in part to public health authorities 
not considering it a rationale choice of resource allocation; lack of integrated 
TB/HIV clinics and a concern among TB patients that receiving CPT stigmatises 
them as being HIV-infected; a lack of integrated CPT dispensing within MCH clinics 
resulting in additional visits required at other health facilities; and limited availability 
of CTX [38, 188, 208, 214, 216, 224, 227, 229, 235]. 
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Specific recommendations from the commentary pieces include: increase HIV  
diagnosis, particularly among children and TB patients, and improve identification of 
patients in need of CPT; develop accessible HIV diagnostic tests for < 18 months; 
increased compulsory HIV testing; increase patient understanding of and staff 
capacity to deliver CPT; ensure life-long adherence to CPT and continuous supply of 
CTX to facilitate this; dispensing larger numbers of pills (3- or 2-month supply 
rather than 1-month supply, particularly when journey distances are long); dispense 
CTX in special 120-tablet packs rather than nurses manually counting pills from 
1000 tablet tins; scale-up integrated TB-HIV clinics to facilitate easier access to TB, 
CPT and ART drugs for co-infected patients or, if not possible, provide CPT within 
TB clinics; evaluate current surveillance systems routinely for completeness and 
accuracy and ensure adequate monitoring of access and retention on CPT; develop 
pharmacy CTX dispensing registers to aid drug forecasting; add columns to TB 
registers to collate data on CPT use; create CPT registers to monitor initiation, 
follow-up, side-effects and drug requirements; decentralise CTX stocks by providing 
CPT at lower level health centres and ensure regular supplies of CTX; and develop 
guidelines on when to stop CPT to ease the demand burden for CTX [32, 38, 221, 
222, 227, 229, 231, 233, 234]. 
 
3.2.5 Review discussion 
The literature available to evaluate the implementation of CPT was limited in 
quantity.  Furthermore, there was heterogeneity of study populations including HIV-
infected adults, HIV-infected children, HIV-exposed infants and TB-HIV co-infected 
patients, resulting in only a small number of studies for each population group.  The 
majority of articles included in this review reported initiation among HIV-TB co-
infected populations, with only 1 article describing the proportion initiating CPT 
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among HIV-infected children and only 2 describing initiation among adults in HIV 
care clinics.  The years in which the studies were conducted varied widely over a 
10-year period.   There were in addition, ranging estimates of CPT initiation within 
and between each population group, with notably low estimates for HIV-exposed 
infants.  This likely reflects the different challenges in scaling-up CPT to the 
different populations.  Moreover, the time since HIV diagnosis by which CPT was 
initiated was rarely provided, making it difficult to compare proportions.   
 
The included studies do not provide enough details to comment on risk factors for 
not initiating CPT and more work is needed to enable the identification at the time 
of HIV diagnosis of patients that are at risk of not initiating CPT.  Moreover, few 
studies examined the duration of time spent on CPT, and the time-point at which 
retention on CPT was estimated differed between studies.  This makes drawing any 
conclusions about retention on CPT challenging.  The lack of reported information 
on time spent on CPT may be because there are no monitoring tools for 
continuation on and adherence to CPT.  This position, for example, is held by 
representatives from the national MoH, Malawi [Jahn A., personal communication 
March 2010, Lilongwe, Malawi].  Retention rates on CPT are important to quantify 
and report because maintaining patients on CPT is vital for OI prevention.  This is 
particularly true for individuals not yet accessing ART, who remain susceptible to 
bacterial infections, and for whom CPT may have the greatest impact, especially as 
there is the potential to delay the need for initiation of ART [203].   
 
Despite these limitations, the studies provide valuable information about CPT 
coverage.  Most notably, many commentary pieces discuss the poor scale-up of 
CPT, citing the 4% coverage estimate from 2005.  This review has shown a clear 
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calendar time effect with coverage rates across all population groups far higher 
than 4% and increasing substantially in recent years.  These increases likely reflect 
enhanced services but it is worth noting that this may, in part, reflect improved 
record keeping.  Where the data on HIV-exposed infants suggest low coverage, 
they may also reflect the late integration (2005) of a CPT indicator relating to 
infants by many MoH and associated poor data recording by health care staff [217].  
One study demonstrated that access to CPT among HIV-exposed infants was low 
(9%), while noting that the number of sites reporting data on CPT was also low 
(between 11 – 17%).  There may be some truth in the statement that 'what gets 
monitored gets done' [229].  Many commentary pieces cited poor record keeping 
and insufficient monitoring as key barriers to scaling-up access to CPT, particularly 
relating to ongoing access to CPT after initiation.  If monitoring systems remain 
poor, the scale-up of CPT, and ensuring continued access to CPT for those initiated, 
may also remain poor.  There is a need to evaluate current monitoring systems 
routinely for completeness and accuracy [222].  
 
The lack of studies describing access to CPT among newly-diagnosed patients in 
HIV care facilities and continued access to CPT after initiation demonstrates the 
need for further studies to examine this.  I, therefore, designed and conducted a 
study to estimate access to CPT among newly-diagnosed patients and time spent 
on CPT after initiation.    
 
3.3 Study design 
3.3.1 Aim, objectives and outline 
The aim of this study was to assess access to CPT for patients in HIV care in 
outpatient clinics in Uganda and Tanzania.  The objectives were: 
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x to describe CPT prescribing and dispensing practices as reported by clinic staff, 
and to describe challenges that may impede regular access to CPT, 
x to estimate time from HIV diagnosis or birth to an HIV-positive mother to CPT 
initiation among patients newly-diagnosed with HIV/birth and to examine risk 
factors associated with this (sex, age and diagnostic clinic), 
x to estimate the proportion of time interrupting CPT for those who initiated and 
risk factors associated with this (sex, age, clinic and WHO stage), and 
x to compare these derived estimates with data reported in monitoring reports. 
 
This study included pilot site visits and interviews with clinic staff to identify 
practices for CPT prescribing and dispensing and to identify issues which may 
influence study design.  The staff interviews were also used to identify perceived 
barriers to CPT scale-up.  The main study was conducted in 8 clinics in Uganda and 
in Tanzania using 2 data-sources: 
 
x all patients newly-diagnosed with HIV and HIV-exposed infants during 
January - March 2009.  These data were extracted from HIV care clinic 
diagnostic registers and exposed-infant registers.   
x all patients who initiated CPT in the same health centre during January - 
September 2009.  These data were extracted from HIV care clinic pre-ART 
enrolment registers.   
 
The records of all patients diagnosed with HIV or infants identified as HIV-exposed 
during January - March 2009 were linked to the records of patients enrolling into 
HIV care by September 2009, and these patients were assumed to have initiated 
CPT (Figure 3.1).  For patients initiated on CPT, longitudinal data on CPT use during  
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Jan 
09 
Mar 09 Sept 09 June 11 
Diagnosed/ 
HIV-exposed 
Initiated CPT 
CPT use after initiation 
Figure 3.1 Time-line for data-collection from HIV diagnosis or birth to an 
HIV positive mother to CPT initiation and CPT use after initiation 
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their time in care were gathered from their patient files up until data-collection in 
June 2011. The study was facilitated through EfA partners at the MRC/UVRI in 
Uganda and at MITU, Tanzania.  
 
The remainder of this chapter describes issues identified during the pilot site visits 
which influenced study design, describes the design of the main study and presents 
the results of the clinic staff interviews which provide a background to CPT 
provision in the Ugandan and Tanzanian study clinics.   The main results of the 
study, estimating the cumulative probability of initiating CPT after HIV diagnosis, 
time interrupting CPT, and comparisons to official monitoring reports are presented 
in the following chapter.  
 
This work provides a summary to national government representatives and 
international researchers of CPT use in 2 African countries.  It is anticipated that the 
results will feed into national implementation strategies for ensuring CPT is 
accessed by those most in need.   
 
3.3.2 Pilot phase and implications for study design 
The pilot phase involved visits to 10 health centres in Uganda and Tanzania in 
October - November 2010 to assess the feasibility of quantitative data collection.  I 
visited a variety of HIV care health centres including those eventually selected for 
inclusion in the study and I examined how data about CPT use were recorded.   
 
The health centres for the pilot phase visits aimed to meet the following site 
eligibility criteria, which were the criteria used to select sites for the main study: 
x sites conducted HIV testing, 
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x site provided HIV care to both adults and children, 
x sites provided CPT through the national MoH system, and  
x the provision of CPT was not dependent upon external support, such as a 
research study.   
 
Sites for the pilot visits and main study were selected in collaboration with the 
national MoH and the local EfA partner and aimed to provide a mix of peri-urban 
and rural sites and to include at least one large hospital and one smaller health 
centre in each country.  I sought to include the greatest number of sites which were 
feasible to visit within the study time-line.  In Uganda, included sites were in the 
Wakiso district and in Tanzania sites were in the Mwanza and Shinyanga districts.  
The districts were selected due to their proximity to the base of the local study EfA 
study partner.  The provision of CPT in two sites from the pilot visits was dependent 
upon external support as sites were involved in research studies and these sites 
were not included in the main study.  
 
The main study, therefore, was conducted in 8 HIV outpatient clinics, 4 in each of 
Uganda and Tanzania.  In Uganda, the study was conducted in 2 peri-urban 
hospitals (1 specialising but not limited to paediatric care) and 2 rural health-
centres.  The Ugandan sites were Entebbe district hospital, MildMay International, 
Kasanje Health Centre II and Kigungu Health Centre III.  All children who are 
diagnosed with HIV within the Wakiso district of Uganda are referred to one of the 
Joint Clinical Research Centre (JCRC), The AIDS Support Organisation (TASO) or 
MildMay (all non-governmental organisations (NGOs) working in collaboration with 
the national MoH), and as such, few other MoH facilities have a normal distribution 
of adults and children accessing HIV care.  MildMay International was included as 
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the largest of these organisations treating children.  In Tanzania, the study was 
conducted in 2 peri-urban hospitals, 1 rural health centre and 1 rural dispensary.  
The Tanzanian sites were Sekou Toure Regional Hospital, the Hindu Union Hospital, 
Pansiansi Dispensary and Buzuruga Health Centre.  The Hindu Union Hospital was 
included because much HIV care in Tanzania is provided through the MoH with 
support from faith-based organisations.   A map of the location of the study sites 
can be found in Appendix 3.1.  The selected health centres were similar to other 
peri-urban hospitals and rural health centres in terms of distance from major cities, 
number and cadre of staff in clinic, facilities available at each clinic and populations 
served.  
 
In each health centre visited during the pilot phase, I obtained spare blank copies 
of the HIV diagnostic registers, pre-ART and ART registers, pharmacy records, 
monitoring and evaluation (M&E) reports and forms used in patient records.  I 
compared the data tools used and their degree of completion across the sites and 
across the countries and established which data items were feasible to collect in the 
main study.  The following issues were identified which influenced study design.    
 
Firstly, all patients who enrol into HIV care (pre-ART patients as well as ART-eligible 
patients) are enrolled in the pre-ART register for pre-ART care, where pre-ART and 
ART-eligible patients receive CPT.   ART-eligible patients enrol firstly in the pre-ART 
register because they spend a short period in pre-ART care receiving ART 
adherence counselling before commencing ART.  Therefore, the pre-ART register is 
useful to gather information on all patients enrolling into care.  Only clinics where 
the diagnostic and pre-ART registers and the submitted clinic monitoring reports 
were available for the same time-period were included in the main study.  As the 
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ability to retrieve historical diagnostic and pre-ART enrolment registers and 
monitoring reports varied between sites, I selected the first quarter of 2009 as the 
entry point for diagnosis.   
 
Secondly, in larger health centres, different diagnostic registers are used in different 
clinics (e.g. within tuberculosis clinic as well as the HIV clinic), and patient 
identification numbers are not always unique, or moreover, linked, between the 
registers.  Furthermore, data are sometimes copied over from one register into the 
‘main’  diagnostic  register  meaning  that  any  individual  patient’s  information  could  
appear twice.  In order to avoid double-counting, the names and initials of each 
patient were, therefore, temporarily recorded.  After establishing which register the 
health facility considered the  ‘main’  diagnostic register, the main register was 
searched for the names of all patients recorded in the secondary registers (e.g. the 
tuberculosis register), and, recognising that names of patients may be the same for 
family members, additionally matched on sex, age and date of diagnosis.   
Immediately after cross-checking, the full names of patients were destroyed.  
 
Thirdly, as the date of CPT initiation was rarely recorded in the pre-ART register, I 
used the date of enrolment in the pre-ART register as a proxy for CPT initiation.  
 
Fourthly, to gather longitudinal data on those who initiated CPT, I matched patients 
manually while in clinic on sex, age and date of diagnosis, between the diagnostic 
and pre-ART register, for patients diagnosed/born January – March 2009.  This was 
necessary as no identification number linking records exists, and information on 
patients transferring-in was rarely recorded.  Similarly, in order to assess time from 
HIV diagnosis to CPT initiation in the absence of a unique patient identifier, I 
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matched patients on the diagnostic and pre-ART enrolment registers on clinic, age, 
sex and date of HIV diagnosis (perfect matching) and further matched on clinic, 
age, and date of diagnosis, but not sex (imperfect matching).  I then matched on 
clinic, but allowed the following variation on any one variable: age by up to 1 year 
difference, date of diagnosis by up to 1 month difference, and allowing variation in 
sex (imperfect matching).  This matching was used to derive a minimum estimate 
of the proportion initiating CPT.  I further matched the records of patients in the 
pre-ART register without a date of HIV diagnosis on clinic, age and sex.  I also 
assumed that the number of patients who could not be matched in the minimum 
estimate had transferred-in for care unofficially and I assumed the same number of 
patients per clinic would transfer-out unofficially and initiate CPT elsewhere.   These 
patients were not included in the main analyses but can be seen to provide a 
maximum estimate of the proportion initiating CPT.  
3.3.3 Study population and period 
In each health centre, a nurse directly involved in patient care was selected for the 
interviews and, if available, the clinician in charge of HIV care was also interviewed.  
Clinic staff members were selected for the interviews based on who was available 
during the days of data-collection.  This was due to many of the health centres 
having a limited number of staff members involved in HIV care and interviewing a 
large number of clinic staff would have unreasonably detracted valuable staff time 
from routine patient appointments.    
 
All patients diagnosed or infants identified as HIV-exposed during January - March 
2009 whose details were entered into the HIV diagnostic register were included.  
There was no exclusion criterion.  A three-month period for diagnoses/births was 
selected to allow an adequate number of patients to be included from both large 
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and small health centres.  For example, small rural sites may diagnose around 15 
patients a month whereas urban hospitals may diagnose around 70.  The study 
captured data on all patients  who  enrolled  into  the  clinic’s  pre-ART register by 
September 2009.  This allowed a six-month delay for patients diagnosed/born at 
the end of March until enrolment into care, and was selected because a 6-month 
period had previously been used as a marker of significant delay in seeking care in 
a previous study in Uganda [213].  In Tanzania, as the date of HIV diagnosis was 
always provided in the pre-ART register, details of patients enrolling in the pre-ART 
register by September 2009 were only gathered for patients diagnosed January – 
March 2009.  By selecting September as the cut-off date for CPT initiation, it 
allowed for a minimum 18-month follow-up period between CPT initiation and data-
collection in June 2011 in which to assess continued access to CPT for patients after 
initiation.  Longitudinal data on participants from the diagnostic cohort who initiated 
CPT in the same health centre by September 2009 were gathered up until the time 
of data-collection in June 2011.   
 
The sampling frame used for this study is outlined in Table 3.7.   
 
3.3.4 Data collection 
A copy of the data collection tools used to gather the qualitative and quantitative 
data can be found in Appendix 3.2.  
 
The following data were gathered from the staff interviews: 
x Interviewee demographics: staff cadre, sex, duration of time in role 
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Table 3.7 Sampling frame to assess access to CPT 
Unit Selection 
Districts 
 
 
Health Centres 
 
 
 
 
Sample size 
Wakiso district Uganda, Mwanza and Shinyanga  districts 
Tanzania  
 
Entebbe district hospital, MildMay International, Kasanje 
Health Centre II and Kigungu Health Centre III,  Uganda; 
Sekou Toure Regional Hospital, the Hindu Union Hospital, 
Pansiansi Dispensary and Buzuruga Health Centre, Tanzania,  
 
Number of health centres: 8 total (4 per country) 
Number of staff for interview: 2 per health facility 
 
Health centre 
staff 
 
1 HIV-care nurse per health centre and, if available, the 
clinician working in the HIV clinic of the days of data-collection 
 
Diagnostic 
cohort 
 
 
Proportion 
enrolling into 
care and on 
whom long-
term access to 
CPT assessed 
all patients (adult and children) diagnosed with HIV (within 
clinic or via outreach) and HIV-exposed infants, January- 
March 2009, according to the diagnostic register 
 
all patients diagnosed January – March 2009 who enrolled for 
care between January – September 2009, as identified in the 
pre-ART register, in the same health centre (i.e. did not 
transfer-in) 
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x Health centre logistics: location of HIV diagnoses registers (e.g. TB clinic, 
maternity unit, inpatient wards, STI clinic, HIV unit) and exposed-infant 
registers  
x CPT prescribing information: criteria used to prescribe CPT to exposed 
infants, infected infants, children and adults (pre-ART and on ART) and 
criteria used to stop prescribing CPT to the same groups; drug availability 
(tablets, syrups, part-adult tablet for infants); number of days-worth of CPT 
prescribed routinely, and estimated frequency of CPT stock-outs, 
x Potential barriers to CPT scale-up: availability of CPT specific guidelines and 
training, 
x Perceived reasons for challenges to scaling-up CPT; reasons reported by 
patients for not taking CPT; staff opinion of importance of CPT 
x CPT monitoring information: type of monitoring and evaluation reports 
which ask for information on CPT (monthly or quarterly) and CPT data 
reported. 
 
I described the aims and objectives of the study to clinic staff invited to interview, 
who were given an information sheet and informed consent form.  If all questions 
were satisfactorily answered, written consent was obtained.   To minimise the 
potential for observer bias, the interview used for the most part closed-ended 
questions with multiple choice responses.  Where questions solicited a short concise 
response  (e.g.  “if  you  feel  CPT  for  patients  on  ART  is  not  very  important,  please  
explain briefly why you  think  this?”),  a  small  space  was  provided  for  free-text 
responses, though the use of such questions was kept to a minimum.  To minimise 
the potential for reporting bias and to avoid influencing the responses of the 
interviewee, no reference to details of the international or national CPT guidelines 
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was given at any point in the interview.  The interviews took around 15 minutes to 
complete and staff were compensated for their time by a small monetary allocation 
to purchase their midday meal.  To ensure confidentiality of responses, the 
interviews were conducted in a room separated from patients and other staff 
members.  If both the person in charge and a nurse were interviewed, these took place 
separately.  In Uganda, I conducted all the interviews myself.  In Tanzania, I 
conducted a practice interview together with the local research assistant in a site 
not used for the study, after which the research assistant conducted the study 
interviews.   
 
Data were collected on HIV-diagnosed patients from all HIV diagnostic registers 
used in each clinic.  Information about HIV-exposed infants was recorded from 
antenatal care registers or Mother and Child Health registers.  The following data, if 
available, were gathered from the registers:  
 
x sex  
x age 
x date of HIV diagnosis/birth 
x unique diagnostic patient identification number  
x name (temporarily) and initials of patients 
 
At diagnosis/birth, no information was recorded in the register on WHO stage, CD4 
count or TB status and it was thus, not possible to examine the association of these 
factors on initiation of CPT.  
 
The following data, where available, were gathered on all patients enrolling in the 
pre-ART register, January - September 2009: 
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x sex  
x age 
x date of enrolment in pre-ART register 
x date of HIV diagnosis 
x unique diagnostic patient identification number 
x CPT start date  
 
From the longitudinal patient records, the following data, if available, were 
gathered:  
 
x Demographic information: sex, data of birth, unique pre-ART identification 
number 
x HIV care baseline information: date of HIV diagnosis, date enrolled into pre-ART 
register, WHO clinical stage or CD4 count at enrolment, date initiated ART (if 
appropriate) 
x Appointment information: appointment date, WHO stage, CD4 count or 
percentage, whether CPT was prescribed or not, CPT formulation (tablet or 
syrup), number of CPT tablets/amount of syrup prescribed, number of 
days/weeks/month-worth of tablets or syrup prescribed, whether there was a 
stock-out of CPT that prevented prescribing, date of next appointment 
 
From the official monthly monitoring reports the following data were gathered, if 
available:  
 
 Number of patients diagnosed HIV-infected 
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 Number of male/female patients diagnosed HIV-infected 
Number of patients diagnosed HIV-infected, by age (<14, 15 – 24, 25 – 34, 
35 – 49, 50 plus, Tanzania) 
Number of patients diagnosed HIV-infected, by sex and age (<5, 5 – <18, 
18 years plus, Uganda) 
Number of babies born HIV positive (Uganda) 
Number of live births to HIV-infected mothers (exposed infants) (Uganda) 
Number pregnant women HIV-infected (Uganda) 
Number of males/females started on CPT, by age (Uganda) 
 
The following data were gathered from official quarterly monitoring reports in 
Tanzania: 
Number of patients enrolled into HIV care (and by sex, and by age and sex; 
<1, 1 – 4, 5 – 14, 15 years and above) 
Number enrolled into HIV care who transferred-in from elsewhere 
Number of pre-ART patients who received CPT  
 
The following data were gathered from official monitoring reports on CPT stock-
outs: 
Number of CTX stock-outs in each month 
 Duration of CTX stock-out (<1 week, > 1 week) 
 
3.3.6  Statistical methods 
The following describes the analytical methods, which were, in the main, the same 
in Uganda and Tanzania.  Important differences are noted.  
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Survival analyses were used to estimate the cumulative probability of CPT initiation 
after HIV diagnosis among newly-diagnosed patients/ after birth among infants 
born to HIV positive mothers.  A life table was derived and a Kaplan Meier curve 
plotted to estimate and show the cumulative probability of CPT initiation from HIV 
diagnosis/birth.  Follow-up time was censored at the end of September 2009 if the 
event had not been experienced.  Dates of initiation which occurred before, but 
within 1 month of, the date of HIV diagnosis (7 Uganda, 36 Tanzania) were 
assumed to be data recording errors and individuals were assumed to have initiated 
CPT on the same day as the date of HIV diagnosis.   
 
Cox models were used to examine differences in the time to CPT initiation by sex, 
age and diagnostic clinic.   In Uganda, the multivariate model was adjusted for sex 
and age but did not adjust for clinic effect due to the age distribution of clinic 
attendees (as expected, the paediatric clinic only had paediatric patients and no 
paediatric patients were diagnosed in other clinics).  In Tanzania, models were 
stratified by diagnostic clinic to allow for differences between clinics.  I also 
considered various transformations of age, as a continuous variable, as a binary 
variable below and above the median age, and with four age categories.  I 
examined all two-way interactions. 
I estimated the proportion of time interrupting CPT after initiation by calculating the 
number of days without CPT tablets, and the total follow-up time on CPT (total 
number of days between first day on CPT and the expiry day of the last CPT 
prescription).   Where the number of days-worth of tablets prescribed was not 
provided but the number of tablets prescribed was, I calculated the number of 
days-worth by dividing the number of tablets prescribed by two (as CPT was 
normally given in twice-daily doses).  Where neither the number of tablets nor the 
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number of days-worth was recorded but CPT was given, I estimated the number of 
days-worth based on the number of days until the next scheduled appointment 
(which assumed no shortfall or surplus of tablets prescribed).   
Using Poisson models, I examined differences in the proportion of time interrupting 
CPT by sex, age, clinic and WHO stage.   Models were then adjusted for the effects 
of all variables.  In Uganda, again, the multivariate model did not adjust for clinic 
effect due to the age distribution of clinic attendees (as expected, the paediatric 
clinic only had paediatric patients and no paediatric patients were treated in other 
clinics).  Further, I restricted the Ugandan analyses to patients aged > 2 years 
because staging additionally differed between adults/adolescents/children and very 
young paediatrics (85% of < 2 year olds were WHO stage I and 8% were WHO 
stage II compared to 60% of > 2 years olds in WHO stage I and 32% in WHO 
stage II).  I considered various transformations of age, as a continuous variable, as 
a binary variable above and below the median age, and with four age categories.   I 
examined all two-way interactions.  
I examined potential explanations for the proportion of time interrupting CPT in 
three ways.  Firstly, I calculated the proportion of appointments where CPT was out 
of stock and examined reported monitoring data on CPT stock-outs.  Secondly, I 
calculated the proportion of patients who were, on average, prescribed a short-fall 
of tablets until their next scheduled appointment.  Thirdly, I calculated the 
proportion of patients who, on average, attended appointments late.  No period of 
grace was given as even one day late or with a shortfall of tablets prescribed means 
an interruption to continuous CPT. 
3.4 Background to CPT use in Uganda and Tanzania 
In Uganda, one interview was conducted in each of the four health centres; three  
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with HIV-care nurses or nursing assistants (all female) and one with an HIV-care 
clinical officer (male).  Health care workers had been in their current role for a 
minimum of 56 months.  In Tanzania, seven interviews were conducted; three with 
nurses or nursing assistants, three with clinical officers and one whose cadre was 
not recorded.  Tanzanian health care workers had been in their current role for a 
minimum of 36 months.  The sex of Tanzanian staff was not recorded.   
3.4.1 Barriers to wide-spread CPT use 
Perceived barriers to CPT scale-up were similar in Uganda and Tanzania, and mirror 
those identified in the commentary pieces included in the literature review at the 
beginning of this chapter.  I describe the barriers in three categories: clinic-level, 
training-related and patient-level barriers.  All health-care workers in both countries 
believed that there have been problems scaling up access to CPT.   
 
Clinic-level barriers 
x perceived priority to fund ART over CPT,  
x difficult drug distribution due to the supply of CPT tablets being in large tins 
to be counted out by the health care workers, rather than as pre-packaged 
strips of tablets, 
x CTX stock-outs: these were reported to occur more frequently than ART 
drug stock-outs, with CTX reportedly  “hardly ever available” (sustained 
periods without stock of CTX were reported to have occurred in the previous 
2-year period two or three times in Uganda, and two, four and five times in 
Tanzania,  with  one  Tanzania  health  care  worker  reporting  that  for  “one  
quarter  of  the  last  2  years  there  was  no  CPT”); poor CTX drug forecasting in 
pharmacies and poor supply chain management led to limited supplies of 
CTX which impeded the ability to prescribe CPT for extended periods 
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between appointments; and limited supplies of CTX resulted in e.g. 60 
tablets prescribed, but the pharmacy only able to dispense 30 tablets, with 
advice given to the patient to procure the remainder independently. 
Training and guidelines-related barriers 
x inadequate training and prescribing knowledge with any training received 
on CPT having been incorporated into the general HIV care training; and a 
need for refresher courses for HIV care nurses, 
x a perception that there were no CPT-specific guidelines, or staff not having 
seen specific guidelines; a lack of clarity in the guidelines about who should 
receive CPT, particularly among children, or about when it was safe to stop 
CPT, and a lack of dosing charts, and  
x an inadequate number of health care staff. 
 
Patient-level barriers 
x transport costs, 
x difficulties keeping frequent appointments if a  patient’s  job  requires  travel, 
or missing appointments to collect CPT from a health centre which may be a 
long walk from home when CPT is sometimes available locally and cheaply 
on the black market, 
x toxicities, 
x barriers for pre-ART patients included frequently missed appointments and 
poor adherence due to lack of experience with any regular drug regimens 
prior to CPT, and 
x barriers for ART patients included, having an increased pill burden and the 
additional need to cope with advanced HIV-related illnesses.  
127 
 
3.4.2 Prescribing practices 
In Uganda,  
x all  described  prescribing  CPT  in  line  with  the  WHO’s  Universal Access option,  
for all HIV-infected children and adults, whether pre-ART or already initiated  
on ART, irrespective of CD4 count or WHO stage,   
x in 2 centres CPT was never stopped, mostly due to the lack of CD4 
monitoring on which to base a decision about improvements in clinical 
status,  
x in 1, CPT was stopped for adults if the CD4 count was above 800 cells,  
and  in  the  remaining  clinic  CPT  was  stopped  if  there  was  a  ‘good  CD4  count, 
good  adherence  measures  and  the  patient  is  stable’,  
x CPT was never stopped for children,   
x all health centres provided CPT to patients monthly, and 2 health centres 
provided CPT to ART patients corresponding to the number of months of 
ART supply given, and 
x CPT for children was supplied in strengths of 120mg tablets (n=2 health 
centres), part-480mg adult tablets (n=1), and in part-960mg adult tablets 
(n=1).  CPT was not available in syrup formulation for children in any health 
centre.  Adult tablets were available in 480mg tablets in three centres and in 
960mg tablets in one.  
 
In Tanzania, prescribing practices varied widely from the WHO international 
guidelines and between clinics.   
x A universal access option for CPT was not being implemented,  
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x for children 1 -5 years, 5 of the health care workers prescribe CPT 
irrespective of clinical status, while 2 health care workers use clinical criteria, 
based on unspecified weight or CD4 count below 350 cells,  
x for children 5 – 18 years, 4 of health care workers prescribe CPT irrespective 
of clinical status.  The remaining health care workers used a variety of 
measures of clinical status, depending on ART status, including CD4 below 
350 cells or below 15%, a combination of WHO stage III and  
body weight, or unspecified body weight,   
x for adults, 3 health care workers prescribe CPT to pre-ART patients based on 
having a WHO stage of III and above or WHO stage II and a CD4 count of 
less than 350 cells and 1 health care worker prescribed based on these 
criteria to ART patients.  The remaining 3 health care workers prescribed 
CPT either based on a CD4 count of below 200 cells, below 350 cells, below 
500 cells, based on WHO stage II irrespective of CD4 count, or irrespective 
of clinical status,   
x 5 of the 7 health care workers stop prescribing CPT if there are good clinical 
reasons, which differed between health care workers: if CD4 count increases 
to above 400 cells (n=4), above 350 cells (n=3), and also if WHO stage is I 
(n=1) 
x pre-ART and ART patients in all centres are given CPT supplies to last for 
one month, dependent on availability.  Pharmacies may dispense less than is 
prescribed if stock is low, and 
x CPT for children is supplied in strengths of 240g syrups in 3 health centres, 
and part-480g adult tablet in 1 health centre and adult tablets were 
available in 480mg tablets in 3 centres and in 960mg tablets in one.    
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Table 3.8 compares the WHO guidelines with the practices described by the health 
care workers in Tanzania.    
3.5 Summary 
The literature review, pilot work and staff interviews have provided a background to 
the issues affecting the wide-spread implementation of CPT in LMIC.  Gaps in 
knowledge were identified about CPT use, particularly relating to HIV-infected 
children, and patients in HIV care facilities, and about continued use of CPT after 
initiation.  I, therefore, designed the study outlined in this chapter to estimate 
access to CPT in HIV care facilities in Uganda and Tanzania.  The pilot work 
identified challenges affecting the design of the study associated with tracking CPT 
access among patients from diagnosis to long-term care, in the absence of unique 
patient identifiers and in clinics using paper-based registers and filing systems.  The  
interviews describe a background to CPT use in Uganda and Tanzania, highlighting 
perceived barriers to scale-up and providing information on prescribing and 
dispensing practices.   
 
The following chapter estimates the cumulative probability of initiating CPT after 
HIV diagnosis/birth, time from HIV diagnosis/birth to, and risk factors for, CPT 
initiation, and CPT use while in care, in Uganda and Tanzania and discusses the 
study findings.
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Table 3.8 Comparison of WHO criteria to prescribe CPT with those reported by seven Tanzanian health care workers 
Age-group WHO guidelines Tanzanian health care workers 
HIV-exposed or 
HIV-infected 
infants 
All infants until 
infection is ruled out 
All, irrespective of clinical status (all 7 health care workers) 
Children (1– 5 
years) 
WHO stage II & above 
or 
WHO I & CD4 <25% 
All, irrespective of clinical status (5 health care workers), or based on an unspecified weight (1 
health care worker), or those with a CD4 count below 350 cells (1 health care worker) 
Children (5 – 
18 years) 
WHO stage II & above 
or 
WHO I & CD4 <25% 
All, irrespective of clinical status (3 health care workers), or based on CD4 cell count below 350 (2 
health care workers), or with a CD4 percentage below 15% (1 health care workers), or with WHO 
stage 3 or 4 and unspecified body weight (1 health care worker) 
Adults WHO III & above 
or 
WHO II & CD4 <350 
cells 
All patients on ART, irrespective of clinical status (1 health care worker), or WHO stage 3 or CD4 
below 350 cells/below 500 cells (3 health care workers/1 health care workers), or WHO stage 2 (1 
health care worker), or unspecified CD4 count or WHO stage (1 health care workers)   
All patients not yet on ART, irrespective of clinical status (2 health care workers), or in WHO stage 
3 or with CD4 count below 350 cell (3 health care workers), or WHO stage 3 or CD4 count below 
200 cells (1 health care worker), or WHO stage 2(1 health care worker) 
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 Use of Cotrimoxazole Preventive Chapter 4
Therapy in Uganda and Tanzania 
 
This chapter presents the results of the study I undertook to estimate access to 
Cotrimoxazole Preventive Therapy (CPT).  The study used data from diagnostic, 
exposed-infant and pre-ART registers and patient records to estimate time from HIV 
diagnosis/birth to CPT initiation among newly-diagnosed/-exposed patients, and 
time spent on CPT.  The study also compares these derived data with data on CPT 
use in official monitoring and evaluation reports.  
 
4.1 Initiating CPT after HIV diagnosis 
In the 4 health centres in Uganda, 429 people, aged 1 month to 70 years, were 
diagnosed during the period January to March 2009.  During the period January to 
September 2009, 681 patients, aged <1 month – 74 years, were enrolled in the pre-
ART registers, of whom 243 were diagnosed January - March 09 (Table 4.1). 
 
On matching details of these 243 patients against the diagnostic register, 205 
matched (108 perfectly and 97 imperfectly).   The records for the remaining 38 
individuals could not be matched and these patients were assumed to have 
transferred-in unofficially.  Therefore, by September 2009, 205 of the 429 (48%) 
patients who were diagnosed with HIV during January – March 2009 were 
estimated to have initiated CPT.   Males accounted for 47% of initiations, and the 
median age of those initiating CPT was 5 years (IQR 1 – 18 years).  The paediatric 
clinic accounted for 77% of initiations. 
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Table 4.1 Numbers enrolling in the pre-ART register between January – 
September 2009 in 4 health centres in Uganda, by study eligibility status 
Study eligibility status Number of patients  
Total on pre-ART register  681 
    Diagnosed January – March 2009 
    Not diagnosed January – March 2009 
    HIV diagnosis date not recorded 
 243 
365 
  73 
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The cumulative probability of CPT initiation was 26% (95% CI 22 – 30%), 33% (29 
– 38%), 39% (35 – 44%), and 45% (40% - 49%) on the same day, within 2 days, 
1 week and 1 month of diagnosis, respectively (Figure 4.1).  The hazard of CPT 
initiation was no different among females compared to males (p=0.61), but differed 
by age and clinic (Table 4.2) (Figures 4.2 and 4.3).  Within one month of 
diagnosis/birth, the most notable difference in initiation was by clinic.  The hazard 
of CPT initiation in the combined rural clinics was significantly lower than that of the 
other settings (HR 0.42, CI 0.22– 0.79 compared to the peri-urban hospital).  When 
examining the rural clinics individually, the hazard of CPT initiation was lower in 
both, (rural clinic number 1, HR 0.55, 0.23 – 1.31, and rural clinic number 2, HR 
0.35, 0.15 – 0.78).  Compared to children < 3 years, the hazard of CPT initiation 
was  higher  among  patients  aged  ≥  3  years  (HR  1.32,  CI  1.00  – 1.75).  After 
adjustments for sex and age, the effect of these variables remained virtually 
unchanged (Table 4.2).    There was no evidence of any interaction between sex 
and age (p=0.97). 
 
In the 4 health centres in Tanzania, 492 people, aged 1 month to 70 years, were 
diagnosed during the period January to March 2009.  During the period January to 
September 2009, 429 patients, aged <1 month – 83 years, were enrolled in the 
pre-ART registers, of whom 402 were diagnosed January – March 2009 (Table 4.3). 
 
On matching details of these 402 patients against the diagnostic register, 294 
matched (167 perfectly and 127 imperfectly).   The records for the remaining 108 
individuals could not be matched and these patients were assumed to have 
transferred-in unofficially.  Therefore, by September 2009, 294 of the 492 (60%) 
patients who were diagnosed with HIV during January – March 2009 were  
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Figure 4.1 Cumulative probability of initiating CPT between January - September 
2009 after HIV diagnosis/birth in four health centres in Uganda 
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Table 4.2 Number diagnosed with HIV/HIV-exposed initiating CPT and factors associated with CPT initiation after HIV diagnosis/birth in 
four health centres in Uganda, January – September 2009 
Variable Diagnosed/ 
exposed 
(n=429, %) 
Initiated CPT 
(n=205) 
Hazard ratio p-value Adjusted hazard 
ratio 
p-value 
Sex 
  Male 
  Female 
 
203  (47%) 
226  (53%) 
 
99 
106 
 
1 
0.93 (0.71 - 1.22) 
p=0.61  
1 
0.89 (0.67 – 1.17) 
p=0.40 
Age        
0 - < 3yrs  
≥3yrs 
Missing 
207 (49%) 
219 (51%) 
3 
85 
120 
1 
1.32 (1.00 -1.75) 
P=0.04 1 
1.35 (1.02 – 1.80) 
 
P=0.03 
Clinic       
 Adult hospital 
 Paediatric centre 
 Rural clinics 
 66 (15%) 
310 (72%) 
 53 (12%) 
35 
157 
13 
1 
1.05 (0.73 – 1.52) 
0.42 (0.22 – 0.79) 
p<0.01  -  - 
 
*notes: the model was adjusted for sex and age.
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Figure 4.2 Cumulative probability of initiating CPT after HIV diagnosis/birth, by 
age, in four health centres in Uganda 
Figure 4.3 Cumulative probability of initiating CPT after diagnosis/birth, by 
clinic, in four health centres in Uganda 
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Table 4.3 Numbers enrolling in pre-ART register between January – September 
2009 in four health centres in Tanzania, by study eligibility status 
Numbers on pre-ART register   
Total number on pre-ART register  429 
  Diagnosed January – March 2009 
  Later found not diagnosed January – March 2009 
 402 
  27 
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estimated to have initiated CPT.   Males accounted for 32% of initiations, and the 
median age of those initiating CPT was 32.5 years (IQR 26 – 40 years).  The large 
MoH hospital accounted for 43% of initiations. 
 
The cumulative probability of CPT initiation was 40% (95% CI 36 - 45%), 50% (46 
– 55%), 55% (50 – 59%), and 59% (55% - 63%) on the same day, within 2 days, 
1 week and 1 month of diagnosis, respectively (Figure 4.4).  The hazard of CPT 
initiation was no different among females compared to males (p=0.24), or among 
patients of different age (p=0.23) (Table 4.4).  The hazard of CPT initiation in the 
rural clinic, where all of 74 patients initiated CPT, was significantly higher than that 
of the other settings (HR 2.71, CI 2.01– 3.67 compared to the large MoH hospital) 
(Figure 4.5).  After stratifying the models by clinic, the effects of sex and age 
remained virtually unchanged (Table 4.4).  There was no evidence of any 
interaction between sex and age (p=0.97). 
 
The maximum estimate of the proportion initiating CPT was 259/429 (60%) and 
402/492 (82%) of diagnosed individuals in Uganda and Tanzania, respectively.  In 
Uganda, this comprised the patients in the minimum estimate plus 38 patients 
assumed to have transferred-out and 16 patients matched from the 73 with no date 
of diagnosis recorded in the pre-ART register.  In Tanzania, this comprised the 
patients in the minimum estimate plus 108 patients assumed to have transferred-
out.  Of the 681 and 429 patients enrolling in the pre-ART register in Uganda and 
Tanzania, respectively, the date of enrolment into care and the date of CPT 
initiation were available in the pre-ART register for 282 patients in Uganda, and 168 
patients in Tanzania.  For these patients, the median number of days between 
enrolment into the pre-ART register and CPT initiation was 0 (IQR 0 – 1) days in  
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Figure 4.4 - Cumulative probability of initiating CPT between January - 
September 2009 in four health centres in Tanzania 
  
 140 
 
Table 4.4 Number diagnosed with HIV/HIV-exposed initiating CPT and factors associated with CPT initiation after HIV diagnosis/birth in 
four health centres in Tanzania, January – September 2009 
Variable Diagnosed/ exposed 
(%) (n=476) 
Enrolled 
(n=289) 
Hazard ratio p-value Stratified hazard 
ratio 
p-value 
Sex 
  Male 
  Female 
  Missing 
 
133 (29%) 
331 (71%) 
12 
 
95 
194 
 
 
1 
0.86 (0.67 - 1.10) 
  p=0.24  
1 
0.87 (0.67 – 1.13) 
p=0.31 
Age (median, IQR) 32 (25 – 40) 33 (26 – 40) 1.01 (0.99 – 1.01) p=0.23 1.00 (0.99 – 1.01) p=0.41 
  0 – <15 years 41 (9%) 28     
  15 - < 30 years 138 (31%) 76     
  30 - < 45 years 182 (41%) 130     
  45 and above 78 (18%) 55     
  Missing  37 -     
Clinic 
  MoH Hospital 
  Rural dispensary   
  Faith-based centre 
  Rural clinic 
 
218 (46%) 
62 (13%) 
122 (26%) 
74 (16%) 
 
121 
29 
65 
74 
 
1 
1.07 (0.71 – 1.60) 
1.17 (0.87 – 1.58) 
2.71 (2.01 – 3.67) 
p<0.01  -  -  
Notes: Age from the pre-ART register was assigned to 12 CPT initiators who had missing data at diagnosis.  Adjusted results are stratified by clinic. 
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Figure 4.5 Cumulative probability of initiating CPT after diagnosis/birth, by 
clinic, in four health centres in Tanzania 
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Uganda and 43 (IQR 0 – 339) days in Tanzania, suggesting that the date of 
enrolment in Uganda, but not in Tanzania, was a suitable proxy for date of CPT 
initiation.   
4.1.1 Comparison of CPT initiators with monitoring and evaluation 
reports 
In Uganda, data from monthly or quarterly monitoring reports were only available 
for the 3 months from January – March 2009 from all 4 clinics.  The reports 
provided data on the number (by sex) of patients newly diagnosed with HIV or 
infants born to HIV-positive mothers (n=370) and the number (by sex) of patients 
newly starting CPT (n=174) (Table 4.5).  These monitoring report data suggest that 
47% of diagnosed/exposed patients initiated CPT in the same period.  According to 
the current study’s estimates, 193 of the 429 (45%) patients diagnosed with 
HIV/identified as HIV-exposed January – March 2009 initiated CPT during the same 
period (Table 4.5).  The overall proportions are, therefore, almost identical, 
although the proportions reported to have initiated CPT in both the rural clinics 
(10% and 8%) and in the paediatric hospital (28%) are far lower than the study 
estimates (32%, 15% and 50%, respectively).  Yet, in the peri-urban clinic, more 
patients were reported to have initiated CPT (101) than were diagnosed/born (64) 
during the same time-period (Table 4.5).  It is possible that the number initiating 
CPT included some patients who initiated CPT after a delay having been 
diagnosed/born in earlier months, although given the median time from 
diagnosis/birth to CPT initiation was 0 days (range 0 – 1 day) in Uganda, this 
number is likely to be low.  Moreover, the total numbers HIV-diagnosed/exposed 
and numbers initiated CPT in the monitoring reports are lower than those estimated 
by this study.   
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Table 4.5 Number of patients newly identified as HIV-exposed or HIV-infected and number initiating CPT January - March 2009 in four 
health centres in Uganda, by monitoring reports and by study estimates 
                                                           Monitoring reports               Study estimates 
 Males Females Total Males Females Total 
Number diagnosed HIV-infected 
  Rural clinic 1  
  Rural clinic 2 
  Paediatric clinic 
  Peri-urban hospital 
 
   6 
  15 
126 
  25 
 
  15 
  24 
120 
  39 
 
  21 
  39 
246 
  64 
 
   7 
  15 
159 
  22 
 
  12 
  19 
151 
  44 
 
  19 
  34 
310 
  66 
  Total 172 198 370 203 226 429 
 
Number initiating CPT  
  Rural clinic 1  
  Rural clinic 2 
  Paediatric clinic 
  Peri-urban hospital 
 
 
  0 
  1 
32 
23 
 
 
   2 
   2 
 36 
 78 
 
 
   2 
   3 
  68 
101 
 
 
   1 
   2 
 79 
   9 
 
 
  5 
  3 
 76 
 18 
 
 
   6 
   5 
155 
  27 
  Total 56 118 174  91 102 193 
Total proportion initiating CPT - - 47% - - 45% 
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While data from monitoring reports were available from three of the four health 
centres in Tanzania, data were not available for the same January – March 2009 
period in any clinic and therefore comparing derived data with reported data in 
Tanzania was not possible.   
 
4.2 CPT use among patients in care 
In Uganda, among HIV-diagnosed/exposed patients for whom longitudinal records 
were retrieved (n=223, 20 files not found or patients were found to have 
transferred-in), 210 started CPT, of whom 175 had information available with which 
to calculate the proportion of time interrupting CPT.  Of these 175 patients on CPT, 
the majority (99, 58%) were female, and the median age was 8 (IQR 3 – 23) years 
(Table 4.6).  The majority (121, 69%) of patients were enrolled in the paediatric 
health centre and the majority of patients (153, 91%) were WHO stage I or II at 
enrolment into care.  The median CD4 cell count at enrolment into care was 350 
(IQR 203  - 505) cells/mm³ (though 137 were missing).   Sixty-nine (39%) patients 
on CPT initiated ART while in care.   
 
Of the 175 patients initiated on CPT, 118 (67%) had at least one day of interrupted 
CPT, with 21 (12%), 30 (17%), 35(20%) and 32 (18%) patients having 1 - 30 
days, 31 – 90 days, 91 – 180 days, and > 180 days without CPT, respectively.  The 
overall proportion of time interrupting CPT was 0.17/person year at risk (CI 0.17 - 
0.17).   The proportion of time interrupting CPT, by patient characteristics, is shown 
in Table 4.6.  This proportion was notably lower for patients aged 0 - 2 years (0.09, 
0.09 – 0.10) compared to those aged 2 - < 15 years (0.16, 0.16 – 0.17), 15 - < 35 
years (0.22, 0.21 – 0.22)  and  ≥35  years  (0.20,  0.19  – 0.21). 
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Table 4.6 Characteristics of patients prescribed CPT and proportion of time 
interrupting CPT, in four health centres in Uganda, January 2009 – June 2011 
Characteristics Patients 
on CPT 
(n=175) 
Person 
years 
at risk 
Person 
years 
interrupted 
Proportion of time 
interrupted 
Sex  
   Males 
   Females 
   Missing 
 
72 (42%) 
99 (58%) 
4 
 
101.3 
134.9 
 
18.6 
21.5 
 
0.18 (0.18 – 0.19) 
0.16 (0.15 – 0.16) 
Age, median (IQR) 
   0 – <2yrs 
   2 - <15yrs 
   15 - <35yrs 
   ≥35yrs 
   Missing 
8 (3 – 23) 
16 (9%) 
97 (56%) 
43 (25%) 
16 (9%) 
3 
 
26.3 
148.0 
46.3 
19.7 
 
2.6 
24.2 
10.0 
4.0 
 
0.09 (0.09 – 0.10) 
0.16 (0.16 – 0.17) 
0.22 (0.21 – 0.22) 
0.20 (0.19 – 0.21) 
Clinic 
Peri-urban Hospital 
Paediatric Hospital 
Rural centres 
 
40 (23%) 
121 (69%) 
14 (8%) 
 
44.3 
183.4 
13.9 
 
8.6 
28.9 
3.4 
 
0.19 (0.19 – 0.20) 
0.16 (0.15 – 0.16) 
0.24 (0.23 – 0.26) 
WHO stage 
   I 
   II 
   III or IV 
   Missing 
 
104 (62%) 
49 (29%) 
14 (8%) 
8 
 
180.0 
47.9 
12.2 
 
28.9  
9.4 
2.2 
 
0.16 (0.16 – 0.16) 
0.20 (0.19 – 0.20) 
0.18 (0.17 – 0.19) 
     
Note: Figures are numbers and percentages as indicated.  Percentages do not include 
missing.  WHO stages III and IV have been combined due to low numbers. 
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There was evidence of a difference in CPT interruption proportion by sex, age, clinic 
and WHO stage (Table 4.7).  Females (IRR 0.79, 0.77 – 0.82) spent less time  
interrupting CPT than males, while patients aged 15 - < 35 years (IRR 1.33, 1.28 – 
1.38)  and  ≥  35  years  (IRR  1.38,  1.31  – 1.46) spent more time interrupting than 
those aged 2 - < 15 years.  There was also significant differences in interruptions 
by clinic with patients in the paediatric clinic spending less time (IRR 0.82, 0.79 – 
0.86) and those in the rural clinics spending more time interrupting (IRR 1.26, 1.18 
– 1.34) than those in the peri-urban hospital.  Patients in WHO stage II spent more 
time (IRR 1.12, 1.08 – 1.17) and those in stage III/IV somewhat less time 
interrupting (IRR 0.93, 0.86 – 1.00) compared to those in stage I.  After 
adjustments for sex, age and WHO stage, the effect of the other variables remained 
unchanged.    
 
There was evidence of interactions between sex and age (p<0.01), sex and WHO 
stage (p<0.01) and age and WHO stage (p<0.01) (Table 4.8).  Among patients age 
2 - < 15 years, the proportion of time interrupting CPT among males was higher 
than  among  females  whereas  for  those  aged  ≥35  years,  the  proportion  among  
males was lower than among females.  Among patients in WHO stages III/IV, the 
proportion of time interrupting CPT was lower among males compared to females 
but higher for those in stages I and II.   Among patients aged 2 - < 15 years, the 
proportion of time interrupting CPT was much lower for those at stage II (compared 
to stages I and III/IV) but similar, or higher, for those in the older age groups.    
 
In Tanzania, 325 longitudinal records were retrieved (77 patients were found to 
have transferred in or their files were not found).  Of these 325, 223 started CPT, of 
whom 194 had information available on which to calculate the proportion of time  
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Table 4.7 Factors associated with time interrupting CPT, in four health centres in Uganda, January 2009 – June 2011 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*note: the multivariate model is adjusted for sex, age and WHO stage
Characteristics Incidence rate ratio 
(95% CI) 
P-value Adjusted incidence 
rate ratios (95% CI)* 
P value 
Sex  
   Males 
   Females 
 
1 
0.79 (0.77 – 0.82) 
p<0.01 
 
 
  
1 
0.74 (0.72 – 0.77) 
 p<0.01 
Age     
   2 - <15yrs 
   15 - <35yrs 
   ≥35yrs 
 
1 
1.33 (1.28 – 1.38) 
1.38 (1.31 – 1.46) 
p<0.01  
1 
1.48 (1.42 – 1.54) 
1.68 (1.58 – 1.80) 
p<0.01 
Clinic 
   Peri-urban Hospital 
   Paediatric Hospital 
   Rural health centres 
 
1 
0.82 (0.79 – 0.86) 
1.26 (1.18 – 1.34) 
p<0.01 - 
 
 
 
WHO stage 
  I 
  II 
  III or IV 
 
1 
1.12 (1.08 – 1.17) 
0.93 (0.86 – 1.00) 
p<0.01  
1 
0.95 (0.91 – 1.00) 
0.65 (0.60 – 0.71) 
p<0.01 
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Table 4.8 The proportion of time interrupting CPT (Incidence rates, CI) for variables with significant interactions in four clinics in Uganda 
 Incidence rates (CI) 
 Sex WHO stage 
Age Group Males Females Stage I Stage II Stage III/IV 
  2 - <15yrs 0.20 (0.20 – 0.21) 0.13 (0.12 – 0.13) 0.17 (0.17 – 0.17) 0.09 (0.09 -0.10) 0.37 (0.31 - 0.44) 
  15- <35yrs 0.22 (0.21 – 0.23) 0.21 (0.20 – 0.22) 0.21 (0.20 - 0.22) 0.25 (0.23 - 0.26) 0.12 (0.11 - 0.14) 
  >=35yrs 0.15 (0.13 – 0.17) 0.25 (0.24 – 0.27) 0.15 (0.13 - 0.17) 0.29 (0.27 - 0.31) 0.17 (0.15 - 0.19) 
WHO stage      
  Stage I 0.21 (0.20 – 0.22) 0.15 (0.14 – 0.15) - - - 
  Stage II 0.22 (0.21 – 0.23) 0.19 (0.18 – 0.20) - - - 
  Stage III/IV 0.08 (0.07 – 0.09) 0.23 (0.21 – 0.25) - - - 
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interrupting CPT.  Of these 194 patients, the majority (117, 64%) were female, and 
the median age was 36 (IQR 27 – 42) years (Table 4.9).  The majority (104, 54%) 
of patients were enrolled in the MoH peri-urban hospital and the majority (121, 
62%) were WHO stage I or II.  CD4 counts were available for 81 patients at their 
first appointment, for whom the median was 188 (IQR 112 - 353) cells/mm³.   Fifty-
nine (30%) patients on CPT initiated ART while in care.      
 
Of the 194 patients initiated on CPT, 114 (59%) had at least one day of interrupted 
CPT, with 26 (13%), 30 (15%), 16 (8%) and 42 (22%) patients having 1 -30 days, 
31 – 90 days, 91 – 180 days, and > 180 days without CPT, respectively.  The 
overall proportion of time interrupting CPT was 0.20/person year at risk (CI 0.20 - 
0.21).   The proportion of time interrupting CPT, by patient characteristics, is shown 
in Table 4.9.   
 
There was evidence of a difference in the proportion of time interrupting CPT by 
sex, age, clinic and WHO stage (Table 4.10).  Females spent more time interrupting 
CPT than males (IRR 1.31, 1.27 – 1.35) as did patients aged 15 – < 30 years and 
30 - < 45 years compared to patients < 15 years (IRR 1.80, 1.69 – 1.91, and 1.35, 
1.28 – 1.43,  respectively).    Patients  aged  ≥  45  years  spent  less  time  interrupting  
than the younger age groups (IRR 0.64, 0.60 – 0.69 compared to < 15 years).  
Compared to patients in the MoH hospital, patients in the rural dispensary (IRR 
2.14, 2.01 – 2.27), faith-based hospital and (IRR 3.46, 3.35 – 3.57) and rural clinic 
(IRR 1.25, 1.18 – 1.32) spent more time interrupting CPT.  Those enrolled into care 
at WHO stage II (IRR 0.60, 0.58 - 0.63), III (IRR 0.68, 0.65 – 0.70) or IV (IRR 
0.63, 0.57 – 0.70) spent less time interrupting CPT compared to those enrolling at 
stage I.   
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Table 4.9 Characteristics of patients prescribed CPT and proportion of time 
interrupting CPT, in four health centres in Tanzania, January 2009 – June 2011 
 
Characteristics Number on 
CPT (194) 
Person 
years at 
risk 
Person 
years 
interrupted 
Proportion of time 
interrupted 
Sex  
   Males 
   Females 
  Missing 
 
66 (36%) 
117 (64%) 
11 
 
79.7 
155.8 
 
13.4 
34.2  
 
0.17 (0.16 – 0.17) 
0.22 (0.22 - 0.22) 
Age, median (IQR) 
   0 – <15yrs 
   15 - <30yrs 
   30 - <45yrs 
  ≥45yrs 
   Missing 
36 (27-42) 
17 (9%) 
40 (21%) 
96 (51%) 
36 (19%) 
5 
 
22.2 
47.2 
123.3 
51.1 
 
3.6 
13.8 
27.1 
5.3 
 
0.16 (0.16 – 0.17) 
0.29 (0.28 – 0.30) 
0.22 (0.21 – 0.22) 
0.10 (0.10 – 0.11) 
Clinic 
 MoH Hospital 
 Rural dispensary 
 Faith-based Hospital 
 Rural clinic 
 
104 (54%) 
12 (6%) 
53 (27%) 
25 (13%) 
 
140.3 
13.5 
66.7 
30.2 
 
16.4 
3.4 
27 
4.4 
 
0.12 (0.11 – 0.12) 
0.25 (0.24 –  0.26) 
0.40 (0.39 – 0.41) 
0.15 (0.14 – 0.15) 
WHO stage 
   I 
   II 
   III 
   IV 
  Missing 
 
43 (22%) 
78 (40%) 
60 (31%) 
12 (6%) 
1 
 
47.5 
109.7 
87.6 
5.9 
 
13.7  
19.2 
17.2 
1.1 
 
0.29 (0.28 - 0.30) 
0.17 (0.17 - 0.18) 
0.20 (0.19 - 0.20) 
0.18 (0.17 - 0.20) 
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Table 4.10 Factors associated with time interrupting CPT, in four health centres in Tanzania, January 2009 – June 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
*note: model is adjusted for all variables in the table.   
 
Characteristics Incidence rate ratio 
(95% CI) 
p-value Adjusted incidence rate 
ratio (95% CI)* 
p-value 
Sex  
   Males 
   Females 
 
1 
1.31 (1.27 – 1.35) 
p<0.01  
1 
0.89 (0.85 – 0.92) 
p<0.01 
Age 
   0 – <15yrs 
   15 - <30yrs 
   30 - <45yrs 
   ≥45yrs 
 
1 
1.80 (1.69 – 1.91) 
1.35 (1.28 – 1.43) 
0.64 (0.60 – 0.69) 
p<0.01  
1 
1.40 (1.31 – 1.49) 
1.50 (1.41 – 1.59) 
0.79 (0.73 – 0.85) 
p<0.01 
Clinic 
   MoH Hospital 
   Rural dispensary 
   Faith-based Hospital 
   Rural clinic 
 
1 
2.14 (2.01 – 2.27) 
3.46 (3.35 – 3.57) 
1.25 (1.18 – 1.32) 
p<0.01  
1 
2.91 (2.73 – 3.10) 
3.11 (3.00 – 3.23) 
1.08 (1.02 – 1.14) 
p<0.01 
WHO stage  
   I 
   II 
   III 
   IV 
 
1 
0.60 (0.58 – 0.63) 
0.68 (0.65 – 0.70) 
0.63 (0.57 – 0.70) 
p<0.01  
1 
0.69 (0.66 – 0.71) 
0.58 (0.56 – 0.61) 
0.43 (0.39 – 0.48) 
p<0.01 
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After adjustments for all other variables, the effects of age, clinic and WHO stage  
remained virtually unchanged.  However, the IRR for females compared to males 
changed direction, with the proportion of time interrupting CPT among females 
becoming lower (aIRR 0.89, 0.85 – 0.92).  This change in direction is likely due to 
the younger age of the females compared to the males (32 vs 40 years) and a 
strong interaction between age and sex (p<0.01).  Interruptions among males and 
females were similar in all age groups but were much higher for females (0.30, 0.29 
– 0.31) compared to males (0.00, 0.00 – 0.00) in the 15-30 year age category.   
 
There was evidence of further interactions between WHO stage and sex (p<0.01), 
clinic and sex (p<0.01), age and WHO stage (p<0.01), clinic and WHO stage 
(p<0.01) and age and clinic (p<0.01) (Table 4.11).  Among individuals in WHO 
stage IV, the proportion of time interrupting CPT among males was much lower 
than among females, but was more similar for all other WHO stages.  Among 
individuals in the rural dispensary, the proportion of time interrupting CPT was 
lower among males than among females.  Among patients in WHO stage III/IV, the 
proportion of time interrupting CPT was much lower among those aged 0 – 15 
years, 15 - < 30 years and ≥ 45 years compared to those aged 30 - <45.  Among 
patients in all clinics, the proportion of time interrupting CPT was higher among 
patients in WHO stage I, II or III compared to patients in stage IV, though only 
slightly higher for those in WHO stage II in the rural clinic.  Among patients in the 
faith-based hospital, the proportion of time interrupting CPT was far higher among 
patients aged 15 - < 30 years  than among patients in the other age categories.   
 
No data were reported in monitoring and evaluation reports, either in Uganda or 
Tanzania, on the proportion of patients initiated on CPT who remain on CPT over 
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Table 4.11 The proportion of time interrupting CPT (Incidence rates, CI) for variables with significant interactions in four clinics in Tanzania 
 Incidence rates (CI) 
 Sex WHO stage Clinic 
Age Group Males Females Stage I Stage II Stage III Stage IV MoH 
hospital 
Rural 
dispensary 
Faith-based 
hospital 
Rural clinic 
0 – 15yrs 0.16  
(0.15 - 0.17) 
0.16  
(0.15 - 0.18) 
0.27  
(0.25 - 0.29) 
0.13  
(0.12 - 0.14) 
0.09  
(0.07 - 0.10) 
0.00  
(0.00 - 0.00)  
0.13  
(0.12 - 0.14) 
0.25  
(0.22 - 0.29) 
0.29  
(0.26 - 0.31) 
0.00  
(0.00 - 0.02) 
15 - <30yrs 0.00  
(0.00 - 0.00) 
0.30  
(0.29 - 0.31) 
0.46  
(0.44 - 0.48) 
0.12  
(0.12 - 0.13) 
0.28  
(0.26 - 0.30) 
0.00  
(0.00 - 0.00) 
0.06  
(0.05 - 0.07) 
0.03  
(0.00 - 0.08) 
0.57  
(0.55 - 0.59) 
0.04  
(0.03 - 0.05) 
30- <45yrs 0.22  
(0.21 - 0.22) 
0.22  
(0.21 - 0.22) 
0.20  
(0.19 - 0.21) 
0.22  
(0.22 - 0.23) 
0.22  
(0.21 - 0.22) 
0.26  
(0.23 - 0.28) 
0.17  
(0.16 - 0.17) 
0.44  
(0.41 - 0.47) 
0.31  
(0.30 - 0.32) 
0.17  
(0.16 - 0.18) 
≥45yrs 0.11 
(0.10 - 0.12) 
0.10  
(0.09 - 0.10) 
0.19  
(0.17 - 0.20) 
0.10  
(0.09 - 0.11) 
0.10  
(0.09 - 0.11) 
0.00  
(0.00 - 0.00)  
0.06  
(0.06 - 0.07) 
0.05  
(0.03 - 0.06) 
0.32  
(0.30 - 0.34) 
0.14  
(0.12 - 0.16) 
WHO stage           
Stage I 0.19  
(0.18 - 0.20) 
0.34  
(0.33 - 0.35) 
- - -  - - - - 
Stage II 0.13  
(0.12 - 0.13) 
0.17 
(0.17 - 0.18) 
- - -  - - - - 
Stage III 0.19  
(0.18 - 0.20) 
0.20  
(0.19 - 0.20) 
- - -  - - - - 
Stage IV 0.00  
(0.00 - 0.00) 
0.28   
(0.25 - 0.30) 
        
Clinic           
MoH 
hospital 
0.15  
(0.14 - 0.15) 
0.10  
(0.10 -0.10) 
0.13  
(0.12 - 0.14) 
0.11  
(0.11 - 0.12) 
0.13  
(0.12 - 0.13) 
0.00  
(0.00 - 0.00) 
- - - - 
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 Incidence rates (CI) 
 Sex WHO stage Clinic 
Rural 
dispensary 
0.17  
(0.15 - 0.19) 
0.37  
(0.35 - 0.40) 
0.00  
(0.00 - 0.00) 
0.35  
(0.32 - 0.38) 
0.26  
(0.24 - 0.28) 
0.00  
(0.00 - 0.00) 
- - - - 
Faith-
based 
hospital 
0.29 
(0.27 - 0.30) 
0.42  
(0.41 - 0.43) 
0.65  
(0.63 - 0.68) 
0.23  
(0.22 - 0.25) 
0.35  
(0.34 - 0.36) 
0.00  
(0.00 - 0.00) 
- - - - 
Rural clinic 0.08  
(0.07 - 0.09) 
0.18 
 (0.17 - 0.19) 
0.15  
(0.13 - 0.16) 
0.26  
(0.24 - 0.28) 
0.04  
(0.03 - 0.04) 
0.00  
(0.00 - 0.00) 
- - - - 
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time, or on CPT interruptions among those on CPT.  It was therefore not possible to 
compare the clinic derived data on use of CPT while in care with reported data.   
4.2.1 Barriers to adequate CPT use while in care 
Data from the Ugandan monthly monitoring reports on CTX stock-outs reported 17 
episodes of stock-outs during the 29 month period from January 2009 to the end of 
May 2011.  For 14 months (48%) at least one clinic was without any supply of CTX.  
For 3 (10%) months during the period, both clinics providing CTX stock-out 
monitoring data had periods without any CTX.   Stock-outs of CTX increased over 
the observed period in the following ways: 
x Frequency: in 2009, stock-outs occurred during 4 months (33%) of the year, 
6 months (50%) of 2010, and during 4 (80%) of the first 5 months of 2011, 
x Number of clinics affected: in 2009, stock-outs affected one facility in any 
one month, while in January 2010 stock-outs affected both clinics and in 
March and April 2011 stock-outs affected both health centres, and 
x Duration: 2 (50%) stock-outs in 2009 lasted more than 1 week, while 6 
(100%) lasted for more than 1 week in 2011 (of which one clinic had stock-
outs of CTX in all of the first four months of the year).   
 
No information on CTX stock-outs was available from monitoring and evaluation 
reports in Tanzania. 
From the patient data, among the 2499 appointments attended by those on CPT in 
Uganda, information on CPT stock-outs was completed at 104 (4%) appointments.  
Of these appointments, 17 (16%) had no CPT in stock.   The number of patients 
who, on average, were prescribed a shortfall of tablets at appointments was 36 
(27%), with a median of 1.3-day tablet surplus (IQR 0.1-day shortfall – 4-day 
surplus) prescribed per appointment.  During the months in which the monitoring 
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reports cited stock-outs of CTX, the following proportion of patients were prescribed 
a shortfall of tablets:  January, June, October and December 2009 (4%, 10%, 26% 
and 35%); January, March, June, September, October, December 2010 (18%, 39%, 
37%, 0%, 24% and 35%); and January, February, March, April 2011 (15%, 14%, 
25% and 40%).  The proportion prescribed a shortfall during months with cited 
stock-outs was higher than the 27% who on average were prescribed a shortfall in 
only 5 of the 14 months.  The number of patients who, on average, attended 
appointments late was 75 (56%), with a median of 1 (IQR 1 – 7) days late per 
appointment.   
 
Information on CPT stock-outs was not completed at any appointment in Tanzania.  
The number of pills or number of days, weeks or months-worth prescribed was 
never recorded, making it impossible to calculate whether patients were prescribed 
a shortfall of pills until their next scheduled appointment.  Of the 192 patients on 
CPT, the number of patients who, on average, attended appointments late was 
107(64%), with a median of 1.7 days late (IQR 1 day early – 9.1 days late) per 
appointment.   
4.3 Discussion 
This study provides valuable insight into the rate of CPT initiation among newly 
diagnosed patients in two LMIC in sub-Saharan Africa, yet has highlighted the 
difficulties in assessing this rate in routine practice.  Few studies have reported such 
information previously, and those that did focused on HIV-exposed infants and HIV-
TB co-infected patients.  Only three previously reported studies have reported CPT 
coverage data on HIV-infected adults and only one has reported such data among 
HIV-infected children.  This study adds to the body of knowledge by estimating CPT 
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coverage in Uganda and Tanzania.  Moreover, this study provides important 
information, not previously described elsewhere, on the amount of time in care  
spent on CPT in eight clinics in these two countries.  
 
Overall, the cumulative probability of initiating CPT within 1 month of diagnosis was 
similar in Uganda (45%) and Tanzania (59%).  The slightly higher likelihood of CPT 
initiation in Tanzania might be explained by the inclusion in Uganda of a large 
health centre specialising in paediatric care.  In Uganda, patients 3 years or older 
were more likely (RR 1.35) to initiate CPT compared to children less than 3 years of 
age and increased CPT initiation in Tanzania may be due to the population being 
older.  Furthermore, Tanzanian patients had more advanced disease at enrolment 
into care than Ugandan patients (12% of Ugandans were WHO stage III/IV 
compared to 37% of Tanzanians).  Sicker patients may be more motivated to enrol 
for care than less sick patients and this may partly explain the increased proportion 
initiating in Tanzania compared to Uganda, however information on staging or CD4 
count was not available at diagnosis and was not possible to examine this effect.  
The differences in proportions initiating CPT in the rural clinics compared to large 
hospitals in both countries (lower rate in Uganda and higher rate in Tanzania) 
suggests that initiation practices in smaller clinics may be dependent on other 
unmeasured confounders rather than simply the type or size of clinic.   
 
The cumulative probabilities of initiating CPT in Uganda and Tanzania fall within the 
wide range of proportions (36% - 97%) reported in the literature for adults, 
mothers in antenatal care, children and infants [211-214].   The higher proportions 
of patients initiating CPT reported in some of these studies are likely explained by 
the different settings in which the studies were conducted: mobile health centres 
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which visited the community rather than in fixed health centres which require the 
patient to travel; and antenatal care clinics requiring no additional enrolment to 
initiate CPT.  The lowest proportion reported previously (36%) among infants, is in 
concordance with my findings that the rate of initiation among very young children 
is lower than among older patients.  Furthermore, my results of the cumulative 
probabilities of enrolling into care to initiate CPT are similar to the 52% of patients 
who returned for disease staging after diagnosis, summarised in a literature review 
[238].   
 
Overall, the proportions of time interrupting CPT were similar in Uganda 
(0.17/person year) and Tanzania (0.20/person year).  The lower proportion of time 
interrupting CPT among females, increased proportion among patients in clinics 
other than the main MoH hospital (with the exception of the large NGO-supported 
paediatric hospital) and increased proportions among older patients compared to 
those < 15 years are also consistent between both countries.  While few previously 
published data are available on the proportion of time with CPT interruptions while 
in care, evidence from the DART trial in adults and recent evidence from the 
ARROW trial in children suggests that, even among patients who are stable on ART, 
stopping CPT increases rates of hospitalisation or death [239] [240].  This highlights 
the importance of encouraging continuous access to CPT, particularly among males, 
in smaller/rural clinics and among older patients.   
 
This study, however, has several limitations.  Firstly, this study relied upon matching 
records of patients between two registers: HIV diagnosis/exposure and pre-ART 
care, as no unique patient identifier exists to link the two registers.  My results are, 
therefore, based on estimates, using perfect and imperfect matching, and should be 
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interpreted with caution.   This highlights the difficulty clinic staff and researchers 
have in assessing the proportion of diagnosed/exposed patients initiating CPT.  For 
example, while in Uganda, whether estimating the proportion accessing CPT in the 
three months after diagnosis using  this  study’s  methods  (45%) or by dividing the 
number of people who start CPT during the 3 month period with the number HIV-
diagnosed/-exposed during the same 3 month period (47%) from the monitoring 
report data, provided very similar proportions.  However, the use of the monitoring 
report data in this way is confusing.  The temptation is to use the two numbers to 
calculate a proportion started on CPT.  However, individual patients starting CPT are 
not necessarily those diagnosed during the same calendar period.  For example, in 
one of the Ugandan health centres, more patients started CPT (101) during the 
same quarter than were diagnosed with HIV (64), suggesting the inclusion of 
patients initiating CPT who were diagnosed in a different period or who transferred-
in.  In the absence of a unique identification number that the patient carries with 
them from diagnosis/birth to enrolment, tracking patients who enrol to initiate CPT 
will remain challenging.  Therefore, published estimates of the proportions of 
diagnosed patients initiating CPT should be interpreted in the context of a thorough 
understanding of how patients were matched and the calculations derived.   
 
Secondly, this study relied upon data routinely collected in busy diagnostic clinics 
and busy pre-ART and ART clinics.  There were many missing data, particularly 
relating to clinical stage at diagnosis, dates of CPT initiation within the enrolment 
register, WHO stage at enrolment, dates of scheduled and actual appointments, and 
number of days/week/months-worth of tablets or syrup prescribed.   This study 
demonstrated that a high proportion of patients enrolling for care were WHO stage 
I/II.  This is likely, to be an underestimate of WHO stage at diagnosis as it is 
 160 
 
possible that sicker patients died before enrolling into care.  It was not possible to 
calculate the information on shortfall tablet supply for one-quarter of all patients in 
care in Uganda, or for any patients in Tanzania.  When this information was not 
available but CTX was reported to have been prescribed, I assumed that an equal 
number of tablets were prescribed for the time interval until the next appointment.  
This is a generous assumption and it is likely that the rates of interruptions I report 
may be an underestimate.  Moreover, no relevant CPT data were available from the 
Tanzanian monitoring reports.  Yet, the MoHs use routinely collected data as the 
basis for programme funding decisions and for, in particular, drug supplies.  This 
study has, therefore, highlighted important gaps in data collection relating to CPT. 
 
Despite these limitations, this study has shown that the cumulative probability of  
initiating CPT remains strikingly low, particularly among very young children.  This 
study has also highlighted high proportions of time interrupting CPT while in care 
and that stock-outs of CTX continue to be a challenge.  Encouraging on-time 
appointment adherence may improve the proportion of time in care with adequate 
drug supply.  However, more complete data are needed on the number of days-
worth of tablets prescribed, and the number of times when CPT is dispensed in 
pharmacy with a shortfall in order to assess whether the problem is due to 
inadequate drug supply or poor on-time appointment attendance.  The proportion of 
patients prescribed a shortfall of tablets during the months in which monitoring 
reports cited stock-outs did not appear higher than the median proportion of 
patients prescribed shortfalls on average.  Moreover, it is likely that this study 
actually underestimates the proportion of time interrupting CPT.  I estimated CPT 
interruptions which occurred before the expiry date of the last prescription, yet 
some patients remained in care for many more appointments after the last known 
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CPT prescription date.  This study therefore assumes that there were no further 
prescriptions of CPT, however, the appointments without CPT may represent further 
interruptions due to stock-outs rather than early stopping of CPT.  Moreover, in 
countries with universal access to CPT policies, CPT should be provided for all 
diagnosed patients.  Yet, in Uganda and Tanzania, the majority of patients took up 
to 4 weeks to enrol for care, meaning that patients were missing drugs during that 
time.   Providing, for example, a one-month supply of CTX on day of diagnosis 
would allow patients who take up to 4 weeks to enrol into care the opportunity to 
have some CPT to cover the time between diagnosis and enrolment.  Further work 
is needed to assess whether the probability of enrolment into care can be improved 
if CPT were provided at diagnosis.  Initiating CPT at diagnosis might highlight the 
importance of immediate and continuous care to all patients diagnosed with HIV,  
which might encourage a greater proportion to return and enrol in care.   
 
Based on this work, it is recommended that monitoring reports be revised to reflect 
the importance of CPT.  Cohort reporting, similar to that used for patients on ART, 
may be a powerful, albeit labour-intensive, mechanism with which to do this.  In the 
same way as is in place for ART patients, data from routine patient appointments on 
CPT use could be entered into the pre-ART register at every appointment to be used 
to compile data for monitoring reports.   For example, pre-ART cohorts could be 
formed and indicators compiled on the proportion of patients initiated on CPT still in 
care and on CPT at 6, 12, 24 etc. months.  This will be useful to track retention in 
care among pre-ART patients.  A further indicator reporting the proportion of 
patients with good CPT adherence, with evidence needed to identify what level that 
should be set at, could also be gathered.  If such mechanisms are to be employed, 
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it is recommended that resources be put in place to minimise the additional burden 
on clinic staff while enabling accurate data capture.   
As more patients are initiated on CPT, particularly with universal access policies, and 
remain on CPT for their duration of time in care, ensuring continued access to CTX 
drugs becomes ever more important.  For pre-ART patients, CPT is one of the few 
interventions available as part of the care package.  As the greatest benefit of CPT 
might be among pre-ART patients, it is vital that better monitoring tools are 
developed to assess their ongoing access to CPT.   
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 Mental health Chapter 5
 
This chapter describes the background, aim, methods and results of a cross-
sectional study I undertook among HIV-infected patients accessing care in Uganda.  
The aim was to estimate the prevalence of common mental disorders (CMD), 
identify at-risk patients and examine the validity of three concise tools that can be 
used by HIV health-care workers to screen for mental health disorders.   
5.1 Background 
Mental disorders reflect anomalies which fit a clinically-recognisable set of 
symptoms or behaviour relating to how a person feels, thinks, acts or perceives 
things.  An important feature of a mental disorder is the association of these 
symptoms or behaviour with distress or interference with personal function [241].  
Globally, mental disorders are common within the general population: each year 
one in twenty people will report a depressive episode (the most common mental 
disorder) with lifetime prevalence considered to be 7%; and depression is the 
leading cause of years lost due to any disability [242] [243].  Depression often 
presents with symptoms of generalised anxiety leading to substantial impairment to 
an  individual’s  every-day responsibilities and, at its worst, leads to suicide [242].  
 
Among HIV-infected populations in LMIC, commonly-observed mental disorders 
include major depressive disorder (MDD), generalised anxiety disorder (GAD), post-
traumatic stress disorder (PTSD), suicidality and alcohol use disorders (AUD) [244].  
According to a recent systematic review of mental illness among HIV-infected 
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patients in LMIC, prevalence of MDD has been reported to range between 0 – 63%, 
and in Uganda one study reported prevalence to be as high as 82% [244] [245].   
Among HIV-infected patients, the consequences of mental disorders can be 
significant and have been reported to include: increased need and use of health 
services (OR 1.43, 1.06 – 1.92), poor access to treatment (OR 2.27, 1.30 – 3.98 
among patients with alcohol abuse history), poor adherence to treatment regimens 
(OR 1.05, 1.00 – 1.10 in one study and OR between 1.87 – 5.86 in a systematic 
review), greater CD4 cell count slope decline (-0.35 vs 0.13, p<0.01), more AIDS-
defining events (HR 1.97, P=0.04), faster disease progression (OR 4.77, 2.17 – 
10.47) and faster mortality (RR 2.0, 1.0 – 3.8)  [42-47, 51-53, 246]. 
 
Identifying common mental disorders among HIV-infected patients is, therefore, 
important.   The most widely recognised criteria to classify mental disorders are set 
out in the Diagnostic Statistical Manual of Mental Disorders (DSM) (American 
Psychiatric Association) and in the International Classification of Disease (ICD10) 
(WHO) [247] [248]. These criteria have been incorporated into clinical interviews 
including the Mini International Neuropsychiatric Interview (M.I.N.I.), the Structured 
Clinical Interview for Diagnosis (SCID), the Clinical Interview Schedule-Revised (CIS-
R), and the Composite International Diagnostic Interview (CIDI) [249] [250-252].   
Clinical interviews are recognised as a gold standard diagnostic measure of mental 
illness [253].  However, due to the time required to carry-out structured interviews, 
they do not lend themselves to rapid administration in a clinical setting or to 
assessments of large populations.  Shorter questionnaires, which are devised to 
screen patients for symptoms which suggest a disorder, are therefore commonly 
used in epidemiological studies.  Among the 32 studies included in two systematic 
reviews examining the prevalence and consequences of common mental disorders 
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among HIV-positive individuals in LMIC, 6 used a clinical diagnostic interview 
(M.I.N.I., SCID, CISR or the CIDI) and 28 used one of 16 short questionnaires, 
known as screening tools, or a study-specific questionnaire [244] [246].   As each 
tool is slightly different, it is possible that they measure slightly different aspects of 
mental disorders (e.g. feeling sad, feeling blue, feeling tired, lack of appetite) and 
this may, in part, explain the range of prevalence estimates for MDD reported in the 
studies [244].  The number of tools in use highlights the lack of knowledge about 
how best to measure mental disorders.  Moreover, the validity of many screening 
tools against gold standard diagnostic interviews has been questioned making it 
difficult to have a true understanding of the extent of the burden of mental health 
disorders among HIV-infected populations [254].  
 
In 2008 the WHO acknowledged that little information about the interaction 
between HIV, AIDS and mental health, particularly regarding alcohol consumption 
was available from LMIC [255].  Globally, there had been minimal emphasis on 
mental health interventions within ART programmes and it was estimated that only 
50% of countries in the African region had any form of mental health policy in place 
[53] [256].   At that time, Uganda was one country with a policy stating that mental 
health services should be linked to HIV services [257].  Nevertheless, treatment of 
severe mental health disorders was only available at ten regional hospitals or at the 
National Mental Referral Hospital.  Furthermore, there were only 1.6 psychiatrists 
(compared to 10 in Europe), 2 psychologists (3 in Europe), 2 psychiatric nurses (25 
in Europe) and 2 social workers per 100,000 population [256].  
 
Recognising that that  there  can  be  ‘no  health  without  mental  health’, the WHO 
identified as a priority the assessment of mental disorders and their appropriate 
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management within HIV care programmes [258] [259].  They recommend that 
primary health-care providers, including HIV counsellors, should be trained to 
recognise common mental disorders and substance-use disorders [255].   
 
It is vital to identify tools which accurately reflect the current version of DSM criteria 
(DSM IV) and ICD 10 criteria and can be used by non-specialist health care workers 
to screen patients accurately for mental disorders.  This will enable scarce resources 
being invested into mental health services to be well-targeted.  Therefore, firstly, I 
conducted a review of the literature and synthesised the evidence from studies 
reporting prevalence of mental illness in HIV-infected individuals in LMIC and 
examining the validity of screening tools used to assess this.   Secondly, I undertook 
a cross-sectional study to estimate the prevalence and risk factors for common 
mental disorders among HIV-infected patients in Uganda using a structured clinical 
psychiatric interview.  Finally, I aimed to validate three short measurement tools 
against these diagnoses.   
 
Within this chapter I refer in detail to the following mental health disorders and 
assessment tools using the given acronyms: 
Major Depressive Disorder (MDD) 
Generalised Anxiety Disorder (GAD)  
Post-Traumatic Stress Disorder (PTSD)  
Suicidality (includes suicidal ideation, self-harm and attempted suicide) 
Alcohol Use Disorders (AUD), composite of Alcohol Abuse or Alcohol Dependence 
Common Mental Disorders (CMD), composite of MDD, GAD or PTSD 
Global Psychological Distress (GPD), composite of MDD or suicidality 
Centre for Epidemiological Studies Depression Scale (CESD) 
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Kessler’s  Psychological  Distress  Scale  (K10  is  10-item version, K6 is 6-item version) 
Alcohol Use Disorders Identification Test (AUDIT) 
5.2 Review 
The aim of the review was to evaluate the burden of, and risk factors for, mental ill-
health among people living with HIV in LMIC, and to identify evidence-based 
screening tools, as assessed in formal validation studies comparing the 
discriminative performance of screening tools relative to a reference gold standard 
measure.  The first objective was to synthesise prevalence estimates of mental 
disorders (MDD, PTSD, GAD, AUD) as assessed using clinical diagnostic interviews 
and to identify reported risk factors.  The second objective was to synthesise the 
evidence for the validity of screening tools.   
5.2.1 Review methods 
My search strategy involved two stages.  Firstly, I used broad search criteria to 
identify English language studies, published since the advent of ART in 1996, which 
validated assessment tools for mental health disorders among HIV-infected persons 
in LMIC.   I searched Medline through PubMed.  The search was last updated on 21-
06-2013.  I used the following search terms resulting in the number of references 
noted to capture mental illness, HIV, LMIC and screening tool validation: 
 
i) mental illness: mental or psychological or psychiatric or alcohol or mental 
disorders or psychological disorders or psychiatric disorders (1,044,847 
references) 
ii) combined with terms related to HIV or AIDS: HIV or AIDS or HIV/AIDS 
(26,077 references) 
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iii) combined with LMIC regional names: developing countries, low-income 
countries, Africa,  Asia, Europe Eastern or Latin America (4,385 
references) 
iv) combined with terms relating to validity: validity or validation (92 
references)  
Having read the 92 titles and abstracts, I selected papers that met the following 
criteria: 
d. participants were HIV-infected 
e. studies focused on validation of screening tools relative to a gold 
standard 
f. measurement was of common mental disorders 
5.2.2 Reviewed studies 
Eight studies met the above inclusion criteria and examined the following mental 
illnesses:  MDD or GAD (8 studies), PTSD (2 studies), AUD (2 studies) (Table 5.1) 
[243, 260-266].  Seven studies used clinical diagnostic interviews as the gold 
standard reference measure, 5 using the M.I.N.I., 1 the CIDI and 1 used the SCID.  
The eighth study used the long version of the self-administered Patient Health 
Questionnaire (PHQ-9) as the gold standard measure.   The following screening 
tools were validated by the given number of studies: CES-D (3 studies), K10 (2 
studies), K6 (1 study), AUDIT (2 studies), PHQ-9 (2 studies; PHQ-short 2 studies), 
Harvard Trauma Questionnaire (HTQ, 1 study), Edinburgh Post-Natal Depression 
Survey (EPDS, 1 study), Hopkins Symptoms Check List (HSCL, 1 study).  I extracted 
information on sample size, gold standard prevalence of common mental disorders, 
the area under the receiver operating characteristic curves (AUROC) for screening 
tools, optimal cut-off points and sensitivity, specificity, positive and negative  
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Table 5.1  Prevalence of mental disorders and validity of screening tools 
Authors Country 
Study 
population 
Gold 
standard 
Disorder 
prevalence 
Screening 
tool AUROC (CI) 
Optimal 
cut-off Sensitivity Specificity PPV NPV 
Akena et 
al. 
Uganda 
[243] 
n=368 HIV 
positive 
patients from 
Kampala 
Hospital Home 
Care 
Department MINI MDD 17% CESD 0.94 (0.89 - 0.99) 18 88% 81%  49%  97% 
     
K10 0.82 (0.72 - 0.93) 23 83% 72%  38% 
 
95%  
     
K6 0.82 (0.71 - 0.93) 13 77% 67%  33% 
 
93% 
     
PHQ-9 0.96 (0.92 - 0.99) 10 92% 81%  37% 
 
98% 
     
PHQ-short 0.82 (0.71 - 0.93) 3 83% 70%  37% 
 
95%  
Spies et al. 
South Africa 
[260] 
n=429 adults 
enrolled into 
HIV care MINI MDD 13% K10 0.77 * 28 67% 77% 29% 94% 
    
GAD 4% 
 
0.78 30 72% 80% 14% 99% 
    
PTSD 5% 
 
0.77 29 75% 78% 15% 99% 
Chishinga 
et al. 
Zambia 
[261] 
n=649 new TB 
treatment or 
ART initiators, 
16 primary 
care clinics MINI MDD 10% CESD 0.78 (0.72 - 0.84) 22 73%  - 76%  -  
    
AUD 15% AUDIT 
0.98 (0.94 - 1.00)F 
0.75 (0.66 - 0.84)M 
24 
20 
60% 
55%  - 
60% 
50%  -  
Myer et al. 
South Africa 
[262] 
n=465 HIV 
outpatients  MINI MDD 14% CESD 0.76 *  - 79% 61% 24% 95% 
    
AUD 7% AUDIT 0.96  -  100% 79% 28%  - 
    
PTSD 5% HTQ 0.74 75 38% 80% 9% 96% 
Pence et 
al. 
Cameroon 
[263] 
n=398 ART 
patients 
attending CIDI MDD 3% 
PHQ-9 
adapted  - 8 36% 89% 9%  
 
95% 
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*confidence intervals not given
regional 
treatment 
centre 
      
 - 10 27% 94% 12% 
 
98% 
      
 - 12 18% 97% 14% 
 
98% 
Monahan 
et al. Kenya [264] 
n=347 HIV 
patients 
attending 
psychosocial 
support 
groups PHQ9 MDD 13% PHQ2 0.91 (0.88 - 0.95) 3 91% 77% 37% 
 
98% 
    
Any Dep 34% PHQ2 0.97 (0.95 - 0.98) 3 85% 95% 90% 
 
92% 
Chibanda 
et al. 
Zimbabwe 
[265] 
n=210 
postpartum 
women (HIV 
positive and 
HIV negative) 
attending 
post-natal 
check-up MINI MDD 33% EPDS 0.82 * 11 88% 87% 74% 94% 
Kaaya et al. 
Tanzania 
[266] 
n=100 
randomly 
selected 
women from 
n=903 HIV 
positive 
pregnant 
women SCID 
MDD 8% 
GAD & MDD 3% 
GAD 1% HSCL 25 0.86 (0.72 - 0.99) 1.06 89% 80%  28%  
 
99%  
     
HSCL 15 - 
depression  0.86 (0.73 - 0.99) 1.03 89% 79% 27%  99% 
     
HSCL- 
revised 0.88 (0.75 - 1.0) 1.06 89% 85%  33% 
 
91% 
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predictive values (ppv, npv).  Where ppv or npv were not provided, I calculated 
these based on available prevalence, sensitivity and specificity information. 
5.2.3 Study populations 
The studies were conducted in Cameroon, Kenya, South Africa, Tanzania, Uganda, 
Zambia and Zimbabwe.  All studies were conducted among outpatients.  Participants 
were drawn from HIV treatment clinics (4 studies), TB and ART treatment clinics (1 
study), a regional HIV treatment centre for pregnant women (1 study), and a post-
natal clinic for HIV-infected and un-infected women (1 study).    The remaining 
study population was derived from patients attending a psychosocial support group.   
 
The smallest study validated tools in 100 women and the largest study in 649 
patients newly-initiating ART or TB and ART treatment. 
5.2.4 Prevalence of mental illness 
All 8 studies assessed the prevalence of MDD.  Between 3 – 33% of study 
participants were classified as having MDD.  Six of the 8 studies estimated 
prevalence around a narrow range between 8 – 17%.  One of these studies 
reported prevalence at 53% however, the data appear to have been presented 
incorrectly and prevalence actually appears to be 13.5% [260].   The remaining two 
of the 8 studies estimated prevalence of MDD at 3% and 33%.   The study 
estimating prevalence at 3% was conducted only among patients on ART, who have 
been shown to have lower levels of depression than HIV-infected individuals not on 
ART [262, 263].  The study estimating the highest prevalence at 33% was 
conducted among HIV-infected women attending post-natal check-ups, who may be 
at increased risk of depression regardless of HIV status [265].    
GAD was assessed by the M.I.N.I. in only one study, which estimated prevalence at  
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4% (though data were incorrectly presented at 18%) [260].   One study assessed 
GAD using the SCID and estimated prevalence at 1% and comorbid GAD and MDD 
at 3% [266].  PTSD was assessed by the M.I.N.I. in two studies.  Both studies 
estimated prevalence at 5% (though data in the first study were incorrectly 
presented at 22%) [260, 262].  AUD were assessed by the M.I.N.I. in two studies: 
one, whose population was 75% female, found prevalence of 7%, while the other, 
whose population was 56% male, found prevalence at 15% [261, 262]. 
 
Of the studies using the M.I.N.I. as a gold standard measure, only 1 reported on 
risk factors for mental illness.  In South Africa, speaking Afrikaans compared to 
Xhosa was associated with an increased risk of MDD, PTSD and AUD (Odds Ratios 
not given).  Younger individuals were somewhat protected from MDD (OR 0.96), 
individuals with a higher household income were protected from PTSD (OR 0.12) 
and females had reduced risk of alcohol use disorders (OR 0.19) [262]. 
 
5.2.5 Validity of screening tools 
All 8 studies validated screening tools for the detection of MDD.  The discriminatory 
ability to identify true and false positives out of the actual positives and negatives 
(as assessed by examining the AUROC curves) of the screening tools for the 
detection of MDD was moderate, ranging as follows: CES-D (0.76 – 0.94), K10 
(0.77, 0.82), PHQ-9 (0.96), PHQ-3 (0.82 – 0.91), HSCL (0.86), EPDS (0.82).  The 
best and worst discriminatory ability were offered, respectively, by the PHQ-9 and 
CES-D, though only one study reported AUROC for the PHQ9.  Where more than 
one study validated a screening tool, there was no consensus on optimal cut-off 
points to be used to identify probable cases: CES-D (18, 22), K10 (23, 28), PHQ-9 
(8, 10, 12), with the exception of the PHQ-3 (where a value of 3 was identified by 
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two studies).  Furthermore, there was large variation in the sensitivity and 
specificity and the positive and negative predictive values at the identified cut-off 
scores and one of the four measures (usually ppv) was always compromised.  For 
example, the three studies validating the CESD found the following: in one study, 
sensitivity and specificity were 79% and 61% with ppv 24% and npv 95% 
respectively; and another study, sensitivity and specificity were 88% and 81% with 
ppv 49% and npv 97%; and in the third study sensitivity was 73% and ppv 76% 
(specificity and npv not provided).  
 
Two studies validated screening tools (K10 and HTQ) against M.I.N.I. diagnoses of 
PTSD [260, 262].  The AUROCs were similar at 0.74 (K10) and 0.77 (HTQ).  
Sensitivity and specificity were 75% and 78% with a positive and negative 
predictive value of 15% and 99%, respectively for the K10.  The HTQ demonstrated 
sensitivity and specificity of 38% and 80% (HTQ), with positive and negative 
predictive values of 9% and 96%.   
 
The discriminatory ability of the AUDIT to detect AUD was examined in two studies 
and varied between the studies.  One study reported AUROCs for males of 0.75 and 
for females of 0.98, and the second study reported an aggregated AUROC of 0.96 
[261, 262].  In one study, sensitivity and specificity were 60% and 60% (females) 
and 55% and 50% (males), using a cut-off score of 24 (females) and 20 (males).   
In the second study, which did not present the cut-off score used, sensitivity and 
specificity were 100% and 79% with a positive predictive value of 28%.  One study 
validated the discriminatory ability of a short version of the PHQ against a long 
version of the PHQ to detect AUD, which had been estimated by the PHQ at 34%.  
The study found an AUROC of 0.97, with sensitivity, specificity and ppv of 80%,  
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95% and 90% [264]. 
5.2.6 Review discussion 
The literature available to evaluate these screening tools was limited.  Furthermore,  
there was heterogeneity of study populations including TB-HIV co-infected patients, 
new ART initiators, ART-naïve patients, pregnant women, postnatal women, HIV 
outpatients, home-care patients, patients attending psychosocial support groups, 
and a mixture of studies conducted in urban and rural populations. There was in 
addition, ranging prevalence estimates of all disorders, particularly MDD, reflecting 
the different populations and differences in the application of gold standard 
diagnostic criteria.   
 
Despite these limitations, the studies provide valuable information about the 
prevalence of mental illness, notably MDD, when assessed using clinical diagnostic 
interviews and about the validity of a variety of screening tools used to measure 
mental disorders in LMIC.  If only studies using strict M.I.N.I. criteria are 
considered, the range of prevalence estimates of MDD as assessed by clinical 
interview was narrower (8% - 17%) than estimates using screening tools seen in 
systematic reviews (0 - 63%).  This suggests a tendency of screening tools to over-
estimate the prevalence of disorders.  These validation studies do not provide 
enough details to comment on common risk factors for mental illness and more 
work is needed to enable the identification of at-risk patients using data routinely 
available within HIV care settings.   
 
The 8 reviewed studies provide some important insight into the validity of screening 
tools.  It is generally accepted that studies with AUROC between 0.50 – 0.70, 0.70 – 
0.90, and 0.90 – 1.00 are considered to have low, moderate and high accuracy, 
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respectively [267].  None of the screening tools validated reported AUROC below 
0.70.  Five out of seven studies reported moderate accuracy and two reported high 
accuracy for the detection of MDD.  The ppv was often sacrificed at the given cut-
offs in order to obtain high sensitivity and specificity scores in the majority of 
studies.  In settings with limited resources, incorrectly identifying patients with a 
disorder and referring them for future treatment is costly and an expensive sacrifice 
of a screening tool.  Moreover, only a limited number of studies examined each 
screening tool and these results should, therefore, be interpreted with caution. 
Given the number of screening tools being used to measure and report on the 
mental health of HIV-infected patients in LMIC, the lack of studies contributing to 
this review demonstrates the need for methodologically-sound validation studies.   
 
Therefore, I designed and conducted a cross-sectional study to estimate the 
prevalence and risk factors for common mental disorders among HIV-infected 
patients in Uganda using a clinical diagnostic interview and I aimed to validate three 
short screening tools against these diagnoses.   
 
5.3 Aims, objectives and outline 
The aim of this study was to estimate the prevalence of common mental disorders 
among HIV care outpatients in Uganda, using a structured clinical interview and to 
examine whether data collected routinely in HIV care outpatient appointments could 
identify at-risk patients.  The study also aimed to validate the CES-D, K10, K6 and 
AUDIT, which could be used by non-specialists health care workers to screen 
patients in HIV-care for common mental disorders and global psychological distress.  
The objectives were to: 
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•  estimate  the  prevalence  of  mental  disorders  among  patients  accessing  HIV  care,  
•  compare case classifications manually-derived by interviewers during the 
structured clinical interview with electronically-derived classifications,  
•  examine  whether  data  collected  routinely  in  HIV  care  could  identify  patients  who  
are at risk of having a common mental disorder, and  
•  validate  the  following three screening tools in this setting:  
 the Centre for Epidemiological Studies Depression Scale (CES-D) (20-
question version),  
 Kessler’s  Psychological  Distress  Scale  (10-question version and the truncated 
6-question version (K10, K6)), and  
 the Alcohol Use Disorders Identification Test (AUDIT)  
against diagnoses of major depression (the primary target disorder of the screening 
tools) and against broadly defined common mental disorders (CMD), global 
psychological distress (GPD), and alcohol use disorders (AUD), using the Mini 
International Neuropsychiatric Interview Plus (M.I.N.I. Plus)  [268-270].   
 
This cross-sectional study was conducted in the HIV-outpatient clinics of Entebbe 
District Hospital and the neighbouring Kigungu Health Centre III, Uganda.  Study 
participants were assessed for mental disorders by trained psychiatric nurses using 
the latest version of the Mini International Neuropsychiatric Interview Plus (M.I.N.I. 
Plus), and demographic and clinical data commonly collected in HIV-care were 
gathered through a study-specific questionnaire.   Participants were invited to a 
second interview with HIV health care workers to obtain a mental health 
assessment using the screening tools.   
 
An important objective of this study is to provide a summary to national government  
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representatives and international researchers of the burden of and risk factors for  
mental disorders among patients accessing HIV care in Uganda.  This will help 
determine whether the routine monitoring of the mental health status of patients 
living with HIV attending peri-urban health centres in Uganda is recommended and 
whether any data routinely-collected can be used to identify patients who would 
benefit from further assessments  and  care.    The  results  of  the  screening  tools’  
validation will inform the design of methods used to measure mental ill-health in 
HIV-care clinics in Uganda. 
5.4 Methods 
5.4.1 Setting, sampling frame and study population  
The study was designed to be conducted in the HIV clinic of Entebbe District 
Hospital, in the Wakiso district of Uganda due to geographical proximity to the EfA 
partner psychiatric researcher (EK).  Entebbe District Hospital is the Municipality and 
serves a population of around 70,000.  It is similar to other peri-urban hospitals in 
Uganda in terms of number and cadre of staff and population served and in terms 
of patient characteristics (literacy and education level, employment status and 
poverty status) [271].  The HIV clinic provides treatment and care to registered out-
patients.  At the time I designed the study, 1,200 HIV-infected adult patients were 
estimated by hospital staff to be listed in the HIV treatment and care programme 
register at Entebbe District Hospital, comprising in majority female patients.  I 
designed the study with the sample size based on an expected 90% participation of 
the 1,200 patients attending the clinic.  Based on the estimates of the prevalence of 
MDD among HIV-infected patients (0 – 63%)  observed  in  Collins’  systematic  review,  
I estimated the prevalence of any CMD at 30%  [244].  With the estimated sample 
size of 1,100 participants, the study had 90% power to detect this (95% confidence 
intervals 27.3% - 32.8%).   
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Patients were eligible for the study if they were an outpatient attending the HIV 
clinic and aged over 18 years old.  The study population includes ART-naïve and 
ART-experienced patients as little was known about mental health disorders in HIV-
infected patients in the region irrespective of ART status.  All patients waiting for 
their routine clinic appointment were invited to participate in the study by a 
psychiatric nurse.  The psychiatric nurses described the study to the patients, who 
were given the Patient Information Sheet and Informed Consent Form.  A copy of 
these forms and all interview tools used can be found in Appendix 5.1.  If the 
patient had all questions satisfactorily answered, they either completed the consent 
form themself or had the consent form read, and signed or thumb-printed the form.  
Recruited study participants proceeded to the psychiatric assessment interview.   
 
The screening tools were designed to be assessed in one-fifth (220) of study 
participants.  This was because the HIV healthcare workers administering the tools 
were not directly employed in this study and it would have been unreasonable to 
detract a large amount of time from their routine clinical work of patient care.  All 
participants eligible and included in the psychiatric assessment component of the 
study were invited, by consecutive sampling, to participate in the screening tools 
validation component of the study until the sample size of 220 patients was 
reached.   
 
Study recruitment from Entebbe District Hospital was expected to take a period of 
four months.  However, by the end of the first month of the study, it was apparent 
that recruitment of participants through Entebbe District Hospital alone would not 
be sufficient to meet this timeline.  The study was conducted during the rainy 
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season and heavy rains impeded access to the clinic for patients and staff on 
multiple days.  In discussion with EK, it was decided to include another HIV 
treatment and care clinic.  Patients were thus also recruited from the neighbouring 
Kigungu Health Centre III which lies about 5 kilometres from Entebbe District 
Hospital and is also in the Wakiso district of Uganda.   Kigungu Health Centre III is 
a lower level health centre compared to the District Hospital in terms of staffing and 
facilities. The clinic serves a population of around 6,500.  Patients attending 
Kigungu health centre III are similar to those attending Entebbe District Hospital in 
terms of clinical health, educational status and employment status [271].  Table 5.2 
depicts the sampling frame used to identify participants for this study. 
5.4.2 Psychiatric assessment interview 
A structured clinical psychiatric assessment interview was conducted face-to-face by 
one of six bilingual (Lugandan/English) psychiatric nurses from Butabika Psychiatric 
Hospital who were employed to undertake recruitment to the study, the 
demographic and clinical data-gathering and the psychiatric assessment interviews.  
The interview had been translated into Lugandan by two Lugandan-speaking mental 
health workers (one psychiatrist and one psychiatric nurse) to allow patients the 
choice of interview language.  The following information, which could be accessed 
routinely during HIV-care appointments, was gathered through a structured 
questionnaire before the main psychiatric assessment: 
 
Demographic data 
x sex  
x age (as reported at interview) 
x weight and height (self-reported) 
 
 180 
 
Table 5.2 Sampling frame for cross-sectional study to estimate prevalence of 
mental health disorders and to validate tools used to monitor it 
Health Centres Sampling: Entebbe District Hospital, extended to include 
Kigungu Health Centre III, both selected due to geographical 
proximity to local study lead 
Sample size Patients for prevalence and risk factor estimate: 1,100 
Patients for screening tools validation: 220 
Population to 
estimate 
prevalence and 
risk factors  
Sampling: all adult patients (pre-ART and ART) electing to 
attend the HIV clinic of the HIV treatment and care 
programmes within the health centres were invited to 
participate 
Population to 
validate 
screening tools 
Consecutive sampling: all patients who had completed  the 
clinical diagnostic interview were invited and recruited 
sequentially until the sample size was met 
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HIV disease-related data 
x length of time since HIV diagnosis (< 3 months, 3 - < 6 months, 6 - < 12 
months, ≥  12 months)  
x length of time attending the HIV clinic (< 6 months, 6 - < 12 months, ≥  12 
months) 
x most recent CD4 cell count (self-reported) 
x ART status (currently on ART, not currently on ART) 
x length of time on ART (< 6 months, 6 - < 12 months, ≥  12 months) 
x ART  adherence  (‘in  the  last  three  days,  have  you  missed  a  dose?  Yes/no’)   
x ART combination 
x Cotrimoxazole status (currently on Cotrimoxazole, not currently on 
Cotrimoxazole) 
x Cotrimoxazole  adherence  (‘in  the  last  three  days,  have  you  missed  a  dose?  
Yes/no’) 
 
The psychiatric nurses assessed the presence of the following disorders which had 
been  identified  in  Collins’  review  as  being  the  most  frequently-reported mental 
disorders among HIV-infected patients: MDD, GAD, PTSD, suicidality and AUD 
[244].  A definition given by the American Psychiatric Association Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) of each disorder is 
given in Appendix 5.2.  The psychiatric nurses used the M.I.N.I. Plus to conduct the 
structured clinical diagnostic interviews [249].  The M.I.N.I. Plus was selected over 
other diagnostic interviews as it was shown by Collins review to be the most 
frequently-used structured clinical diagnostic interview [244].    
 
The M.I.N.I. Plus solicits responses about symptoms through separate disorder  
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modules.  General questions screen out individuals who are not likely to be at risk.  
Sub-questions assess the presence of symptoms and, with exception of the 
suicidality and AUD modules, a final question assesses whether any of the identified 
symptoms interfere with normal day-to-day life.   The questions require Yes/No 
responses, with the exception of two questions within the suicidality module which 
have multiple-choice responses.  Affirmative responses score one point and negative 
responses score zero, with multiple-choice responses scoring between one and 
three points.  The M.I.N.I. Plus uses 71 questions through the individual modules to 
assess CMD, GPD and AUD.  Some questions, however, may be skipped according 
to previous responses but these  ‘skip  rules’  can  be  numerous  and  complicated (for 
example, the suicide module has five skip rules within its 20 questions).  Case 
ascertainment for each M.I.N.I. Plus disorder is based on i) affirmative responses to 
the screening questions and ii) the number of affirmative responses to the screening 
and sub-questions combined or the sub-questions alone.  However, a disorder is 
only classed as being present if the final question about whether the identified 
symptoms cause the patient problems in their daily life is answered affirmatively.  At 
the end of each disorder module the interviewer manually tallied the number of 
affirmative responses in order to perform case ascertainment.  Participants who met 
the M.I.N.I. Plus criteria for a disorder were informed of their status and offered a 
referral for further assessment and care within Entebbe Hospital.  
 
Each interview, including the collection of psychosocial data, took 30 - 45 minutes to 
complete, depending on the skip rules involved in the M.I.N.I. Plus.  Each 
participant was given 5000 Ugandan shilling (USD$2) to cover transport costs.   
5.4.3 Screening tool validation interview 
The psychiatric nurses invited all participants (identified cases and non-cases) who  
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had completed the psychiatric assessment interview to complete the short screening 
tool validation interview until the desired number of participants was recruited.  To 
minimise the potential for reporting bias in the form of quick responses due to 
tiredness after the psychiatric assessment interview, participants who agreed to 
participate in the validation interview were given a break and light refreshment 
between interviews.  The screening tool validation interview was conducted by staff 
working as patient counsellors within the HIV treatment and care clinics. 
 
To screen for CMD and GPD, the HIV care counsellors used the CES-D and Kessler’s  
Scale [268] [269].  While the primary target disorder for both tools is MDD, they 
also screen for broadly-defined mental disorders and are intended to yield a global 
measure of distress based on severity of symptoms [269] [272].  The scales solicit 
responses about feelings or behaviour during the period one week (CES-D) and four 
weeks (K10/K6) prior to the interview by asking questions with multiple choice 
responses.  While the CES-D has been used and adapted to take account of HIV-
specific somatic complaints, at the time of designing this study it had never been 
validated in peri-urban health centres in Uganda against diagnoses based on the 
DSM IV or ICD 10 criteria [245].  And, while the K10/K6 has been used in the World 
Mental Health Surveys in high-income countries and validated in India to identify 
mental disorders, validity data from other LMIC remain few  [269], [272] [273] 
[274]. 
 
To screen for broadly-defined AUD, the HIV counsellors used the AUDIT [270].  The 
AUDIT was developed by the WHO to pick up the early signs of hazardous drinking, 
harmful drinking and mild dependence [275].   It has been validated against other 
screening tests and against blood biomarkers known to reflect heavy drinking [276].  
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Validation work in New York City supports the use of the AUDIT among HIV-infected 
persons in busy clinical settings, however data from LMIC are few and it has never 
been validated among an HIV-infected population in Uganda [277].  The AUDIT 
solicits responses about consumption of alcoholic beverages during the year prior to 
interview. 
 
The order in which the screening tools were administered was consistent across all 
participant  interviews  (Kessler’s  Scale,  the  AUDIT  and  then  the  CESD)  to  give a 
break between the two tools screening for Global Psychological Distress and MDD.  
The following number of questions are used in the screening tools to assess 
broadly-defined disorders: CES-D (20), K10 (10), AUDIT (10) and each interview 
using all 3 tools took around 10 minutes to complete.  The HIV care counsellors 
administering the interviews were blinded to the initial M.I.N.I. Plus assessment 
results in order not to influence their manner of administering the screening tools. 
 
All screening tools are scored on a Likert scale where each question, for example, 
’were  you  bothered  by  things  that  do  not  normally  bother  you?’  has  the  following  
possible responses: 0=rarely/none of the time, 1=some/a little of the time, 
2=occasionally/a moderate amount of the time, 3=all of the time.  If a question was 
positively  phrased  (for  example,  ‘did  you  feel  you  were  just  as  good  as  other  
people?’),  this  required  the  scores  to  be  reversed  (for  example,  0=all  of  the  time  
and 3=none of the time), so that for each tool, a total score was generated where 
high scores indicate the presence of more symptomatology.  As the screening tool 
interview was aimed at validating the tools rather than providing an assessment of 
mental ill-health per se, while scores were added up by the interviewers to 
distinguish probable cases from non-cases for the purposes of validation, no results  
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from the screening tools were given to study participants. 
5.4.4 Staff training, ethical considerations and data entry 
With the assistance of a psychiatrist employed as study manager, I implemented a 
four-day training programme for the research nurses in Entebbe, to minimise 
potential error in the administration of the interviews. Training involved going 
through each interview question to ensure comprehension on the part of the study 
team and to ensure the Lugandan translation of words for feelings and emotions 
would be clear to participants.  Furthermore, as it was essential that the psychiatric 
research nurses were familiar with the complex M.I.N.I. Plus skip rules, we 
employed role-play to practise their use.  During the training we agreed 
standardised ways to repeat questions if the participant did not understand (e.g. the 
question would be broken down into shorter phrases and comprehension of each 
phrase ensured, rather than substituting words).  In a similar way, using role-play, 
the HIV counsellors at the health centres were trained by the study manager in the 
use of the screening tools.  After the training, the data-collection tools were pilot-
tested at Entebbe District Hospital.   Each research nurse explained the study and 
invited patients to participate in the pilot work.  After obtaining consent, 2 patients 
were interviewed by each research nurse.  This allowed the nurses the opportunity 
to practise interviews to ensure comprehension of language and become familiar 
with the M.I.N.I Plus skip rules and scoring methods.  After the pilot testing, some 
very slight linguistic modifications were made to the data-collection tools. 
 
Both the psychiatric assessment and screening tool validation interviews took place 
in private areas of the HIV health clinics separated from other patients.  The 
psychiatric research nurses with their clinical training and the HIV counsellors with 
their experience working with HIV patients, were used to soliciting responses in a 
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sensitive manner and were equipped to handle possible emotions that arose during 
the interviews.  
 
Data management was carried out by a designated data manager (Gertrude 
Mutonyi) in the Statistics section of MRC UVRI, according to the standard 
procedures of the statistics section. A database was created by MRC UVRI and 
maintained in MS-ACCESS containing tables corresponding to data from the 
interviews.  Data were double-entered into the database in the Statistics section and 
validated using the Standard Operating Procedures of the Statistics Section.  Once 
data-entry was completed, the interview forms were stored in the Archives of the 
statistics section, with the same security arrangements that apply to all data forms 
from MRC/UVRI projects, with data only accessible to the study leads and data 
entry officers.    
5.4.5 Statistical methods 
For the purpose of estimating prevalence, identifying risk factors and validating 
screening tools to identify non-specific mental disorders in the HIV care setting, I 
generated three variables for the following widely-recognised composite disorder 
groupings: 
 
i. common mental disorders (any one of: major depression, generalised 
anxiety, post-traumatic stress) (CMD) 
ii. global psychological distress (either major depression or suicidality) (GPD) 
iii. alcohol use disorders (either alcohol dependence or alcohol abuse) (AUD) 
 
The above disorder grouping estimates were generated for individuals who 
completed all the M.I.N.I. Plus modules for the relevant disorders.  However, the 
 187 
 
interviewers’  task  to  assign  cases  and  non-cases manually is not straight forward 
due to a complex scoring system and  the  interview’s  complex  skip  rules.  Firstly, the 
scoring methods for case classifications are different for each disorder potentially 
leading to errors when manually counting scores from the M.I.N.I Plus.   Secondly, 
the complex skip rules mean that the M.I.N.I Plus may not be administered correctly 
as questions which should have been skipped are answered, leading to a potential 
over-ascertainment of cases, and questions which should have been answered are 
skipped, leading to a potential under-ascertainment of cases.  Thirdly, a disorder is 
only said to be present if the final question in each module about problems caused 
by symptoms is answered affirmatively.  However, this question is easily missed and 
case ascertainment can be incorrectly based only on the total score of the screening 
and sub-questions.  Therefore, I calculated the following three prevalence estimates 
for all individual disorders and for disorder groupings above:  
 
i. Interviewer estimate: based  on  the  interviewers’  manual  case classifications,  
ii. Maximum estimate: taking account of all questions answered, ignoring errors 
in the administration of the M.I.N.I Plus skip-rules, and ignoring responses to 
the final case-defining question which may have been missed in error by 
some participants,   
iii. Gold standard estimate: according to strict administration of the M.I.N.I Plus 
skip-rules.   
 
I assessed how well the interviewers administered the M.I.N.I Plus and categorised 
cases and non-cases.  To do this, I calculated the validity of the  interviewers’  
manual classifications from the M.I.N.I. Plus for the main outcome of any CMD 
against the electronically derived maximum and gold standard prevalence estimates, 
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using the latter two estimates to represent true cases and non-cases.  I calculated 
sensitivity and specificity and the positive and negative predictive values. 
 
 
Using logistic regression models, I examined the association of the following 
variables with any CMD (maximum estimate): sex, age (<30, 30 – 34, 35 – 40, 
>40), BMI (<18.5, 18.5 - <25, 25 - 30, >30), current CD4 (<100, 100 - <200, 200 
- <350, 350 – 500, >500), time since HIV diagnosis (< 3, 3 – <6, 6 – 12, > 12 
months), time in HIV programmes (<6, 6 – 12, > 12 months), currently on ART or 
not, time since initiating ART (<6, 6 – 12, >12 months), ART combination, ART 
adherence (missed a dose or did not miss a dose), currently on Cotrimoxazole 
prophylaxis, and Cotrimoxazole prophylaxis adherence.  Participants with multiple 
missing data were dropped from the logistic regressions.  Factors with a large 
number of missing values (BMI and CD4 count) were not included in the 
multivariate regression model.  Potentially conflicting responses between variables 
(e.g. time in HIV programme < 6 months and being on ART 6 - 12 months) were 
assumed to mean an overlapping time period at 6 months or attendance at a 
different HIV/ART clinic prior to the current clinic and included.  For potentially 
collinear factors (time since HIV diagnosis and time in HIV programme, and ART 
status and time since initiating ART, and Cotrimoxazole prophylaxis status and 
Cotrimoxazole adherence), I used likelihood ratio tests to find the simplest factor 
which best fitted the data and did not include the other factors in the multivariate 
model.  I forward fitted the multivariate models adjusting for factors found to be 
independently associated at p<0.1 at the univariate level.  I used likelihood ratio 
tests to find the model which best fitted the data, examining age as both categorical 
and continuous.  Other continuous variables (e.g. BMI and CD4 count) were 
examined as categorical variables using accepted standards or commonly-used 
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categories.  Finally, I estimated the association of the demographic and clinical 
characteristics with any CMD having adjusted for the significant effects in the 
multivariate model.  I used likelihood ratio tests to assess for any interaction 
between factors found to be associated at the univariate level and all other factors. 
Using the same methods, I conducted a sensitivity analyses with the gold standard 
prevalence estimate which accurately reflects true M.I.N.I. Plus case classifications.   
 
I validated the screening tools against the M.I.N.I Plus using the strict case 
classifications derived among participants who had followed the skip rules correctly 
(gold standard estimate).  Firstly, I estimated the M.I.N.I Plus prevalence of CMD, 
GPD and AUD, and for each disorder grouping, and I examined the number of cases 
of the constituent disorders.  I used these estimates as the gold standard measure 
of disease.   Secondly, I estimated the prevalence of CMD, GPD and AUD using the 
recommended cut-off points for each screening tool.   I estimated the sensitivity 
and specificity of the screening tool case classifications against the M.I.N.I. Plus 
classifications.  Thirdly, I assessed  each  screening  tool’s  ability  to  differentiate  cases  
from non-cases by estimating the AUROC curves and I compared how the 3 tools 
performed.  Using the values from the AUROCs, I identified the cut-off scores which 
gave near equal sensitivity and specificity and I estimated the prevalence of 
disorders if these cut-off scores were used.  
 
I examined differences in patient characteristics and prevalence of mental disorders 
between participants who completed the screening tools and those who completed 
only the M.I.N.I. Plus.  I examined the difference in the screening tool scores when 
the scores were generated manually by the HIV care counsellors administering the 
tools or electronically.  Finally, using the same methods as above, I examined the 
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validity of the screening tools against the M.I.N.I. Plus maximum prevalence 
estimates. 
 
5.5 Results 
5.5.1 Patient characteristics and disorder prevalence 
Between May - August 2010, a total of 692 patients attending the study clinics on 
the same days as the psychiatric research nurses were invited to participate, of 
whom 12 (2%) declined.  Reasons given for non-participation included no time due 
to work commitments, the need to think more about participating, wanting to 
discuss participation with family members, and coming from districts outside of 
Wakiso district and thus being unable to return for an interview.  No further details 
were gathered on patients who declined participation.  680 patients were screened 
for enrolment and allocated an interview time.  Of these, 62 did not return for their 
interview despite being contacted by telephone. No data on these individuals were 
available.  618 participants were recruited to the study and completed the 
psychiatric assessment interview.  Of these, 531 (86%) came from Entebbe District 
Hospital, 80 (14%) from Kigungu health centre and 7 (1%) were missing this 
information.  Figure 5.1 depicts the recruitment process.   
 
Of the 618 study participants, the majority (449, 73%) were female (Table 5.3).  
The median age of participants was 35 (IQR 29 – 41) years.  The median Body 
Mass Index was 22 (IQR 20 – 25) kg/m².  The median latest reported CD4 cell 
count was 301 (IQR 169 – 469) cells/mm³ with 176 (34%) of participants with non-
missing data reporting their latest CD4 cell count to be less than 200 cells/mm³.    
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Declined and no data gathered   12 
Agreed to participate but failed to 
attend interview   62 
618 patients recruited to study 
(Entebbe hospital 531) 
(Kigungu health centre 80) 
(7 missing health centre information) 
Patients attending study clinics and 
invited to participate   692 
Figure 5.1 Flow of patient recruitment to the study 
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Table 5.3 Characteristics of 618 participants examined for any Common Mental 
Disorder (CMD) in two health centres in Wakiso District, Uganda 
Characteristic Number (%) Number (%) with CMD 
Sex  
   Male 
   Female 
 
169 (27%) 
449 (73%) 
  
11   (7%) 
57 (13%) 
Age (years) 
    Median (IQR) 
   <30 
   30 – 34 
   35 – 40 
   >40  
  Missing 
 
35 (29 - 41) 
162 (26%) 
134 (22%) 
147 (24%) 
173 (28%) 
2 
 
 
19 (12%) 
23 (17%) 
13   (9%) 
13   (8%) 
BMI (kg/height2) 
    Median (IQR) 
    <18.5 (Underweight) 
    18.5 - (Normal weight) 
    25 -  (Overweight) 
   > 30 (Obese) 
   Missing 
 
22.2 (20.2 – 25.1) 
  56  (9%) 
389 (65%) 
116 (19%) 
  35  (6%) 
22 
 
 
  6 (11%) 
47 (12%) 
10  (9%) 
  4 (11%) 
Most recent CD4 cell count     
    Median (IQR) 
    <100 
    100 – 
    200 –  
    350 – 
    >500 
 
301 (169 - 469) 
  66 (13%) 
110 (21%) 
130 (25%) 
105 (20%) 
115 (22%) 
 
 
  5  (8%) 
11 (10%) 
14 (11%) 
16 (15%) 
10   (9%) 
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Characteristic Number (%) Number (%) with CMD 
     Missing 92 
Time since diagnosis (months) 
    <3  
    3 –  
    6 –  
    > 12  
     Missing 
 
 77  (13%) 
 28   (5%) 
 45   (7%) 
465 (76%) 
3 
 
 8 (10%) 
  1 (4%) 
 7 (16%) 
51 (11%) 
Time in HIV programme (months) 
    < 6 
    6 – 12 
    >12  
      Missing 
 
121 (20%) 
  66 (11%) 
427 (70%) 
4 
 
15 (12%) 
  8 (12%) 
45 (11%) 
Currently on ART 
    Yes 
    No 
    Missing 
 
399 (65%) 
212 (35%) 
7 
 
38 (10%) 
29 (14%) 
Time since initiating ART 
  Not on ART 
  On ART < 6 months 
  On ART 6 – 12 months  
  On ART >12 months 
  Missing 
 
212 (35%) 
  33  (5%) 
  38  (6%) 
326 (54%) 
9 
 
29 (14%) 
  3  (9%) 
  4 (11%) 
31 (10%) 
ART combination 
    Combivir-Nevirapine 
    Triomune 
    Other combinations 
 
319 (53%) 
 59 (10%) 
 15 (2%) 
 
29   (9%) 
  7 (12%) 
  2 (13%) 
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Characteristic Number (%) Number (%) with CMD 
    Not on ART 
    Missing 
212 (35%) 
13 
29 (14%) 
ART adherence 
   Did not miss dose     
   Missed dose in last 3 days 
   Not on ART 
   Missing 
 
375 (62%) 
  20   (3%) 
212 (35%) 
11 
 
37 (10%) 
  1  (5%) 
29 (14%) 
On Cotrimoxazole prophylaxis 
    Yes 
    No 
    Missing 
 
598 (97%) 
  18  (3%) 
2 
 
65 (11%) 
  3 (17%) 
Cotrimoxazole adherence 
   Did not miss dose     
   Missed dose in last 3 days 
   Not on CPT 
   Missing 
 
548 (89%) 
  49 (8%) 
  18 (3%) 
1 
 
57 (10%) 
  7 (14%) 
  3 (17%) 
 
Note: Figures are numbers and percentages as indicated.  Percentages do not include 
missing.  Feasible inconsistent responses were given by seven participants relating to 
differences in time knowing HIV status, time of attendance in the study clinic and time on 
ARVs and their data are included here.   Numbers (%) with CMD do not include missing. 
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The majority of participants 465 (76%) had known their HIV status for more than 
12 months, 399 (65%) were on ART (the majority on a combivir-nevaripine 
regimen) and 598 (97%) were currently taking Cotrimoxazole prophylaxis.  A high 
number of participants reported good adherence to ART (375, 95%) and to 
Cotrimoxazole prophylaxis (548, 92%).  Twenty-five (4%) of the 618 participants 
were dropped from the logistic regressions as complete information on all variables 
was not available.   
 
For the 618 patients enrolled into the study, the prevalence of CMD was estimated 
to be between 6.9 – 11.0%, the majority of cases being MDD (65) (Tables 5.4).  
Prevalence of GPD varied from 11.1 to 13.4%, which represented a high prevalence 
of suicidality (7.8% -  8.6%).  The majority of cases of suicidality (80% - 98%) 
were of mild suicidal risk.  Very few participants were diagnosed with alcohol use 
disorders (prevalence 0.7% - 0.8%), nearly all of which was alcohol dependence.  
Unless otherwise stated in Table 5.4, the sample size for the estimates was 618 
participants.   
 
Across all disorders, the interviewers classified as cases a similar number of 
participants to the number classified in the electronically-derived maximum estimate 
and closely resembling the number classified in the gold standard estimates (Table 
5.5).  Compared to the gold standard estimate of CMD, the interviewers correctly 
identified 36 of the 39 cases (sensitivity 92%) and 510 of the 523 non-cases 
(specificity 98%).  Thirty-six of the 49 cases of CMD identified by the interviewers 
were true cases (positive predictive value 73%) and 510 of the 513 participants 
identified by the interviewers as non-cases were true non-cases (negative predictive 
value 99%).  However, an additional fifty-three participants were dropped from the  
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Table 5.4 Interviewer, Maximum and Gold standard prevalence estimates of 
mental disorders among 618 HIV-outpatients attending clinics in Uganda, May - 
August 2010 
Disorder Interviewer 
Prevalence 
Maximum 
Prevalence  
Gold standard 
Prevalence  
Common Mental Disorders 
    Any 
     Missing 
    Major Depression 
    Missing 
    Post-Traumatic Stress 
    Missing 
    Generalised Anxiety  
    Missing 
 
62 (10.1%) 
5 
65 (10.5%) 
1 
11 (1.8%) 
2 
14 (2.3%) 
9 
 
68 (11.0%) 
 - 
65 (10.5%) 
 - 
11 (1.8%) 
 -  
  6 (1.0%) 
 - 
 
39 (6.9%) 
53 
43 (7.4%) 
39 
 9 (1.5%) 
5 
 2 (0.3%) 
12 
Global Psychological Distress 
    Missing 
83 (13.4%) 
 -  
83 (13.4%) 
 -  
47 (11.1%) 
193 
Suicidality 
    Missing 
48 (7.9%) 
7 
48 (7.8%) 
 -  
38 (8.6%) 
174 
Alcohol Use Disorders 
    Any 
    Missing 
    Dependence 
   Missing 
    Abuse 
    Missing 
 
7 (1.1%) 
7 
5 (0.8%) 
7 
2 (0.3%) 
14 
 
5 (0.8%) 
 -  
4 (0.7%) 
 -  
1 (0.2%) 
-  
 
4 (0.7%) 
10 
4 (0.7%) 
10 
0%  
10 
Note: Interviewer  estimate  uses  the  interviewers’  manual  case  classifications;;  Maximum  estimate  
ignores errors in the administration of the M.I.N.I.; Gold standard estimate is according to strict 
M.I.N.I. criteria.  
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Table 5.5 Classifications of any M.I.N.I. Plus Common Mental Disorder manually 
by interviewers and by electronically-derived gold standard estimate 
                                     M.I.N.I  Gold standard      
                                         classifications     
Total 
 
Interviewer classifications 
 
No CMD 
 
CMD 
 
Unclassified 
 
   No CMD 510   3 40 543  
   CMD   13 36 13   62 
   Total 523 39 53 615 
Note: 53 participants were dropped from the gold standard estimate due to completion 
errors but were classified by the interviewers 
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gold standard estimate due to errors following the skip rules, yet despite the lack of 
adequate data to assign diagnoses, the interviewers classified 13 of these 
participants as cases and 40 as non-cases.   
5.5.2 Risk factors  
Compared to men, women were more likely to be diagnosed with any CMD (OR 
1.98, 95% CI 1.01 - 3.89, p=0.03), and younger individuals somewhat more likely 
(0.77 per 10-year increase, 0.57 – 1.05, p=0.09) (Table 5.6).   The effect of age 
was better explained by linear increase than as age-groups (p=0.06).  There was no 
evidence of an association between CMD and: BMI, current CD4 count, time since 
HIV diagnosis, time in HIV care programme, having initiated ART,  time since 
initiating ART, ART combination, taking Cotrimoxazole prophylaxis or adherence to 
ART or Cotrimoxazle.   
 
The multivariate model was adjusted for the effect of sex and age.  After adjusting 
for the effects of sex, younger individuals (OR 0.83 per 10-year increase, CI 0.61 – 
1.13, p=0.05) remained more likely to be at risk of any CMD, with borderline 
significance.  After adjusting for the effects of age, females remained at increased 
risk (OR 1.80, CI 0.90 – 3.61, p=0.05).  In addition, after adjusting for sex and age, 
the increased risk to patients not currently on ART (OR 1.28, CI 0.73 – 2.22, 
p=0.08) became slightly more important.  There was no evidence of any interaction 
between sex or age and any patient characteristic.  The model with sex and age 
alone fitted the data no worse than a composite model with clinic time (p=0.87), 
ART status (p=0.39), ART formula (p=0.72), ART adherence (p=0.48) or CPT 
adherence (p=0.52).   
 
In sensitivity analyses, using CMD as defined by the gold standard prevalence  
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Table 5.6 Risk factors associated with having any Common Mental Disorder among patients attending two HIV clinics in Wakiso district, 
Uganda 
                     Univariate               Adjusted*  
Risk factor OR (95% CI) P-value OR (95% CI) P-value 
Sex  
   Male 
   Female 
 
1 
1.98 (1.01 - 3.89) 
 
P=0.03 
 
 
1 
1.80 (0.90 – 3.61) 
 
p=0.05 
Age (trend) 0.77 (0.57 - 1.05) P=0.09 0.83 (0.61 - 1.13) P=0.05 
BMI (kg/height2) 
    <18.5  (Underweight) 
    18.5 -  (Normal weight) 
    25 -     (Overweight) 
   > 30     (Obese) 
 
0.96 (0.39 - 2.37) 
1 
0.75 (0.36 - 1.54) 
0.97 (0.33 - 2.87) 
 
P=0.89 
 
 
* 
 
- 
Most recent CD4 cell count     
    <100 
    100 – 
    200 –  
    350 – 
    >500 
 
0.86 (0.28 - 2.62)  
1.17 (0.47 - 2.88) 
1.26 (0.54 - 2.97) 
1.76 (0.75 - 4.12) 
1 
 
P=0.62 
 
 
* 
 
- 
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                     Univariate               Adjusted*  
Risk factor OR (95% CI) P-value OR (95% CI) P-value 
Time since diagnosis (months) 
    <3  
    3 –  
    6 –  
    > 12  
 
1 
0.29 (0.04 - 2.49) 
1.26 (0.41 - 3.92) 
1.00 (0.45 - 2.21) 
 
P=0.50 
 
* 
 
 -  
Time in HIV programme (months) 
    < 6 
    6 – 12  
    >12  
 
1 
0.83 (0.32 - 2.15) 
0.78 (0.42 - 1.47) 
 
P=0.75 
 
1 
0.81 (0.31 - 2.12) 
0.85 (0.45 - 1.63) 
 
P=0.19 
Currently on ART 
    Yes 
    No 
 
1 
1.46 (0.87 - 2.47) 
 
P=0.16 
 
1 
1.28 (0.73 - 2.22) 
 
P=0.08 
Time since initiating ART 
  Not on ART 
  On ART < 6 months 
  On ART 6 – 12 months  
  On ART >12 months 
 
1.48 (0.86 - 2.56) 
0.99 (0.28 - 3.43) 
1.16 (0.38 - 3.48) 
1 
 
P=0.56 
 
* 
 
 - 
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                     Univariate               Adjusted*  
Risk factor OR (95% CI) P-value OR (95% CI) P-value 
ART combination 
    Combivir-Nevirapine 
    Triomune 
    Other combinations 
    Not on ART 
 
1 
1.13 (0.45 - 2.87) 
1.79 (0.38 - 8.46) 
1.53 (0.88 - 2.65) 
 
P=0.47 
 
1 
1.10 (0.43 - 2.79) 
1.93 (0.40 - 9.31) 
1.32 (0.74 - 2.37) 
 
P=0.20 
ART adherence 
   Did not miss dose     
   Missed dose in last 3 days 
   Not on ART 
 
1 
0.48 (0.06 - 3.69) 
1.42 (0.84 - 2.41) 
 
P=0.27 
 
 
1 
0.45 (0.06 – 3.48) 
1.23 (0.70 - 2.15) 
 
P=0.12 
Currently taking CPT 
    Yes 
    No 
 
1 
1.92 (0.53 - 6.91) 
 
P=0.35 
 
* 
 
 - 
CPT adherence 
   Did not miss dose     
   Missed dose in last 3 days 
   Not on CPT 
 
1 
1.43 (0.61 - 3.35) 
1.98 (0.55 - 7.18) 
 
P=0.47 
 
1 
1.37 (0.58 – 3.22) 
1.93 (0.53 - 7.06) 
 
P=0.12 
*Notes: the OR is adjusted for factors (sex and age) found to be significant at the P<0.1 level in the univariate analyses.  There were 22 missing Body Mass 
Index values and 92 missing CD4 cell counts therefore these variables were not included in the adjusted models.  Time since diagnosis was not fitted to the 
multivariate due to co-linearity with time in HIV programme and time in HIV programme fitted the data no worse; time since initiating ART was not fitted to 
the model due to co-linearity with ART status and ART status fitted the data no worse.  CPT status was not fitted to the multivariate as 97% of all participants 
were taking CPT
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estimate, there was no longer any evidence for the effect of any patient 
characteristic, though the results had reduced power.  There was, of note, a slight 
non-significant change in the direction of effect for patients who: were obese (OR 
1.32), had been enrolled in care for 6 – 12 (OR 1.04) or >12 (OR 1.11) months, had 
been on ART for 6 – 12 months (OR 0.86), were on Triomune (OR 0.97) or had 
missed a dose of CPT (OR 0.97).   
5.5.3 Validity of screening tools 
Of the 618 study participants, 223 (36%) completed the screening tools.  Due to 
errors in following the M.I.N.I. Plus skip rules, no gold standard M.I.N.I. Plus 
classifications were made for the following number of patients who answered the 
screening tools 17 (CMD), 68 (GPD), 4 (AUD) (Figure 5.2).  Among screening tools 
participants, 16 (8%), 22 (14%) and 2 (1%) had CMD, GPD and AUD, respectively, 
according to the gold standard M.I.N.I. Plus estimate.  The majority of cases of CMD 
were of MDD (13 cases).  Table 5.7 shows the number of cases of each constituent 
disorder contributing to the CMD, GPD and AUD groupings.  No validation analyses 
were undertaken on the ability of the screening tools to detect MDD due to the 
large overlap between cases of MDD and any CMD.  No validation analyses were 
undertaken on the AUDIT due to the low number of cases of AUD.   
 
Among the participants completing the screening tools, the median scores for the 
CESD  and  Kessler’s  scale  can  be  seen  in  Table  5.8.    When using the case 
classification cut-off points for  the  CESD  and  Kessler’s  scale recommended by the  
authors, sensitivity and specificity for the CMD and GPD were low against the gold 
standard estimates.  When using these cut-off points, prevalence of any CMD was 
33%, 30% and 32% (CESD, K10, K6 respectively) and prevalence of GPD was 31%, 
31% and 35% (CESD, K10, K6 respectively).  The median score for the AUDIT was 
 203 
 
Figure 5.2 Number of study participants who completed the M.I.N.I. Plus and 
screening tools, and number who followed the M.I.N.I. Plus skip rules correctly 
and have a gold standard case classification 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completed M.I.N.I. Plus 
618 
Completed 
screening tools 
and M.I.N.I. Plus 
223 
Did not follow M.I.N.I. Plus skip rules 
correctly and thus no gold standard 
categorisation 
 
Any Common Mental Disorder  17 
Global Psychological Distress  68 
Alcohol Use Disorders  4 
Screening tool and M.I.N.I. Plus gold 
standard categorisation 
 
Any Common Mental Disorder  206 
Global Psychological Distress  155 
Alcohol Use Disorders  219 
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Table 5.7 Number of cases of Common Mental Disorders, Global Psychological 
Distress and Alcohol Use Disorders, according to Gold standard M.I.N.I. Plus 
estimate, among participants who completed the screening tools 
 
M.I.N.I. Disorder Cases 
Any Common Mental Disorder  16 
     Major Depressive Disorder 13 
     Generalised Anxiety Disorder   0 
     Post-Traumatic Stress Disorder   1 
     Comorbidity Major Depressive  & Generalised Anxiety Disorder   0 
     Comorbidity Major Depressive  & Post-Traumatic Stress Disorder   2 
Global Psychological Distress  22 
     Major Depressive Disorder   5 
     Comorbid Major Depressive Disorder & Suicidality    8 
     Suicidality    9 
Any Alcohol Use Disorder   2 
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Table 5.8 Median score for the CESD, K10, and K6, sensitivity and specificity 
using screening  tool’s  cut-off points against M.I.N.I. CMD and GPD, and 
prevalence of CMD and GPD using the screening tool cut-off points 
 
 Median score 
(IQR)/total 
Sensitivity & 
Specificity CMD 
Prevalence 
of CMD  
Sensitivity & 
Specificity GPD 
Prevalence 
of GPD 
CESD 8 (IQR 1 – 20)/60 33%, 68% 33% 30%, 69% 31% 
K10 14 (IQR 11 – 21)/50 31%, 71% 30% 27%, 68% 31% 
K6 9 (IQR 6 – 13)/30 38%, 68% 32% 36%, 65% 35% 
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0 (IQR 0 – 1) out of 40 (not included in table).   
 
The CES-D, K10 and K6 differentiated cases of CMD from non-cases poorly with the 
following AUROCs, respectively: 0.60 (0.45 - 0.75), 0.57 (0.43 - 0.71) and 0.57 
(0.42 - 0.71) (Table 5.9).  There was no evidence of a difference between the three 
tools in their ability to differentiate cases from non-cases (p=0.98).  Figure 5.3 
compares the AUROCs for the three tools.  The optimal cut-off scores which 
provided the best balance between sensitivity and specificity maximised sensitivity 
at 60%, 56% and 56% and specificity at 60%, 54% and 49% for the CES-D, K10 
and K6 respectively.   Using these cut-off points, prevalence of CMD was 41% 
(CESD), 47% (K10) and 51% (K6). 
 
The CES-D, K10 and K6 similarly differentiated cases of GPD from non-cases very 
poorly, with respective AUROCs of 0.58 (0.45 - 0.71), 0.48 (0.34 - 0.63) and 0.50 
(0.37 - 0.64) (Table 5.10).  There was no evidence of a difference between the 
tools (p=0.38).  Figure 5.4 compares the AUROCs for the three tools.   The optimal 
cut-off scores which provided the best balance between sensitivity and specificity 
maximised these at close to 50% for all three tools.  Using these cut-off points for 
the CES-D, K10 and K6, prevalence of GPD was 43% (CESD), 47% (K10) and 51% 
(K6).   
 
In sensitivity analyses using the M.I.N.I. Plus maximum prevalence estimates, the 
accuracy of the screening tools in the larger population was little improved.  There 
was no evidence of a difference in the ability of the 3 tools, CES-D, K10 or K6, 
respectively, when comparing their ability to classify cases and non-cases of CMD 
(AUROC 0.59, 0.64, 0.65, p=0.36) and GPD (AUROC 0.60, 0.57, 0.61, p=0.51).  
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Table 5.9 Discriminatory ability to differentiate between cases and non-cases of any M.I.N.I. Plus-defined Common Mental Disorder of the 
Centre for Epidemiological Studies Depression Scale (CESD) and Kessler’s  Psychological  Distress  (K10-item and K6-item) Scales 
 
 CESD scale Kessler’s  10-item scale  Kessler’s  6-item scale  
Area under Receiver Operating Characteristic curve (CI)   0.60 (0.45 – 0.75) 0.57 (0.43 – 0.71) 0.57 (0.42 – 0.71) 
AUROC when 3 tools compared among same participants 
(P=0.98) 
0.60 0.59 0.58 
Optimal cut-off point 12 15 9 
Sensitivity at optimal cut-off point 60% 56% 56% 
Specificity at optimal cut-off point 60% 54% 49% 
Prevalence of using optimal cut-off 42% 47% 51% 
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Figure 5.3 Comparison of the ability of the Centre for Epidemiological Studies 
Depression  Scale  and  Kessler’s  Psychological  Distress  (10-item and 6-item) 
Scales to detect any MINI-defined Common Mental Disorder 
 
 
 
 
 
  
 
  
0.
00
0.
25
0.
50
0.
75
1.
00
S
en
si
tiv
ity
0.00 0.25 0.50 0.75 1.00
1-Specificity
CESD AUROC: 0.6007 K10 AUROC: 0.5888
K6 AUROC: 0.5927 Reference
P-value of equality 0.98
Comparison of Screening tools for Any Common Mental Disorder
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Table 5.10 Discriminatory ability to differentiate between cases and non-cases of Global Psychological Distress of the Centre for 
Epidemiological  Studies  Depression  scale  (CESD)  and  Kessler’s  Psychological  Distress  (K10-item and K6-item) Scale 
 
 CESD scale Kessler’s  10-item Scale Kessler’s  6-item Scale 
Area under Receiver Operating Characteristic curve (CI)  0.58 (0.45 - 0.71) 0.48 (0.34 - 0.63) 0.50 (0.37 - 0.64) 
AUROC when 3 tools compared among same participants 
(P=0.38) 
0.58 0.51 0.54 
Optimal cut-off point 11 15 9 
Sensitivity at optimal cut-off point 55% 50% 45% 
Specificity at optimal cut-off point 56% 53% 49% 
Prevalence when using optimal cut-off point 43% 47% 51% 
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Figure 5.4 Comparison of the ability of the Centre for Epidemiological Studies 
Depression   Scale   and   Kessler’s   Psychological   Distress   (10-item and 6-item) 
Scales to detect M.I.N.I. Plus-defined Global Psychological Distress 
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There was no evidence of a difference in prevalence of CMD or GPD between those 
who completed the screening tools and those who did not.  There was also no 
evidence of a difference in patient characteristics between the two groups, with the 
exception of ARV drug formula (P=0.02): of participants who completed the 
screening tools, more were receiving an ARV formulation other than Combivir-
Nevirapine or Triomune compared to those who completed only the M.I.N.I. Plus, 
though the numbers on other formulations were very low.  Median scores for the 
screening tools as calculated manually by the nurses were similar to the scores 
generated electronically.   
 
5.6 Discussion 
This study is one of only a few studies conducted among HIV-infected individuals in 
Africa assessing the burden of mental ill-health using structured interviews and 
assessing the validity of the CES-D, K10 and K6.  I found a substantial burden of 
mental ill-health (6.9% - 11% any CMD and 11.1 – 13.4% GPD) among HIV-
outpatients in Uganda.  I found younger patients, females and those not on ART 
slightly more likely to experience any CMD.  The validity of the tools, when 
compared to the gold standard clinical diagnostic interview was poor.  Using either 
the authors’ recommended cut-off points for the CES-D, K10 or K6 or the optimal 
cut-off points identified in this study, the prevalence of any CMD and GPD was 
between 30% - 51%, in comparison, respectively, to the 8% and 14% estimated 
when using the M.I.N.I Plus gold standard estimate.  The use of these tools may 
overestimate prevalence considerably and this study, therefore, provides important 
evidence against the use of these screening tools among HIV-infected patients in 
health centres in Uganda.    
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The level of disorders I found was lower than previous study estimates of MDD in  
Uganda (83%) or found in Collins systematic review (0 - 63%) [244, 245].  This is 
likely due to the large number of studies using screening tools to report prevalence 
rather than rigorous clinical interviews.  In studies validating screening tools (CESD, 
K10, AUDIT) among non-HIV infected populations in LMIC, reported prevalence of 
MDD (2% – 73%) and of AUD (8 - 67%) when not using clinical diagnostic 
interviews was also high [278-286].  The current study results are in line with 
prevalence estimates of MDD (3 – 17%) from the studies using clinical diagnostic 
interviews among HIV-outpatients which I reviewed [243, 260-263, 266].  My 
results are also similar to a large multi-country study reviewed by Collins, where 
prevalence of MDD was between 2 - 15% [244, 287].  The highest prevalence 
estimate of MDD (17%) was derived in the only other study validating screening 
tools against a clinical interview in Uganda.  However, disease classification in that 
study did not include the final case-defining question and reported prevalence is 
possibly an overestimation of cases [243].  I found that when estimating prevalence 
of CMD by not including the final case-defining question prevalence was 4% higher 
than when based on strict M.I.N.I. criteria.  
 
The comorbidity of MDD and suicidal risk I found among validation study 
participants (8/17 participants with suicidality also were diagnosed with MDD) is 
consistent with review findings that GAD and MDD are related to suicidal ideation 
among HIV-infected patients in LMIC [244].  This study found lower levels of AUD 
(1%) than those found in the studies reviewed by Collins which used diagnostic 
interviews to estimate AUD prevalence ( 7%  -  44%), though some of these studies 
were small and conducted among inpatients [244, 261, 262, 288-290].  It is 
possible that the current study findings reflect the true burden of AUD in this 
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population, who were 73% female, as lower levels of alcohol abuse have been 
reported among HIV-infected females compared to males in South Africa [262].  
However, it is feasible that the majority of female participants did not feel 
comfortable discussing alcohol consumption with clinic staff.   More research on the 
burden of alcohol use disorders among HIV-infected patients is needed, particularly 
in peri-urban and rural health clinics where the majority of patients may be female.   
 
I found that younger individuals and women were slightly more likely to have CMD, 
and that patients not currently on ART had a slight increased risk.  Findings from a 
study in South Africa suggested, in fact, that decreasing age (OR 0.96, CI 0.92 – 
0.99) was inversely associated with MDD, though details of the number of years per 
decrement were not given [262].  Most research regarding risk factors for CMD or 
MDD has focused on psychosocial risk factors rather than data routinely collected in 
ART clinics [244].  In this study, no clear risk factors among data collected in 
routine HIV care emerged.  While it may be important to target women, younger 
individuals and those not yet on ART for mental health screening and management, 
more research assessing which routinely collected clinic data can identify at-risk 
patients is needed.   
 
The CES-D, K10 or K6 did not reliably detect any CMD or GPD with good precision in 
comparison to the M.I.N.I. Plus in this peri-urban clinical setting.  The study 
population was made up of immune-compromised individuals (34% of the current 
study had CD4 cell counts < 200) with low levels of literacy (58% had either only 
primary or no formal education) [291].  These factors, which are not unusual 
among HIV-infected individuals in peri-urban clinical settings in LMIC, may have 
influenced participants responses to the screening tools: one characteristic of the 
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screening tools is their use of tiered responses (‘none of the time’, ‘some of the 
time’, ‘most of the time’, ‘all of the time’) compared to the binary ‘yes’/’no’ 
responses in the clinical assessment.  It has been suggested that self-reported 
rating scales in this tiered format may bias responses depending on the literacy 
level of respondents [260].  Furthermore, the performance of the CESD has been 
shown to be better among individuals with CD4 cell counts > 200 cells, than among 
individuals with advanced disease cognitive impairment may mask reporting of 
depressive symptomology [262]. 
 
When validated against diagnoses of any CMD, I found AUROC estimates for the 
CESD (0.60 at detecting CMD, 0.58 for GPD) and K10 (0.57 CMD, 0.48 GPD) lower 
than estimates observed in previous studies validating the CESD (0.76, 0.78) and 
K10 (0.77) against MDD among HIV-infected populations in LMIC [260-262].    
However, 2 of the 3 previous studies excluded patients from participation if they 
had a significant degree of cognitive impairment, whereas the current study had no 
selection criteria based on cognitive impairment status.  In the previous studies 
therefore, the screening tools were not validated in patients who may have 
struggled to understand the tiered response system and this may, in part, explain 
the higher degree of validity attributed to the screening tools [260, 262].   One 
further study, conducted in an urban hospital in Kampala, Uganda, found the CESD, 
K10 and K6 to be highly accurate at identifying MDD (AUROC 0.94, 0.82, 0.82, 
respectively) in an HIV-infected population.  However, the population in the 
Kampala study had a higher level of education than the current study population 
(only 46% of the Kampala study population had only primary education) and was 
healthier (only 17% of the Kampala population had CD4 cell counts < 200) [243, 
291].   The greater number of years of education and healthier status may have 
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influenced the ability of the Kampala study participants to interpret and respond to 
the tiered options of the screening tool questions and may explain the higher 
degree of validity attributed to the screening tools.   
 
I found, respectively for the CESD, K10 and K6, low sensitivity (60%, 54%, 49% for 
CMD and 55%, 50%, 40% against GPD) and low specificity (60%, 54%, 49% 
against CMD and 56%, 53% and 49% against GPD) at the identified cut-off points.  
This is in keeping with the reviewed studies. Even when AUROCs appeared 
acceptable, if data were presented they showed that one of sensitivity, specificity or 
the predictive value was usually compromised: for example despite an AUROC of 
0.77 for the K10 in South Africa, the associated specificity of 77% resulted in a 
sensitivity of 67% and a ppv of 29%; and in the second South African study 
reviewed, when an AUROC for the CESD of 0.76 was selected with the associated 
sensitivity of 79%, specificity was 61% and ppv only 24% [260, 262].  The validity 
of findings for these screening tools among HIV-infected populations in LMIC are 
consistent with findings of high AUROCs and low sensitivity, specificity or PPV in 
studies  validating  the  CESD  and  Kessler’s  Scale  among  non-HIV infected individuals.  
For example, the K10 and K6 were found to be moderately accurate with an AUROC 
of 0.77 and 0.75, respectively, in Burkina Faso among post-natal women.  However, 
while they detected 91% and 85% respectively of true non-cases both detected 
correctly only 59% of true cases [283].  In a household survey in South Africa the 
K10 and K6 had an AUROC of 0.73 and 0.72 respectively, against gold standard 
diagnoses, but no cut-off points were identified and to obtain a ppv above 50% 
sensitivity was only 4% [292].  And according to the authors of an Indian study, the 
K10 showed considerably compromised ppv (53%) at the given sensitivity (65%) 
[274].   
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The importance of using a screening tool with a good balance of sensitivity, 
specificity and predictive value cannot be underestimated in countries with limited 
resources.  There is a need not to miss true cases for whom the potential impact of 
a mental health disorder may be serious (e.g. suicide), but it is also important not to 
refer non-cases for further expensive and time-consuming assessments in a setting 
with already over-stretched resources and a limited number of trained psychiatric 
professionals.  Furthermore, the stigmatising effect of being diagnosed with a 
mental health disorder must be considered and care must be taken not to 
misdiagnose, particularly when the presence of mild symptoms may not cause 
measurable morbidity or mortality [293].   
 
Among validation study participants, while I found a substantial burden of suicidality 
(17/22 cases of GPD included cases of suicidality), the CES-D, K10 and K6 correctly 
identified respectively only 55%, 50% and 45% of true cases of GPD and only 56%, 
53% and 49% of true non-cases of GPD.  This lack of validity is in line with previous 
suggestions that the limited breadth of items in the screening tools do not cover 
important clinical domains relating to suicidality [260].  Given the high level of 
suicidality observed in this study, finding a screening tool which is able to identify 
patients at risk is vital. 
 
There are potential limitations to the generalisability of the current study findings.   
From my review of the literature the current study is the only study to have 
examined the validity of the CESD and K10 in HIV-infected patients in a LMIC 
against the composite diagnosis of any CMD (which included PTSD and GAD as well 
as MDD) or against GPD (MDD or Suicidality).  It is worth noting that MDD, not 
composite groupings of CMD or GPD, is the primary target disorder for the CESD 
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and K10, though both tools are designed to detect general distress.  Nonetheless, 
15/16 cases of M.I.N.I. defined CMD were of MDD in the validation sample and the 
results can therefore also apply to the accuracy of the tools at detecting MDD in this 
population.   
 
A limitation of this study is that while the study aimed to recruit 1,100 patients, the 
nurses were only able to recruit 618 participants in the time available for the study.  
This was due to the study being conducted during the rainy season and for 3 
consecutive weeks heavy rains fell on the days that the ART clinic was open at 
Entebbe hospital resulting in two main problems.  Firstly, some of the psychiatric 
research nurses were travelling from Kampala and were unable to make the journey 
due to the heavy rains, and secondly, the research nurses who were able to attend 
Entebbe hospital and Kigungu health centre reported severely reduced number of 
patients attending the clinic on those days as there is no place at either health 
facility to shelter from the rains.  This reduction in sample size will have reduced the 
power of the study when estimating prevalence and examining risk factors.  This 
study identified no clear risk factors for CMD from routinely collected clinic data.  It 
is possible that a larger study may enable the identification of risk factors.  A further 
limitation to the generalisability of the findings is that of the 692 patients who were 
invited to participate, 74 (11%) either declined, or accepted but never returned for 
interview.  It is likely that patients not participating differ from those who took part 
in the study.  It is possible that they may have higher prevalence of CMD making 
them less likely to take part. 
 
A further limitation of this study is that the validation component was conducted in 
just over 200 participants and data, in particular, for the validation of GPD were 
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only available for 155 patients who correctly answered the M.I.N.I. questions on 
suicide.  The validation analyses therefore were conducted against a relatively small 
number of M.I.N.I. defined cases of CMD (16) and GPD (22).   However, even the 
upper limits of the confidence intervals for the AUROCs for CMD and for GPD  did 
not suggest that the tools were accurate at detecting these disorder groupings.  It is 
worth noting that the original validation component was planned to be conducted in 
one-fifth of the original 1,100 sample whereas the reduced overall number of 
recruited study participants (n=618) actually meant that the validation analyses 
were conducted in a greater proportion of the total study population.  A further 
possible limitation is that I validated the tools against very strictly applied M.I.N.I. 
criteria, including only participants who correctly followed all the skip rules.  It is not 
clear how strictly other studies validating tools against gold standard interviews 
followed diagnostic criteria.  However, my sensitivity analyses when using the 
maximum prevalence estimates also found that the tools performed poorly in this 
population.   
 
A further possible limitation is that the present study was limited to two health  
centres in one district of Uganda.  However, the socio-demographic characteristics 
of this study sample reflect those of patients attending other peri-urban health 
centres in the country and there is no reason to believe that prevalence, risk factors 
and screening tool validity would be different in other peri-urban health centres in 
Uganda.   
 
In the study population, data on weight and height and latest CD4 cell count were 
gathered from self-reports which may have introduced a level of inaccuracy.  It had 
been hoped to gather such data through clinical assessments but after discussion 
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with the clinic staff, it was felt that this additional work would have detracted time 
from routine tasks of clinic appointments.  Data on ART status were also taken from 
self-report  and  for  patients  who  responded  as  ‘currently  not  on  ART’,  the  
interviewers did not further explore whether a patient was ART naïve or had 
interrupted ART.  
 
A further possible limitation of this study is that it did not exclude patients 
previously diagnosed with a mental disorder.  It has been suggested that validation 
studies are at risk of bias by the inclusion of previously diagnosed patients, as this 
will lead to an overestimation of prevalence within a given study cohort and the 
identification by the screening tool of an increased number of cases compared to 
that which would be identified within a routine clinical setting [293]. However, 
assessments of mental ill-health are not routinely conducted among patients in HIV-
care or in general outpatient clinics in peri-urban health centres in Uganda and 
formally recognised cases of mental disorders would be unusual.  Therefore, the risk 
of bias by any potential inclusion of previously identified cases would be low.   
 
The burden of mental illness, particularly MDD and mild suicidal risk, found among 
HIV-infected patients in this study is concerning.  The current study focused on 
patients attending outpatient appointments, and while more than one-third of the 
study population reported CD4 <200 cells/ml, it is possible that they are a healthier 
population than HIV-infected individuals not attending clinic appointments for whom 
the burden of mental illness may be even greater.  The impact of untreated mental 
illness on adherence to HIV treatment has been demonstrated in multiple studies 
[246].  However, there are few clear factors among data commonly collected in HIV 
care which could be used to identify patients at risk of CMD.  The attractiveness, 
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therefore, of screening tools with few questions which can be self-administered or 
interviewer-administered in a number of minutes to each patient attending HIV care 
appointments or which could be used easily in home-based care visits is clear.   Yet, 
the area of screening tool validation against gold standard diagnostic interviews has 
received little attention in the context of HIV in LMIC and particularly little among 
patients with extremely low CD4 counts, or in peri-urban and rural health centres 
treating patients with limited years of education and low levels of literacy.  These 
health centres, manned by HIV clinic staff with little or no psychiatric training, are 
likely to become the mainstay of the majority of future services as countries move 
towards decentralised HIV care.  More research is urgently called for to assess 
which screening tools are valid measures of mental illness among HIV-infected 
patients in these settings. 
 
In this study, I found a substantial burden of mental ill-health among HIV-
outpatients in Uganda with women, younger individuals and those not yet on ART 
slightly more likely to have CMD. This is important information for targeting mental 
health screening, management and referrals within HIV-care programmes.  
However, compared to the M.I.N.I. Plus,  neither  the  CESD  nor  Kessler’s  scale  
reliably detected CMD or GPD, and vastly overestimated prevalence.  I do not 
recommend their use in HIV clinics in Uganda.     
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 ART programme monitoring tools  Chapter 6
 
 
This chapter describes the background, aim, methods and results of a cross-
sectional study I undertook among ART programmes in Malawi, Uganda, the 
Ukraine and Tanzania.  The aim was to compare the implementation by national 
Ministries of Health (MoH) of tools recommended internationally to monitor the 
health of the population on ART and to compare other outcome measures used to 
assess the health status of the treated population.  A secondary aim was to discuss 
challenges arising from monitoring the health of the HIV-infected population on ART 
using currently recommended or collected indicators.   
6.1 Background 
The outcome measures used to assess and report on the health of the treated 
population are not homogenous, as was seen in Chapter 2.  The reasons for the 
lack of uniformity in reporting methods may be, in part, due to heterogeneous 
reporting requirements of different ART treatment programmes.  Programme 
funders have their own reporting requirements and MoH also require reports on the 
status of their national care programmes.  In 2008, it was not known what 
monitoring systems were being used to assess the health of the treated population 
in different treatment programmes in LMIC.   
 
When the number of patients on ART in LMIC were few, clinic staff and programme 
managers initially monitored the health status of the population in their care by 
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manually aggregating data from individual patient treatment cards and sending 
reports to programme funders and MoH [294].  Subsequently, as the number of 
patients in care grew, paper-based clinic registers were introduced and remain in 
practice.  Upon entry into an HIV care programme, each patient is assigned one line 
in the clinic register across which data on their health status at HIV enrolment, ART 
initiation and follow-up visits are entered.  Programmatic monitoring became, and 
remains, based on extracting and aggregating data from the register and reporting 
on patients in care, in the form of totals, proportions, means and medians, at 
regular intervals [294].   For example, data are reported on the proportion of the 
population in a treatment programme alive and on first line therapy 12 months after 
initiating ART [295].    These  data  are  called  ‘indicators’,  defined as a brief proxy 
measure that represents summary information and that is capable of measuring 
changes [296].   In LMIC, indicators for monitoring reports are usually calculated 
manually from the paper-based register, as electronic record systems are rare.  For 
example, 95% of sites visited by a MoH Team in Malawi employed paper-based 
reporting [297].   Indicators are reported on the cumulative number of patients in 
care in cross-sectional monitoring reports.  Additionally, to assess the long-term 
progress of groups of patients in care, a unique monitoring system has evolved with 
the creation of life-long reporting cohorts, to be monitored continuously over time.  
A cohort is derived by grouping patients who enrol in the ART register during, for 
example, the quarter January – March.  Indicators are calculated for this cohort 
routinely throughout the life-time of their follow-up.  For patients who enrol in the 
following quarter, another reporting cohort is formed and indicators relating to their 
follow-up are calculated over time.    
 
Monitoring reports aim to use a small number of key indicators to assess the quality  
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of health care services and measure the effectiveness of the response to HIV [298] 
[299].   Indicators have different uses.  For example, they can serve to evaluate the 
effectiveness of country-wide programmes by assessing increases in ART coverage.  
Within ART programmes, they can be used to track patient status over time, to 
detect immediate problems including increased mortality rates and to inform 
resource allocation choices.  For donors, indicators assess compliance with their 
guidelines, ensure accountability for funds and serve to guide further programme 
funding decisions.   
 
The number of stakeholders involved in various aspects of HIV care, including the 
WHO, UNAIDS, PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (GFATM), has resulted in a plethora of guidelines, recommendations, 
glossaries, tools and frameworks on how best to monitor HIV programmes, and the 
generation of a wealth of similar yet slightly different monitoring indicators in LMIC 
[300] [300] [301] [299] [302] [303] [304] [305] [306] [69, 307, 308].  Further, 
early warning indicators (EWI) exist to monitor how well sites are performing in 
relation to minimising the risk of HIV drug resistance (HIVDR) [300].  However, 
there is little consensus on priority indicators recommended by international 
agencies.  Table 6.1 shows indicators relating to outcomes on ART, recommended 
by major international funders of ART programmes (PEPFAR and the GFATM) and 
by the WHO in 2008 [69, 307, 308].  However, only one indicator specific to the 
outcome of patients in ART care is commonly recommended: the proportion alive 
and on treatment 12 months after ART initiation and even this is subtly different for 
the three organisations.  Indicators relating to, for example, on-time drug pick-up, 
concurrent prophylaxis, morbidities, and screening and treatment for Tuberculosis 
(TB), are prioritised differently by international organisations.  A multitude of  
 224 
 
Table 6.1 Comparison of indicators recommended to monitor ART care in LMIC as at end 2008 (similar indicators are across the same 
rows) 
 
WHO Global Fund PEPFAR 
Survival at 6,12,24 months after initiation of ART Percentage of adults & 
children known to be on 
treatment after 12 months 
on ART 
Percentage of persons still 
alive after 6,12,24 months 
on ART 
  Percentage of deaths 
attributable to HIV 
Percentage of patients lost to follow-up after 12 months on ART   
Percentage of persons starting first-line ART who are still on a recommended 
first-line ART regimen 12 months later 
  
Distribution of reasons for drug substitution, regimen switching, 
termination/interruption, & poor adherence 
  
Percentage of persons who attended all appointments during a year   
Percentage of individuals who demonstrate ≥90%  pill  count  adherence   
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WHO Global Fund PEPFAR 
Percentage of persons picking up all prescribed drugs on time during a 
quarter 
Number and percentage of 
facilities offering ART that 
meet national targets for 
ART patient on-time drug 
pick-ups 
 
Percentage of quarters in which there were no drug stock outages Number and percentage of 
health facilities dispensing 
ART that experienced 
stock-outs in the last 
12months 
 
Percentage of patients on ART whose functional status is working at 
6,12,24months 
  
Median  CD4  increase  &  percentage  with  CD4  count  ≥200  cells/mm³  at  6,12  
months on ART 
  
Percentage with side-effects, OIs, other problems  Percentage of patients on 
ART with AIDS related 
morbidity 
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WHO Global Fund PEPFAR 
  Percentage of chronically 
ill patients with severe 
pain & symptoms who 
report that their pain & 
symptoms were controlled 
  Quality of live for PLWHA 
Number of patients on Cotrimoxazole (CTX), Fluconazole, Isoniazid 
prophylaxis at end of month 
Number and percentage of 
HIV positive TB patients 
who received CTX 
preventive therapy 
Percentage of HIV positive 
patients who are given 
CTX preventive therapy 
Number and percentage attending HIV treatment and care services screened 
for TB symptoms and diagnosed with TB 
Number and percentage 
receiving HIV treatment 
and care services screened 
for TB symptoms  
Percentage of clients 
attending HIV testing and 
counseling who test 
positive and are screened 
for TB  
Number and percentage of ART patients simultaneously on TB treatment 
within last year 
Number and percentage of 
HIV positive incident TB 
cases that received 
treatment for TB and HIV   
Percentage of HIV-positive 
incident TB cases that 
receive treatment for TB 
and HIV 
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additional indicators (not shown) are recommended to report on the number of 
patients accessing ART and the number of additional services provided to patients 
on ART (e.g. the GFATM requests the number and percentage of health facilities 
which offer ART and also provide psychosocial support services, while PEPFAR 
request reporting on the number of individuals receiving ART with evidence of 
severe malnutrition who receive food and nutritional supplementation).  These 
indicators, too, are prioritised differently by different organisations.  In attempts to 
consolidate the plethora of indicators, UNAIDS created an online indicator registry.  
In 2008, this contained over 200 indicators from various funders and international 
health bodies relating to HIV care, including 55 specific to ART care [309].  Clinic 
staff members at the forefront of care find themselves burdened with a complex 
matrix of monitoring reports, particularly when programmes are supported by 
multiple funders [72].  The difference in recommendations highlights an uncertainty 
regarding which indicators are most useful for routine monitoring.   
 
Recognising the complexity of HIV programme monitoring, international 
organisations and national governments have committed to developing a common 
monitoring and evaluation system throughout a country with appropriate 
mechanisms to assess progress [310] [311].   In 2006, guidelines were published by 
the WHO for monitoring patients on ART, and templates made available online of 
standardised tools to collect and report such data [69].  Further work has included 
the publication by UNGASS in 2008 of 25 Core and 15 Recommended Indicators for 
HIV care,  two of which relate to assessing the health of patients on ART [295, 
309].  This has been the most comprehensive step in ART monitoring 
standardisation to date.   
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Given the increasing labour-intensiveness of monitoring systems, it is vital that only 
the most relevant indicators are collected.  It is important, therefore, to understand 
what data are currently collected in HIV programmes in LMIC.  Therefore, firstly, 
having previously reviewed the different outcomes reported by individual studies on 
patients in ART treatment cohorts (Chapter 2), I aimed to conduct a review of the 
literature to identify comparisons of which indicators or outcome data are reported 
nationally in LMIC.  I also aimed to review which indicators are recommended to be 
reported by authors in published literature.  Finally, I undertook a cross-sectional 
study to compare the implementation of the WHO and UNGASS recommended 
monitoring tools used to assess the health of the treated population in four LMIC.   
 
6.2 Review 
The main aim of the review was to synthesise the information from studies 
comparing which indicators or outcome data are reported to national MoH in LMIC 
ART programmes.  A secondary aim was to synthesise recommendations in 
published articles on which indicators are useful to collect to assess the health of 
the treated population.  
6.2.1 Search strategy 
My search strategy involved two stages.  Firstly, I used broad search criteria to 
identify English language studies published since the advent of ART in 1996 which 
compared or commented on monitoring outcomes or indicators used to assess the 
health of the population in ART care in LMIC.   I searched Medline through PubMed.  
The search was last updated on 16-11-2013.  I used the following search terms 
resulting in the number of references noted to capture programmatic monitoring of 
patients in HIV care: 
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i) terms related to HIV or AIDS: HIV or AIDS or HIV/AIDS (147, 692 
references) 
ii) combined with terms relating to monitoring: quality indicators, health 
system indicators, epidemiological monitoring (1,178 references)  
Having read the 1,178 titles, I excluded titles that described monitoring of or 
indicators used: in HIV prevention programmes; to assess the quality of services 
provided; titles which described patient monitoring techniques (e.g. telephone 
appointments versus face-to-face appointments), or titles which described indicators 
used the patient-level (e.g. to measure quality of life, to predict infections, or 
predictors of adherence). 
 
Thirty-six titles remained.  Having read these abstracts, I selected articles which 
described or commented on indicators or monitoring strategies for the population of 
patients in ART care, and were not related to indicators or outcomes used in clinical 
trials, were not specific to certain population groups (e.g. prisoners, or patients on 
methadone), and did not describe indicators for use at the patient-level (e.g. 
indicators of quality of life).  Four articles remained, 3 in English, 1 in Spanish 
(Table 6.2) [312-315].  I was unable to access the full text of the Spanish article 
thus the review is based on data extracted from the abstract.   
6.2.2 Review results 
At the time of the updated literature search, no comparison of national monitoring 
tools used in ART programmes in LMIC was identified.  One of the identified articles 
proposed a series of indicators derived after conducting a literature review of 
opinion articles.  The article which I was unable to retrieve described an expert 
panel review and proposed a set of indicators.  One article described a study 
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Table 6.2 Articles recommending ART programme monitoring tools or indicators 
 
Author Article aim Methods Results 
Catumbela 
[312]  
to identify a core set of 
indicators for assessment 
of HIV/AIDS patients 
literature review of 
organisations and authors 
proposing HIV care indicators 
65 indicators identified, including 15 relating to 
outcomes in care, 16 to monitoring, 12 to therapy 
indicators 
van 
Wichmann 
(GESIDA) 
[313]* 
to design quality of care 
indicators to be used in 
HIV units to identify 
results and introduce 
improvement measures 
committee of health 
professionals discussion, 
review by external reviewers, 
invited on public website for 
comments 
66 indicators discussed, reduced to final 22: a number 
relating to results in HIV care, of which a number 
relate to the follow-up of patients on ART and 
mortality rates.  Justifications were given for selected 
indicators as a measure of quality, dimension 
evaluated, calculation methods, standard to be 
achieved and commentary on the validity 
Liu [314] to test a hypothesis that 
incrementally setting 
quantitative targets for 
key M & E indicators 
would facilitate AIDS 
policy implementation in 
core indicators were 
developed  and implemented 
'07 - '09, with incrementally-
derived targets 
Indicators relating to being on ART were: number on 
ART with follow-up visits, proportion with CD4 count 
monitoring, proportion with viral load monitoring.  
Setting targets for core indicators facilitated 
implementation of national AIDS programme 
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Author Article aim Methods Results 
China 
Hong 
[315] 
to assess whether 5 of 
the WHO EWI HIVDR 
should be monitored in 
Namibia 
data of 5 WHO EWI HIVDR 
were extracted from 9 sites 
Supports monitoring of the following 3/5 WHO EWI 
HIVDR: proportion of sites initiating 100% of patients 
on first-line regimen, proportion of sites with ≤20% 
LTFU, proportion of sites with 0% switched to second-
line.  Patient retention on first-line at 12 months, on-
time drug pick-up and continuity of ART drug-supply 
were not deemed to be feasible to report 
Note: * abstract only retrievable
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evaluating the feasibility of collecting some of the WHO early warning indicators 
(EWI) of HIV drug resistance (HIVDR) in Namibia, and the final article described the 
use of indicators with quantitative targets as a measure of assessing ART roll-out in 
China. 
 
Similarities or commonalities of proposed indicators were seen in the following three 
areas: 
Retention in care 
i) Percentage of patients initiating ART at the site who are still on ART 
after 12 months; and whose initial ART regimen was changed during 
the first 12 months to a regimen with a different drug class (target: 
0%), 
ii) Proportion of patients on anti-retroviral treatment who survived and 
remained in treatment for 12 months 
iii) Follow-up of patients on ART; mortality of patients on ART (abstract 
article) 
Viral suppression 
i) Proportion of ART-naıve  patients  whose  viral  load  was suppressed 
during the first 6 – 12 months of treatment 
ii) Undetectable HIV viral load at 48 treatment weeks 
Continuity of care 
i) Percentage of patients initiating ART at the site who are LTFU during 
the 12 months after starting ART (target: <20%), 
ii) Proportion of patients with continued care  
 
The following additional indicators were recommended by individual articles: 
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i) Percentage of patients initiating ART at the site who are initially 
prescribed, or who initially pick up from the pharmacy, an appropriate 
first-line ART regimen (target: 100%) 
ii) Proportion of patients receiving ART who have been monitored for viral 
load at least once a year to monitor treatment failure 
iii) Proportion of patients receiving ART monitored for CD4 cell count at 
least once a year to determine treatment effectiveness 
iv) Proportion of patients with previous ART regimen change for whom 
reason for change in regime is documented 
v) Proportion of patients on ART with at least 95% (good) reported 
adherence on last visit 
vi) Proportion of patients on Cotrimoxazole prophylaxis with at least 95% 
reported adherence on last visit 
vii) Proportion of HIV-positive patients in HIV care or treatment (pre-ART or 
ART) who started TB treatment 
viii) Proportion of HIV-positive clients given treatment for latent TB Infection 
 
6.2.3 Review discussion 
Few articles were available for this review and the full text was not available for 
retrieval from one of the articles recommending a list of indicators.  This 
compromises the ability to establish clear recommendations to monitor ART care.  
However, even among expert panels, there remains little consensus on which data 
are important to collect from ART programmes.  Moreover, no articles compared 
across LMIC the indicators which are reported to national MoH.  Despite 
international recommendations, the priorities of LMIC national ministries of health 
remain unclear.    This is an important area of research as it is ultimately national 
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MoH who are responsible for the patients in their countries. Therefore, I designed a 
cross-sectional study to compare outcomes requested by national MoH to assess 
ART programmes in four LMIC. 
6.3 Aim, objectives and outline 
The aim of this study was to compare the degree to which internationally 
recommended monitoring tools and indicators used to assess the health of the ART 
treated population had been incorporated into national monitoring systems by the 
MoH in Malawi, Uganda, the Ukraine and Tanzania.  The secondary aim was to 
discuss challenges arising from monitoring the health of the HIV-infected population 
on ART using these currently recommended or collected indicators.  The objectives 
were to: 
 
•  compare across the four countries the implementation in 2008 and 2010 and 
frequency of use of the WHO and UNAIDS recommended ART programme 
monitoring tools in national monitoring systems,  
• compare the consensus with the international recommendations on the type of 
data collected in MoH reports and the inclusion of data required to calculate the 
UNGASS indicators,  
•  compare the concordance with the four countries of additional data collected, 
focusing on the use at end 2010,  
•  compare the age stratification used in reports, and to  
•  discuss  the  internal,  external,  content  and  context  validity  and  the  predictive  value  
over time of key indicators which were collected in the national monitoring reports. 
 
This work will provide a summary to national MoH and international researchers of 
similarities and differences in current practice relating to the monitoring of the 
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health of patients in ART care.  Commonalities across countries will highlight which 
indicators are perceived by national MoH to be the most important.   
6.4 Methods 
6.4.1 Settings and tools to be compared 
National monitoring tools were compared from countries selected by convenience 
sampling.  This was based on countries with partner organisations within the EfA 
collaboration who had staff capacity to support this study. Therefore, this study 
compared monitoring systems recommended by the MoH in Malawi, Uganda, the 
Ukraine and Tanzania.   
 
I compared the implementation of the WHO template tools recommended in 2006 
and the UNGASS Core and Recommended Indicators, proposed by organisations 
working through UNAIDS in 2008.  The tools and indicators were accessible online 
to MoH in LMIC and were the most up-to-date international recommendations for 
monitoring the health of the treated population.   I did not examine the use of 
indicators recommended by individual donors (e.g. PEPFAR or GFATM) as these 
requirements are in addition to national MoH requirements, and would only apply to 
programmes funded by certain donors.   
 
Comparisons with the recommended tools and indicators were conducted with tools 
designed for use in ART programmes by the MoH in each country.  I compared the 
recommended tools with MoH tools in use in 2008 and 2010.  These times were 
selected to follow on from the announcement of the WHO tools in 2006 and the 
UNAIDS recommendations in 2008 and for national systems to have incorporated 
the tools and indicators.    
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6.4.2 Gathering monitoring tools 
During visits to each country, I met the ART programme Monitoring and Evaluation 
(M & E) officer representatives of the MoH: Andreas Jahn (Malawi), Wilford Kirungi 
and Norah Namuwenge (Uganda), the heads of Odessa and Donestk regional AIDS 
centres (the Ukraine), and had electronic communications with Geoffrey Somi 
(Tanzania) due to travel logistics.  I discussed the rationale for and the aims and 
objectives of the study and sought and obtained consent from the MoH for their 
monitoring tools to be compared.  From each MoH representative, I obtained 
copies, as available of: individual treatment cards, ART registers, and cross-
sectional and cohort monitoring reports.   I gathered copies of the data-collection 
and reporting tools which were in use in national ART programmes at the end of 
2008 and 2010.   
 
I obtained copies of the international monitoring tools and indicators by internet 
download from the HIV M & E sections on the websites of the WHO and UNAIDS 
[69, 316].   
6.4.3 Analytical methods 
Firstly, I examined the frequency of requested reporting by each MoH and whether 
or not the MoH was implementing the internationally recommended monitoring 
tools.  Secondly, for each tool, using tables created in Microsoft Excel, I examined 
the consensus with the international recommendations on the type of data collected 
in the MoH reports, and the inclusion of data required to calculate the UNGASS 
indicators.   I grouped data items for comparisons into categories broadly 
representing patient status at ART initiation, outcomes on therapy and treatment 
received. I compared the tools used in the four countries at the end of 2008 and 
2010.  Thirdly, for each tool, I compared the concordance with the four countries of 
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additional data collected, focusing on the use at the time of data-collection at the 
end of 2010.  As no template tool was available for the cross-sectional reports, I 
examined the collection of UNGASS-related data in the MoH cross-sectional reports 
and compared data items collected across the countries.  Where additional data-
items were collected by a country without being recommended in the international 
tools, this was noted.  Finally, I compared the age stratification used in reports.  
 
I discuss the implications of using key indicators which were collected in the 
national monitoring reports requested by the MoH in the four countries.  I focus the 
discussion on the internal, external, content and context validity of monitoring 
indicators and their predictive value over time.  
6.5 Results 
6.5.1 Recommended and available monitoring tools 
To monitor the health of the population on ART, the WHO 2006 guidelines 
recommended the use of the following tools: 
i) individual treatment cards to gather information on patients in care,  
ii) ART registers to gather information of the patient-population in care, 
iii) cross-sectional monitoring reports to report aggregated information on 
the population in care, and  
iv) cohort monitoring reports to report aggregated information on reporting 
cohorts of patients in care 
Template tools for a patient treatment card, ART register and cohort monitoring 
report were accessible from the website of the WHO.  No template was available for 
cross-sectional reporting, despite this being recommended in the WHO guidelines 
[69].   
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The following UNGASS indicators were the only two that specifically related to the 
health of patients in ART care: survival at 12 months (defined by UNGASS as the 
percentage of adults and children with HIV known to be on treatment 12 months 
after initiation of ART); TB incidence (percentage of estimated HIV positive incident 
TB cases that received treatment for TB and HIV).   
 
For all four countries, I accessed patient monitoring cards, ART registers, and cross-
sectional and cohort reports, with the exception of the 2008 Malawian ART register 
which was not available.   
6.5.2 Implementation of recommended monitoring tools 
In 2008, Malawi, Uganda and Tanzania were using all the tools recommended in the 
2006 guidelines to monitor the health of patients on ART.   The Ukraine was using 
only a patient master card and a cross-sectional report.  While all four countries 
were using a cross-sectional monitoring report, reporting frequency varied between 
quarterly reporting in Malawi to the more labour-intensive monthly reporting in the 
Ukraine and Uganda.   Tanzania reported both quarterly and at monthly intervals.  
Malawi collected reports on the health of treated cohorts at 12-monthly intervals 
while Uganda and Tanzania reported cohort outcomes at 6 months, then 12-
monthly.   
 
By 2010, all four countries were using all four types of ART programme data 
collection and reporting tools.  The frequency of cross-sectional reporting was 
standardised, with reports completed quarterly, rather than monthly, in all 
countries.  However, the frequency of cohort reporting continued to vary, with the 
Ukraine reporting at the same 12 month frequency as Malawi, while the frequency 
of cohort reporting in Uganda and Tanzania remained unchanged.   
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6.5.3 Concordance in the number of recommended data collected and 
reported 
 
Table 6.3 shows the number of data items recommended for collection in the 
international template tools.  Twenty-nine items were recommended to be collected 
in the patient master card and 14 items were recommended for collection in each of 
the ART register and cohort report.  Table 6.3 also shows the discordance between 
the number of items recommended and the number collected and reported across 
the four countries.   The proportion of the template data collected in each country 
ranged from 24% to 100% in 2008, and from 36% to 97% in 2010.  For example, 
the template ART register recommends 14 data-items, but in 2010, Malawi collected 
only 6 (43%) of the items recommended in the template.   
 
Across all the tools, by 2010, Uganda, the Ukraine and Tanzania collected 
individually between 71% and 97% of recommended data.  However, common use 
across all the countries of the same recommended data was low both in 2008 and 
2010, with the exception of the 2008 ART register.  The available 2008 ART 
registers from Uganda and Tanzania showed a high degree of concordance in 
recommended data in and across the two countries.  However, in the 2008 master 
cards and cohort reports, only 10% and 21% of the recommended data were 
commonly collected in all four countries.  Across all the registers with available 
templates, despite progress towards collecting standardised data by 2010, less than 
half of the recommended data remained commonly collected in all four countries: 
48% in the patient master card, 29% in the ART register and 29% in the cohort 
reports.
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Table 6.3 Number of data-items in internationally recommended template tools, number (%) of recommended data-items collected in 
Malawi, Uganda, the Ukraine and Tanzania (2008, 2010), and number (%) of recommended template data-items commonly collected 
 2008 2010 2008 2010 2008 2010 2008 2010 
Data-collector Number of data-items 
collected 
Patient master card ART register Cross-sectional 
report 
Cohort report 
Recommended 
template tool 
Total number of data-items 
29 14 
Template not 
available  
14 
Malawi Number (proportion) of 
template data-items 
collected 
12 (41%) 20 (69%) 
Data not 
available 
6 (43%) - - 5 (36%) 5(36%) 
Uganda Number (proportion) of 
template data-items 
collected 
27 (93%) 28 (97%) 13 (93%) 12 (86%) - - 13 (93%) 10 (71%) 
Ukraine Number (proportion) of 
template data-items 
collected 
7 (24%) 22 (76%) 
Tool not in 
use (0) 
10 (71%) - - 
Tool not 
in use (0) 
10 (71%) 
Tanzania Number (proportion) of 
template data-items 
collected 
21 (72%) 24 (83%) 14 (100%) 12 (86%) - - 12 (86%) 13(93%) 
All countries Number (proportion) of 
template data-items 
commonly collected in all 
countries 
3 (10%) 14 (48%) 13 (93%)* 4 (29%) 3 1 3 (21%)^ 4 (29%) 
*2009 Malawi unavailable & Ukraine not using register therefore 2-country consensus comparison;^No cohort reporting done in Ukraine 2008 therefore 3-country comparison 
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6.5.4 Concordance in type of data recommended with those collected 
and reported 
Table 6.4 shows the concordance between types of data relating to ART care 
recommended in the Template Master Card (TM) and Template ART Register (TR) 
with items in the equivalent MoH tools in 2008 and 2010.  Table 6.5 shows the 
concordance between types of data relating to ART care recommended in the 
Template Cohort (TC) reporting tool with data collected in the MoH cohort reporting 
tools, and additionally shows data collected in MoH Cross-Sectional Monitoring 
Reports (CS) in 2008 and 2010.   
 
In the master cards in 2008, there was much discordance between recommended 
data and those used nationally.  The only commonly collected template data were 
patient demographics, weight (and height for children), and WHO stage or CD4 
count at enrolment into care.  By 2010, though many data at enrolment were not 
recorded by all countries, a far larger degree of consensus was observed.  Of note, 
key recommended primary outcome data relating to deaths, transfers-out and 
treatment interruptions and switches were commonly collected across all countries.  
Many secondary outcomes were also commonly reported by 2010, including for 
example information on TB status at each appointment, ART adherence and OI 
prophylaxis and diagnosis.   
 
Within the ART register, in 2008 Uganda and Tanzania, the only countries with 
available data or using the tool, collected all the recommended data relating to ART 
initiation, outcome and treatments, with the exception of Isoniazid prophylaxis (IPT) 
which was not collected in Tanzania at the time.  By 2010, all four countries were 
collecting the recommended ART initiation data on demographics, ART start date
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Table 6.4 Concordance between types of data-items recommended in Template 
Master Card (TM) and Template ART Register (TR) data-collection tools with 
data-items used in Malawi (Mw), Uganda (Ug), the Ukraine(Ur) and Tanzania 
(Tz), (2008, 2010) 
 2008 2010 2008 2010 
Type of data-item Patient master card ART register 
Enrolment information     
*Patient demographics (sex, age)  TM,  TR Ur, Mw, Ug, Tz Ur, Mw, Ug, Tz Ug, Tz Ur, Mw, Ug, Tz 
Transfer-in status  TM,  TR Mw, Ug, Tz Mw, Ug, Tz Ug, Tz Mw, Ug, Tz 
Prior ART exposure  TM Ug, Tz Mw, Ug, Tz - - 
Date confirmed HIV positive, date enrolled to 
care  TM 
Ug, Tz Ug, Tz, Mw - - 
HIV status of family members  TM Ug Ug - - 
Date eligible for ART, date ready to start ART  
TM 
Ug, Tz Ur, Ug, Tz - - 
Reason for ART eligibility TR - - Ug, Tz Mw, Tz 
*ART start date  TM,  TR Mw, Ug, Tz Ur, Mw, Ug, Tz Ug, Tz Ur, Mw, Ug, Tz 
ART type  TM,  TR Ur, Mw, Ug Ur, Mw, Ug Ug, Tz Ur, Mw, Ug, Tz 
Weight & height (children)  TM,  TR Ur, Mw, Ug, Tz Ur, Mw, Ug, Tz Ug, Tz Ur, Ug, Tz 
WHO stage or CD4 count  TM, TR Ur, Mw, Ug, Tz Ur, Mw, Ug, Tz Ug, Tz Ur, Ug, Tz 
Functional status  TM,  TR Ug, Tz Tz Ug, Tz Ug, Tz 
Primary Outcomes     
*Death + date  TM Mw, Ug Ur, Mw, Ug, Tz - - 
*Discharge/transfer-out and date  TM Mw, Ug Ur, Mw, Ug, Tz - - 
*Regimen interruption/stopped ARVs and date  
TM 
Mw, Ug, Tz Ur, Mw, Ug, Tz - - 
Regimen switch/change and date  TM, TR Mw, Ug Ur, Mw, Ug, Tz Ug, Tz Ur, Mw, Ug, Tz 
*Lost  TM Mw, Ug Mw, Ug, Tz - - 
Appointment information     
Weight, height (for children)  TM Mw, Ug, Tz Ur, Mw, Ug, Tz - - 
*TB status  TM Ug, Tz Ur, Mw, Ug, Tz - - 
Adherence  TM Mw, Ug, Tz Ur, Mw, Ug, Tz - - 
OI diagnosis, treatment  TM Ug, Tz Ur, Mw, Ug, Tz - - 
OI prophylaxis   TM, TR Mw, Ug, Tz Ur, Mw, Ug, Tz Ug, Tz Ur, Ug, Tz 
INH prophylaxis/treatment TR  -   -  Tz Ug, Tz 
TB treatment TR  -   -  Ug, Tz Ur, Ug, Tz 
WHO stage  TM Ur, Ug, Tz Ur, Ug, Tz - - 
CD4 count or percent  TM,  TR Ur, Ug, Tz Ur, Ug, Tz Ug, Tz Ur, Ug 
Functional status  TM,  TR Ug, Tz Ur, Ug, Tz Ug, Tz Ur 
Regimen type  TM Ur, Tz Ur, Mw, Ug, Tz - - 
Pregnancy status  TM,  TR Ug, Tz Ur, Ug, Tz Ug, Tz Ur, Ug, Tz 
PMTCT  TM  Ur, Ug - - 
Duration of time on ART  TM Ug Ur, Ug - - 
Side –effects  TM Ug, Tz Mw, Ug - - 
*items used to calculate UNGASS indicators relating to the number alive at 12 months and TB status 
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Table 6.5 Concordance between types of data-items recommended with data-
items used in Template Cohort Report (TC) and in Cross-Sectional Monitoring 
Reports (CS)  in Malawi (Mw), Uganda (Ug), the Ukraine(Ur) and Tanzania (Tz), 
(2008, 2010) 
 
 2008 2010 2008 2010 
Type of data-item Cohort report Cross-sectional report 
ART initiation     
*Number registered for ART care (cumulative & this 
quarter) 
- - - Mw 
*Number started on ART: in the original cohort (TC) 
                                    : at beginning & at end of 
quarter 
                                    : this quarter 
                                    : cumulative 
                                    : excluding transfer-ins 
Mw, Ug, Tz 
- 
Mw, Ug, Ur, Tz 
- 
- 
Ug, Ur, Tz 
Ug, Ur, Mw 
Mw 
Tz 
- 
Ug, Tz 
Ug, Mw 
Mw 
Tz 
Number of transfers-in from another facility (TC) Ug, Tz Ug, Ur, Tz   
Number transferred-in on ART (cumulative and/this 
quarter) 
  - Mw, Tz 
Number of Transfers-out from this cohort (TC) Mw, Ug, Tz Mw, Ug, Ur, Tz   
Net current cohort (TC) Ug, Tz Ug, Ur, Tz   
Number restarted on ART (this quarter & cumulative)    Ug Mw 
Number starting ART by reason: WHO stage/CD4 count 
(cumulative & this quarter) 
  Mw Mw 
Number started on ART with TB (cumulative & this 
quarter) 
  Mw Mw 
Number started on ART with KS (cumulative & this 
quarter) 
  - Mw 
Number of baseline CD4 counts done (and median CD4) 
for person started on ART in last month 
  Ug  
Number on any first-line/second-line regimen (this 
quarter) 
  - Tz 
Primary outcomes      
*Current number on ART at end of reporting period 
   : by sex and age 
   : by sex, age and funder 
  Mw, 
Tz, Ug 
Mw 
Tz, Ug 
Ur 
*Number not on ART at end of quarter due to death/ 
default/transfer-out/ stopping ART (cumulative) 
  Mw, Ug, Ur Mw, Tz 
*Number/percentage of cohort alive and on ART (TC) Mw, Tz, Ug Mw, Ur, Ug, Tz   
*Number dead; stopped treatment (TC) Mw, Ug Mw, Ug, Ur, Tz   
*Number lost to follow-up (TC) Mw, Ug Mw, Ug, Tz   
Number died within 1/2/3/>3 months of ART (cumulative)   Mw Mw 
Number in need of ART and receiving/ not yet receiving 
ART  
   Ur 
Secondary outcomes     
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Number on original first-line regimen (TC) Tz, Ug Ug, Ur, Tz   
Number on alternative first-line regimen (TC) Tz Ur, Tz Mw Mw, Ur 
Number on second-line (TC) Tz, Ug Ug, Ur, Tz   
Number on any/specific first-line regimen; on any/specific 
second line regimen 
(by sex and age) 
(by sex, age and by funder) 
  Mw, Ug, Tz 
Tz, Ug 
Ug 
Tz, Ur/Mw, 
Ug 
Ug 
Ur 
Total on any non-standard regimen   - Mw, Ur 
Number who switched    Ur  
CD4 median or proportion=>200 (optional) (TC) Tz, Ug Ug, Tz   
Functional status (TC) Tz, Ug  Ur, Tz   
Number with side-effects (cumulative)   Mw Mw 
*Number with TB: assessed (this quarter) 
                         : confirmed (cumulative/this quarter) 
                         : on treatment (cumulative/this quarter) 
  - Ug 
Mw, Ur 
Mw, Ug 
Number of IDUs and number with hepatitis    Ur 
Adherence: number picking up ART 6/6 months (TC) 
                : number picking up ART12/12 months (TC) 
                : based on drug pick-up in previous months 
                : based on missed doses this quarter 
Tz, Ug 
Tz, Ug 
Tz 
- 
 
 
Ug 
Mw 
 
 
 
Mw 
*items used to calculate the UNGASS indicators relating to the number alive at 12 months and TB 
status 
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and regimen type.  Remaining recommendations at initiation on WHO clinical stage 
or CD4 count, weight, height for children and functional status and recommended 
data at follow-up were recorded to varying degrees.   
 
In the 2008 cohort reports, recommended primary outcome data which are 
essential  to  calculate  the  ‘survival’  indicator  as  accurately  as  possible  data  were  not  
commonly reported.  Only in 2010 did the three African countries report the 
percentage of the original cohort alive and on ART, distinguishing between patients 
who had died, stopped treatment or become lost to follow-up.  The Ukraine did not 
report on losses to follow-up when calculating this key indicator.  Further 
differences were observed in the reporting on secondary outcomes such as drug 
switches and adherence.   
 
No template was available for the cross-sectional reports and the variability in data 
collected in the reports, both in 2008 and 2010, was high.  Variation was in part due 
to reporting being done on the cumulative number of patients in care or on the 
current group of patients in care.  Furthermore, while data on, for example the 
number of patients alive and on ART at the end of the reporting period, were 
recorded in all countries, they were not commonly disaggregated by sex and age.   
While the number of patients still on a first-line regimen was recorded in all 
countries, only Malawi and the Ukraine additionally reported the number on 
alternative first-line or non-standard regimens.   Data on adherence was reported in 
Malawi and Uganda, but it was calculated differently in the two countries, based on 
missed doses in Malawi and drug pick-up in Uganda.  
6.5.5 Concordance with additional data-items 
Table 6.6 shows the types of data, additional to those items recommended in the  
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Table 6.6 Discordance in additional data-items not specifically recommended but 
used in master card (MC), ART register (AR) and cohort report (CR) in Malawi 
(Mw), Uganda (Ug), the Ukraine(Ur) and Tanzania (Tz), (2008, 2010) 
 
 2008 2010 
Type of data-item All reports  
Enrolment information   
ART funding source (MC) Ur, Ug Ur 
TB identification number (MC)  Tz 
Route of transmission (MC) Ur  
ART initiation   
Date eligible for ART, date ready to start ART (AR)  Ur 
First-time initiation/Re-initiation/prior ART exposure (AR) Tz Mw, Tz 
Occupation (AR)  Mw 
Free drugs or paying for drugs/funding source (AR) Ug Ur 
CD4 count or percent (MC) Ur, Ug, Tz Ur, Mw, Ug, Tz 
Viral load (MC) Ur Ur 
TB & KS status (MC, AR) Mw (MC) Mw (MC), Mw (AR) 
KS status (MC) Mw Mw 
Pregnancy status (MC, AR) - Mw (MC), Ug (MC), 
Mw (AR) 
Absolute lymphocyte count (MC) Ur, Ug, Tz - 
PMTCT (MC) Mw - 
Number on 1st line regimen at beginning of period (including subs) (CR) 
Number on 2nd line regimen at beginning of period (inc switch) (CR) 
Fraction of patients with CD4=>150cells (CR) 
Median CD4 at beginning of period (CR) 
Number with CD4% not classified as severe at beginning of period (CR) 
- Ug 
Primary Outcomes   
*Adverse outcome: death (AR) Ug, Tz Ur, Mw, Ug 
Death within 1/2/3/>3 months of ART (AR)  Mw 
*Lost to follow-up/default (AR) Ug, Tz Ur, Mw, Ug 
*Stopped ART (AR) Ug, Tz Ur, Mw, Ug 
*Transferred out (AR) Tz Ur, Mw, Ug 
Appointment information   
Number of times restarting ART after default/stop> 2 months while at 
this site: 1st, 2nd, 3rd, 4th restart (AR) 
 Mw 
Clinical stage (AR)  Ug 
Number with CD4 count done (CR) - Ur 
Number/proportion of adults with CD4 count equal to or above threshold 
(CR) 
Tz (>200 
cells) 
Ug (>200cells) 
Ur (>350cells) 
Ug (>250 cells) 
Tz (>200 cells) 
Number of infants, young children and children with CD4 above threshold 
/not classified as severe (CR) 
Ug Ur, Ug 
*TB status (AR)  Ur, Ug 
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TB prophylaxis (MC) Tz Tz 
Diflucan / Fluconazole (AR) Tz Ug 
Heamoglobin (MC) Tz Ur, Tz 
Viral load (MC, AR) Ur (MC) Ur (MC), Ur (AR) 
Number with viral load done and number with VL < 75 copies/ml (CR) - Ur 
Child MUAC (MC)  Ug 
Weight, child height (AR) Tz Ur, Ug 
Exposed infants: feeding practices at 2 months, CPT started by 2 months, 
HIV result (MC) 
 Ug 
Nutritional status, supplements needed/given (MC) Tz Tz 
IDU status & Hepatitis status (MC, AR)  Ur (MC), Ur (AR) 
Adherence: missed drug pick-up (AR) 
               : missed appointment (AR, CR) 
               : not specified (AR) 
               : good, moderate, poor (CR) 
Ug 
Tz (AR) 
Ug 
Ug (AR), Ug (CR) 
Ur 
Ur 
Number who regularly and promptly received ARV (CR)  Ur 
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templates, collected and reported in MoH monitoring tools, and their discordant use 
across the countries.  For example, in the 2010 patient master card, data relating to 
TB status in Malawi and to viral load in the Ukraine were collected at ART initiation 
although these were not the template data and were not recorded elsewhere.  At 
follow-up  appointments,  data  were  collected  in  the  master  card  in  Uganda  on  child’s  
mid-upper arm circumference and in the Ukraine on intravenous drug use status.  
Similarly, in the 2010 cohort reports, Uganda, the Ukraine and Tanzania report on 
the proportion of adults with CD4 count above a certain threshold.  However, the 
threshold in all three countries was different, from 200 cells in Tanzania, to 250 cells 
in Uganda, to 350 cells/mm³ in the Ukraine.  Malawi recorded information 
specifically on the time since ART when deaths occurred, though this was not 
recorded elsewhere. 
6.5.6 Consensus on paediatric age groupings 
In the absence of ART outcome indicators specific to paediatric populations, the 
tools used to report on those in care captured data for the combined clinic 
population and the population disaggregated by age.  However, different age bands 
were used across the tools.  For example, when reporting on the number of patients 
on ART in the 2010 cross-sectional reports, infants were categorised as those aged 
less than 17 months in Malawi, less than 12 months in Uganda and Tanzania, and 
aged 0 – 3 years in the Ukraine.  Children were categorised broadly as 18 months – 
14 years in Malawi, as 1 – 4 years and 5 – 14 years in Uganda and Tanzania, and as 
4 – 10 and 11 – 14 years in the Ukraine.  Within the same cross-sectional reports, 
data on the number on first and second-line regimens were disaggregated into 
broad  categories  of  ‘children’  in  Malawi  and  those  aged  0  –14 years on Uganda, 
Tanzania and the Ukraine.   The cohort reports were disaggregated less by age.
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In Malawi, a separate cohort survival analysis for all children aged less than 15 
years was reported at 12 months but at no other time, while Tanzania did not 
disaggregate the cohort reports by age.  Uganda reported on the baseline and 
follow-up median CD4% for children less than 5 years of age at all cohort reporting 
times while the Ukraine reported on the number with CD4% above specified 
thresholds for children aged 0 - 12 months, 12 - 35 months and 36 months and 
above. 
6.6 Discussing challenges with ART programme monitoring tools 
This section discusses the challenges arising from monitoring the health of the HIV-
infected population on ART using the observed recommended or collected 
indicators.   Key challenges of certain indicators are described in Table 6.7.  I 
discuss these challenges in more detail below. 
6.6.1 Internal validity  
Programme managers need to be able to rely on monitoring indicators to make 
correct inferences about the health of the treated population to inform patient care.  
However, data inaccuracies will compromise this ability.  For example, an audit of 
routinely reported data in Malawi indicated that 28% of sites inaccurately reported 
the cumulative number of patients alive on ART or the number on first line regimen 
at end of quarter.   This resulted in a 5% and 12% undercount of the number of 
patients on ART, and on first line regimen, respectively [297].  Furthermore, an 
examination of ART databases in LMIC found nearly 11% of missing data for key 
variables, which would contribute to inaccurate indicators [317].  Manual monitoring 
systems used to report on ART care in LMIC are susceptible to incomplete data and 
data entry errors and the cohort monitoring system may be particularly at risk of 
data errors  [72, 297, 317].   Cohort monitoring requires the creation, as patients 
initiate ART, of new reporting cohorts within an ART programme at specified 
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Table 6.7 Indicators commonly collected to monitor the health status of the treated population within HIV treatment and care programmes 
 
ART programme 
indicator 
Construct being measured Validity  
Number initiating ART at 
beginning of reporting 
period 
Total number of patients newly 
initiating ART in a clinic during a 
specific reporting period 
Fails to account for drug-experienced patients transferring, 
overestimating those in care and underestimating survival 
Proportion of treated 
population alive and 
known to be on ART 6, 
12, 24 months after ART 
initiation 
Survival of treated population Measures retention in care. 
High numbers of transfers out may underestimate country-wide 
retention.  
Absence of person-time denominator compromises details of length of 
survival after initiation. 
Absence of information on vital status for patients not returning for care 
biases survival estimates. 
Cross-programme comparisons highly susceptible to misinterpretation. 
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ART programme 
indicator 
Construct being measured Validity  
Proportion of patients lost 
to follow-up 6 months 
after ART initiation 
Retention in care 
 
Resources available to trace the vital status of those lost to follow up 
vary between programmes making comparisons inappropriate. 
Median CD4 cell count  
or percentage increase 6 
months after ART 
initiation 
Improvement in immunological 
status of treated population 
Fails to take into account those no longer in care, who may have lower 
CD4 cell counts, overinflating population CD4 cell counts 
Complex numerical calculations routinely produced from paper-based 
systems may lead to data inaccuracies. 
Proportion demonstrating 
>90% adherence by self-
report 
Adherence to treatment regimen May be influenced by expectation of socially desirable answer. 
Challenging to measure in infants using liquid formulations. 
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intervals, for example, quarterly.  With the numbers of patients accessing ART 
increasing, creating new cohorts routinely will result in growing numbers of cohorts 
to be reported on over time.  As reporting is required on the health of patients in 
each cohort throughout the time for which any patient remains in care, this will lead 
to an ever-increasing level of data to be collected and reported.   And the number 
of data items required to compute some of the indicators can be vast, far exceeding 
the number of indicators themselves.   For staff working in busy ART facilities, 
manually computing multiple indicators at frequent intervals is time-consuming and 
impacts on the completeness and accuracy of reports [317], [297], [72].  
Ultimately, the scope for error in generating monitoring reports will depend on 
competing priorities for clinic staff. 
 
In the absence of universal electronic record systems, further challenges to the 
current paper-based systems include extracting and deriving data for reports from 
records stored in different sections of health centres, e.g. antenatal care, 
tuberculosis treatment wards and ART clinics.  Commonly, registers kept in each 
department are unlinked and unique patient identifiers which are common across 
the departments are rare [93].  This may lead to over-counting of patients.  For 
example, some patients initiate Cotrimoxazole Preventive Therapy (CPT) in an 
antenatal clinic but also go on to register in the pre-ART register when initiating HIV 
care.  This register is likely to have a tick-box column asking if the patient has been 
initiated on CPT.  Reporting on the number of patients initiated on CPT using data 
from both the antennal clinic and the pre-ART register, in the absence of unique 
patient identifier common to both clinics, not surprisingly results in double-counting 
of patients and an overestimation of the indicator.   
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6.6.2  Construct validity 
Programme managers must be able to rely on indicators to measure the theoretical 
construct they intend to measure to obtain robust estimates of the size and health 
of the population in care.  However, a number of fundamental indicators may not 
measure what they intend to measure.   
 
The ability of the denominator used for most indicators, number initiating ART at 
the beginning of the reporting period, to represent correctly those in care is 
questionable.  The cohort grouping, rarely, if ever, distinguishes between patients 
newly initiating therapy and drug-experienced patients transferring in from another 
clinic.  Yet the number of patients transferring between clinics can be high.  In 
Malawi, for example, 12% of patients who registered in the national ART 
programme during the second quarter in 2009 had transferred from another clinic 
[318].   Failure to capture these details will considerably inflate the reported number 
of new ART initiators.  For donors who use information on the number of patients 
enrolling for ART to provide accountability for spending, a slight over-count in the 
number of persons provided with ART may have limited consequence, or indeed 
may appear good for the donor.  However, for programme managers aiming to 
understand the survival of patients since they initiate ART, the cohort will contain 
patients who have remained alive on ART for a number of months already and are 
likely to be healthier than new initiators.  Furthermore, the inflated number of new 
initiators, used by programme managers as the denominator for most indicators, 
will fundamentally bias reported indicators.   For example, in a hypothetical 
scenario, if 360 new ART initiators die by 12 months, the proportion of new 
initiators to have died will appear to be 18% if a cohort has 2000 patients.  
However, assuming transfers-in accounted for 12% of the cohort (as per the Malawi 
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data), the true number of new initiators would be 1785 patients and the same 
number of cases would result in the proportion (20%) of patients to have died being 
higher.  The more prevalent the outcome of interest, the more extreme the bias will 
be.  Moreover, for the MoH or researchers, monitoring patient survival after ART 
initiation, this will be underestimated as cohorts which fail to take into account 
transfers-in will include some patients who have been on ART for longer than the 
time registered in the clinic. 
 
Understanding survival on ART in LMIC has further challenges. In survival analysis, 
patients contribute different durations of follow-up until an event, (in this case 
death).  However, in LMIC, as many clinics lack the infrastructure to capture patient 
data electronically or the statistical software for complicated computations, 
calculating  ‘survival’  is  not  practical.    Therefore,  as seen in the literature review, 
facilities  create  reporting  cohorts  and  attempt  to  capture  ‘survival’  by  reporting  the  
number of patients on ART at the beginning and end of a discrete time period.  This 
indicator, in reality, captures the proportion retained in care of those who enrolled 
for therapy.  There is no person-time denominator and the important detail of how 
long people are alive after starting therapy is lost.   
 
Moreover, the status of patients not returning for ART is captured as died, lost to 
follow-up (LTFU), stopped ART or transferred-out.   Yet, accurately estimating each 
of these indicators themselves is complicated and failure to distinguish between 
them will bias retention and survival estimates.  For example, a review of 17 studies 
in LMIC demonstrated that 40% of patients recorded as LTFU whose outcome could 
be ascertained through active follow-up had died [319].  Failure to account for the 
fact that some patients who are recorded as LTFU will have died will lead to an 
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overestimation of survival.  Conversely, it is likely that some patients who are 
recorded as LTFU will have transferred unofficially and be receiving ART elsewhere.  
Failure to account for these patients, or to account for patients who transfer-out 
officially and follow-up their transfer, will negatively bias survival estimates and 
underestimate true retention in a country-aggregated monitoring system.  For 
example, in northern Malawi, 90% of patients who were recorded as having 
transferred-out from ART-clinics were alive and on ART elsewhere, while the 
remaining 10% were not  [320].  However, assuming all patients who transfer-out 
will follow-up on the transfer is likely to be over optimistic.  The ability to capture 
data accurately on deaths and transfers will greatly influence interpretation of 
survival and retention on ART.  
 
It has been demonstrated, among southern African IeDEA cohorts that the 
competing risk of death may bias standard analyses of LTFU by as much as 6.4% 
[91].  Similarly, adjustments to correct mortality estimates for LTFU have been 
proposed. One method derives a correction factor (from the percentage of patients 
LTFU and an estimated ratio of mortality among patients lost and not lost) and 
applies it to estimated mortality among patients not lost from care, and was 
proposed by members of the IeDEA collaboration [92].  Other methods involve 
imputing data based on mortality estimates from studies which traced patients 
LTFU, or using combinations of imputed data and linkages to vital registers  [93] 
[90].  Using these three methods, programme mortality estimates which fail to 
account for mortality among patients LTFU were estimated, respectively, to be 
biased by nearly 10%, between 27 - 73%, and by over 100% [92] [90, 93].  As 
expected, bias in mortality estimates has been noted in studies reporting high LTFU 
[92].   
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Treating HIV as a chronic condition means that managers must maximise retention 
in care because patients who interrupt ART risk ongoing HIV transmission, 
incomplete virological suppression, immunological decline, opportunistic infections 
and death [298].  However, programme performance must not be assessed using 
‘retention’  as  a  stand-alone indicator as this gives equal weight to the number of 
patients who have died as to those transferring-out or stopping ART [321].   
Programme managers and funders must base human-resource planning and clinical 
care decisions on data relating to retention, survival, deaths, LTFU and transfers-out 
with extreme caution.  
 
Further examples of indicators representing complex constructs that are difficult to 
observe directly include measures of patient satisfaction and adherence to ART, 
which may capture a perceived socially-desirable answer rather than the true one.  
Furthermore, assessing the progress of an ART programme based on patients 
retained in care may overstate performance.  For example, evaluating a programme 
on the median CD4 count increase after 6 months fails to take account of those no 
longer in care who are expected to be sicker than those retained in follow-up [322]. 
6.6.3  Content validity 
It is vital that the data content of an indicator represents what the indicator aims to 
measure.  For example, the indicator proportion of a cohort whose functional status 
is working aims to measure increased productivity, and thus successful ART [69].  
Therefore,  the  data  classifying  a  patient’s  functional  status  as  working, ambulatory 
or bedridden must truly represent productivity and health status.  However, a 
patient’s  functional  status  may  change,  due  to  necessity,  without  an  associated  
health improvement.  Furthermore, interpreting functional status classifications may 
differ.  One site may record patients actively employed, while another records all 
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patients able to work but not necessarily employed.  Moreover, functional status is 
often poorly completed on patient treatment cards (personal communication A Jahn 
December 2009) and, as such, programmes may inaccurately estimate productivity 
changes.  
 
Certain indicators are recommended to be collected as proxies to monitor the 
development of HIV drug resistance within a treated population.  However, these 
indicators may not represent the constructs they intend to.  For example, in a study 
in Namibia, 100% of surveyed sites met the target of 100% of patients initiated on 
an appropriate first-line regimen, yet only 67% of sites met the target of 0% 
switched to a second-line regimen [315].  Both indicators cannot purport to 
measure how well a site is doing to prevent HIVDR when there is a difference of 
more than 30% in their estimates.  
 
Recently, assessments of pharmacy refill adherence have been shown to be as 
accurate as CD4 counts for detecting patients at high or low risk of virological failure 
[258].  However, while measures such as pharmacy refill or weight gain may 
indicate improved immunological or virological status at the patient level, producing 
it routinely from paper-based systems may result in poor quality data used to 
calculate even a sound indicator [323, 324].  The validity of using such manually-
derived aggregates to assess the health of the treated population has never been 
examined.   
6.6.4  External validity 
As indicators  are  used  to  learn  from  more  ‘successful’  programmes  to  improve  
patient  care,  and  to  compare  programmes’  performance  to  inform  resource-
allocation decisions, indicators must make correct inferences about different  
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populations.   
 
A  programme’s  mortality  and  retention  indicators,  cautiously  interpreted  within  the  
programme’s  context,  can  provide  vital  information  to  managers  to  ensure  high  
quality of care.  However, using these indicators to assess performance across 
programmes is problematic, particularly if different inclusion criteria have been 
used.  For example, enrolling patients based on demonstrated good prophylaxis 
adherence  and  an  absence  of  alcohol  problems  may  result  in  a  programme  ‘out-
performing’  another  which  has  no  selection criteria [325]. 
 
Furthermore, some sites trace patients LTFU to encourage them back into care.   By 
ascertaining the vital status of those LTFU, a site may report a high number of 
deaths.  Increased reporting of deaths is also likely if sites adjust their survival 
estimates using correction factors or imputed data for patients LTFU [92] [84, 90, 
93].  Comparing these indicator estimates to programmes without the ability to 
trace patients or adjust estimates is clearly inappropriate. 
 
Stratifying indicators by age groups is important within a programme to evaluate 
the effectiveness of ART for infants, children, adolescents and adults.  However, 
subtle differences in age stratifications in different programmes make cross-
programme comparisons challenging.  Moreover, reporting the same indicators for 
adults, children and adolescents may be inappropriate.  For example, indicators 
report the proportion of patients demonstrating >90% adherence.   However, in 
infants, given that their medication is a liquid formulation, measuring adherence is 
particularly challenging [326].   And, adolescents, a substantial epidemic of whom is 
emerging in sub-Saharan Africa [327], experience particular issues as a result of 
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long-term infection, including stunting, puberty delay and histories of chronic ill 
health [328]. Specific indicators to monitor their progress are required. 
 
6.6.5  Predictive value over time 
As directly assessing long-term progress on ART is problematic in LMIC, it is 
imperative that routine indicators can be used to predict longer-term outcome in 
terms of survival and treatment failure.  For example, in LMIC, both the incidence of 
TB and mortality among HIV-infected patients attending ART programmes are 
higher during the first few months on ART than later months [329] [182].   An 
indicator measuring the proportion of a population with active TB, for example, 3 
months after ART initiation may closely predict the survival of the treated population 
12 months after ART initiation.  Knowledge of the value of an indicator, for example 
more than 20% of a cohort with active TB at 3 months, corresponding to the poor 
outcome of a programme, should enable managers to respond to predictors of 
failure early.  However, the ability of early indicators to predict longer-term survival 
has never been evaluated. 
 
Furthermore, in the context of life-long ART care and cohort reporting, defining 
clear endpoints on indicators will reduce the reporting burden.  For example, 
UNAIDS encourage annual reporting on survival.  However, the most appropriate 
time-points at which to collect indicators have never been evaluated.   An 
understanding of the risk of death and morbidity over time will help inform the 
decision on the optimal time-points for indicator reporting.  For example, given that 
children under 5 years of age appear to have a more rapid disease progression 
compared to young adults, more frequent monitoring, specifically shortly following 
therapy initiation, may be necessary in paediatric programmes [35].    
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6.7 Discussion  
This study compared tools prioritised by national MoH to monitor the health of the 
population in ART care, and discussed challenges with monitoring in this way.  
Understanding which indicators are commonly collected across LMIC provides 
programme funders and organisations responsible for designing ART programme 
data-capture tools with information on what data are perceived to be most relevant.  
Furthermore, understanding the gaps between what data are recommended to be 
collected by international organisations and what are requested by national systems 
highlights differences in perceived priorities. 
 
This study, however, has some limitations.  Firstly, the lack of availability of the 
WHO template cross-sectional monitoring report impeded the ability to assess the 
influence of international recommendations in all monitoring tools.  However, this 
study highlighted discordance in the data reported in cross-sectional reports across 
the four countries, suggesting that having a template tool available was useful for 
national MoH.  
 
A further limitation of this study is that I assessed only the uptake of WHO 
recommended tools and indicators.  I did not consider in detail indicators 
recommended by international agencies, such as PEPFAR and the GFATM.   These 
agencies require funder-specific monitoring reports from programmes which they 
fund to justify their expenditure.  Yet, these funder reports are additional to reports 
to national MoH, and represent the priorities of funder.  By assessing the 
implementation of the WHO recommendations it was feasible to assess national 
priorities, before considering any funder indicators that countries are compelled to 
include. 
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A further limitation of this study is that I compared the uptake of WHO 
recommended tools and indicators in four countries, each of which has its own 
distinct HIV epidemic, most notably in the Ukraine.  However, the inclusion of 
different countries allowed the comparison, against universal monitoring 
recommendations, of priorities in countries facing different challenges in responding 
to HIV.  As such, this study highlighted the influence of nationally perceived 
priorities. 
 
Despite these limitations, this study starkly highlighted, even by 2010, the lack of 
common use of recommended data in national tools used to monitor the clinical 
progress of the treated population.  Additionally, I observed the collection of items 
not recommended in the templates or used to calculate UNGASS indicators, such as 
the number in a cohort picking up drugs for 6 out of 6 months, which closely 
resembled indicators recommended by international donors such as the GFATM 
[308].   Some data items collected in 2008 were no longer collected in 2010, while 
others recommended in the templates were not taken up by any of the four 
countries.  Sometimes data were country-epidemic-specific such as on injecting 
drug use in the Ukraine.  It is thus clear that national monitoring systems are 
designed not solely based upon one set of international recommendations but also 
include indicators from other funders or organisations and are based on national 
experiences of which indicators are feasible and useful to collect.   
 
While  the  monitoring  of  HIV  programmes  can  be  used  to  identify  a  ‘good’  
programme, enabling lessons to be learnt from one programme to improve the 
performance of others, the variety of indicators and age stratifications used make 
comparisons across programmes challenging.  Moreover, this lack of consensus in 
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number and type of priority data collected and reported across the range of 
monitoring tools highlights the uncertainty regarding which data collected at the 
patient-level, and which reported indicators are, in fact, most useful to assess the 
health of the treated population.   Even recent international indicator selection 
processes for monitoring ART care have been based on assessing a variety of 
factors including technical merit and feasibility of use rather than any scientific 
evaluation of the indicators themselves [330] [296].   
 
ART programme monitoring reports aim to use indicators to assess the quality of 
health care services and measure the effectiveness of the response to HIV [298] 
[299].   To assist the interpretation of indicators, emphasis must be placed on 
explaining how numerators and denominators in reported data are derived.  
Information must be provided on whether or not transfers-in were included in the 
cohort denominator and explanations should be given of whether any tracing of 
LTFU to ascertain vital status has taken place or whether any correction factor has 
been applied to deaths and LTFU estimates.  Only by capturing accurate information 
on deaths and transfers, can a true picture of country-wide retention in ART 
programmes and survival on ART in LMIC be drawn.  New monitoring systems have 
been proposed for LMIC to increase reporting accuracy, including the use of web-
based technologies [331].  However, given the lack of infrastructure, the wide-
spread implementation of such systems seems unlikely in the short-term and the 
current system seems likely to remain in place.  
 
It is vital therefore to understand which data currently reported by sites, are 
actually useful in assessing the performance of a treatment programme.  It would 
be of value to know for example, if the data on the number on ART at end of a 
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reporting period shown in Table 6.5, common to all four countries, are enough to 
monitor the progress of the treated population within ART programmes.  However, 
as the internal, external, construct validity and predictive value of current indicators 
have never been evaluated, it is not known whether fundamental indicators, 
including survival, capture the construct they intend to measure or accurately reflect 
the health of the treated population [244].  This compromises the ability of 
programme managers to monitor their population in care.  Furthermore, as it is not 
known which indicators can predict the longer-term outcome of the patient 
population, it is not known which key indicator(s) can enable managers to respond 
to potential predictors of failure early.  It is not known, moreover, how accurately 
currently-used monitoring indicators reflect the welfare of those in care [20] [68] 
[56].   Therefore, until there is a better evidence for these monitoring indicators, 
conclusions drawn about the overall quality of performance of a programme based 
on one set of indicators are susceptible to misinterpretation.  
 
Valid indicator estimates are essential to furnish programme managers with the 
information necessary to provide the best treatment to the patients entrusted in 
their care.  Resources within health facilities are being stretched in order to provide 
the data for monitoring indicators.  There is, therefore, an obligation to ensure that 
the effort is worthwhile, and the reported data adequately reflect the welfare of the 
treated population.  There must be a balance between indicators that are useful to 
compute, and the feasibility of data collection by clinic staff.  For example, in 
practice, paper-based  ‘survival’  is likely to remain the mainstay for ART programme 
reporting for years to come.   
 
I recommend, therefore, as priority, a scientific study to evaluate the validity and  
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predictive value of indicators currently collected at the programme level, against the 
survival and retention of patients within the treated population.  I present the 
design of such a study in the next chapter.  This will provide the evidence base 
through which indicators can be refined and will guide decisions on which constructs 
and indicators should be selected to monitor ART programmes.
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 Validating programmatic indicators Chapter 7
 
 
This chapter represents the main recommendation of my thesis regarding research 
needed to establish how best to monitor the health of patient populations treated 
within ART programmes.  Only by having a more accurate understanding of the 
health of patients in care can improvements in services be provided and, ultimately, 
longer survival with HIV achieved.  This chapter describes a study I designed to 
examine the ability of reported programmatic indicators to represent the health 
status and predict the longer-term outcome of the population treated within ART 
programmes in LMIC.   The study includes a retrospective and a prospective 
component within ART programmes in LMIC.    
7.1 Background 
Between 2004 - 2005, with the support of international donors, the wide-scale roll-
out of free ART commenced in many LMIC.  Most ART care in LMIC is delivered 
through a combination of NGOs and public sector services, many partly funded by 
the national MoH in combination with international organisations such as PEPFAR or 
the GFATM.  Currently, our understanding of the success of ART programmes in 
LMIC is based on indicators from routine monitoring reports compiled for 
programme funders, national MoH, international agencies or scientific journals.  ART 
programme indicators are used to monitor performance, measure achievements and 
determine accountability [332].  The WHO Early Warning Indicators (WHO EWI) of 
HIV Drug resistance are used to assess how optimally clinics are performing to 
minimise the development of HIV drug resistance (HIVDR) [300].   ART 
programmes which have been delivering ART for a minimum of 12 months are 
requested to compile the WHO EWI.  All ART programmes, whether with high, 
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medium or low patient number burden, in rural or urban settings, resourced with 
specific data-collection staff or simply nurses, using electronic data-capture systems 
or paper-based systems requiring manual manipulation, are required to compile the 
same indicators for monitoring reports for the MoH.   
 
The number of patients seen, however, in health centres varies considerably.   By 
2012 in Malawi, for example, 651 static health centres were providing ART to 
404,905 patients [333].  Of the Malawi health centres, 28 (4%), 55 (8%) and 568 
(87%) were considered to be high, medium and low patient burden centres with the 
number of patients varying accordingly.  Since free ART began in Malawi, high, 
medium and low burden health centres have initiated cumulatively > 5000 patients 
(average >625 per year), 2000-5000 patients (average 250 - 625 per year), and 
<2000 patients (average <250 per year) on ART, respectively [333].  As health 
centres have become more familiar with ART distribution, the number of patients 
seen annually has increased.  However, as the demands of health centres of 
different sizes differ, monitoring indicators may be calculated differently according 
to the size of the health clinic and the resources available for report compiling.   
 
Moreover, while a plethora of indicators have been recommended by funders, 
international organisations and researchers, ART programme monitoring indicators 
have never been evaluated programmatically.  It is, therefore, not known which, if 
any, most accurately reflect the health of the treated population, or whether their 
ability to reflect this is equal in different types of health centres with differing 
amounts of resources [244].  Even recent indicator selection processes by UNAIDS 
for monitoring ART care have been based on assessing a variety of factors including 
technical merit and feasibility of use rather than any scientific evaluation of the 
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indicators themselves [330] [296].  Until there is better evidence for these 
monitoring indicators, conclusions drawn about the overall performance of a 
programme based on one set of indicators are susceptible to misinterpretation.  As 
guidelines change to recommend ART initiation earlier in the course of HIV infection 
and more individuals become eligible for therapy, accurately monitoring the 
longitudinal health of patients in ART programmes becomes ever more crucial to 
inform best practice of treatment roll-out.  It is vital, therefore, to evaluate the 
ability of commonly-used indicators to assess the health of the population in care.   
 
I, therefore, designed the study described in this chapter.  I received scientific and 
logistical advice from colleagues at the MRC CTU (Abdel Babiker), University College 
London (Deenan Pillay) and MRC UVRI (Pontiano Kaleebu) and in particular, from 
the MoH in Malawi (Andreas Jahn) and Uganda (Wilford Kirungi).  
7.1.1 Preparation 
To raise awareness of this study and to invite collaboration with key stakeholders 
involved in designing ART monitoring tools, I have sought to inform from an early 
stage the WHO, UNAIDS, UNICEF, UK DfID, the International Union Against 
Tuberculosis and Lung Disease (the Union), the GFATM and PEPFAR.  I did this 
through a series of face-to-face meetings with the following representatives from 
each organisation: the WHO (Yves Souteyrand, Chika Hayashi), UNAIDS (Mathew 
Warner Smith), UNICEF (Nina Ferick, Ruslan Malyuta), UK DfID (Malcolm McNeil, 
Sue Kinn), the Union (Anthony Harries) and the GFATM (Rifat Atun).   I was unable 
to meet in person a representative from PEPFAR but liaised electronically Gillie 
Arthur and Stefan Wiktor. Additionally, I held telephone discussions with 
representatives from the UNAIDS Monitoring and Evaluation Reference Group 
(MERG) (Liza Tong at the HIV/AIDS alliance, UK and Roger Drew, the DfID 
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representative on the MERG).   In addition to international organisatons, I had the 
opportunity to have meetings with a representative from the national Ministry of 
Health Uganda (Wilford Kirungi) and Malawi (Erik Shoulten), to discuss the 
objectives of this study and to ensure this study would be relevant in LMICs.   
 
During these meetings and telephone conversations, I presented the issues that I 
had identified when comparing the monitoring indicators used by national MoH in 
Malawi, Tanzania, Uganda, and the Ukraine (Chapter 6) and I highlighted the need 
for a stronger evidence-base behind monitoring indicators.  The importance of the 
issues was confirmed by all individuals during this consultation process.  
7.2 Aim, objectives and outline 
The study aims to evaluate the ability of monitoring indicators collated through ART 
treatment programmes to capture the construct they intend to measure and their 
ability to predict the longer-term outcome of the treated population.  The study also 
aims to identify appropriate easy-to-generate indicators to monitor the health of 
ART-treated populations in LMIC.   
 
The objectives are to: 
x estimate the long-term clinical response to ART and risk of death over time 
following therapy initiation to guide optimal time points at which indicators 
should be compiled, 
x estimate the immunological and virological response to ART (including 
development of drug resistance at 12 and 24 months), 
x evaluate the ability of current survival and resistance indicators to reflect 
individual level data accurately,  
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x evaluate the ability of current indicators to predict the longer-term survival 
of the treated population, 
x evaluate the ability of the WHO EWI of HIVDR to predict the development 
of HIV drug resistance, and 
x identify appropriate easy-to-generate indicators to monitor the health of 
individuals treated within HIV programmes  
 
In this study I will gather data collected routinely in a variety of ART treatment 
programmes across multiple countries to enable the examination of the 
performance of monitoring indicators in a variety of settings.  The study will involve 
a retrospective component and as well as a prospective component.  Retrospective 
data will allow me to estimate long-term survival and to evaluate indicators used to 
measure the clinical progress of patients in care over the three year period prior to 
the commencement of the study.  Prospective data will allow me to gather 
additional data, specifically from blood samples to estimate the rate of HIVDR 12 
and 24 months after ART initiation, and to evaluate the WHO EWI HIVDR.   
 
This work is intended to provide an evidence-base to identify which indicator(s), 
collected at which time-points, best reflect the welfare of the treated population and 
thus should be used to assess health within HIV treatment programmes.   
7.3 Methods 
7.3.1 Survival and resistance indicator components: study countries 
In order to assess how well the indicators perform across LMIC geographical  
regions, the retrospective and prospective components of this study will each take 
place in multiple countries.  The study countries included will reflect the estimated 
number of people living with HIV across the following geographical regions: sub-
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Saharan Africa (25,000,000), South and South East Asia (3,900,000), Latin America 
(1,500,000), Eastern Europe and Central Asia (1,300,000), East Asia (880,000) and 
the Caribbean (250,000) [95].  For example, as sub-Saharan Africa has the greatest 
number of people living with HIV, it will contribute the greatest number of countries 
to the study, and the Caribbean will contribute the least.   
 
As a minimum, ART clinics in Malawi and Uganda will be included, based on 
previous discussions with the MoH and areas of expertise of the EfA partner 
organisations and the MoH identified during the study described in Chapter 6.  
Malawi was selected for the interest and experiences of the Lighthouse Trust and 
the MoH in attempting to verify the accuracy of data used to monitor clinical 
outcomes of patients in care.  Malawi’s  MoH  routinely  send  small  teams  to  all  ART  
sites in the 5 main zones of the country to supervise quarterly indicator reporting 
[334].  Uganda was selected due the role of the MRC UVRI in working with the MoH 
HIVDR Working Group.   
 
The remaining countries will reflect countries with the highest prevalence of HIV 
within each region, therefore: sub-Saharan Africa (Lesotho 23%, Botswana 23%, 
Swaziland 27%), South and South East Asia (Thailand 1.1%, Cambodia 0.8%), Latin 
America (Guyana 1.3%), Eastern Europe and Central Asia (the Ukraine 0.9%), East 
Asia (China <0.1%) and the Caribbean (Bahamas 3.3%) [95].  Inclusion will depend 
on likely interest and engagement in the study of the national MoH.  
 
Having data from a variety of countries will enable an assessment of the 
performance of monitoring indicators in countries with different rates of HIV 
prevalence, different programmatic funders, and differing levels of MoH involvement  
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in data generation.   
 
The methods for the survival indicators and HIV drug resistance indicators 
components are described separately below. 
7.3.2 Survival indicators: study population 
In the retrospective component of the study I will collect data from ART treatment 
programmes on patients who initiated ART as early as 2004, when free ART became 
widely available in LMIC.  All adult, adolescent and child patients who enrolled in 
clinic ART registers and newly initiated ART since 2004 will be eligible for inclusion.  
Patients who transfer-in for care and are registered in the ART register as new 
initiators in the clinic will be enrolled into the study.  Where clinic ART registers are 
not available from 2004, the earliest copy of the ART register will be used and 
patients will be enrolled into the study from the earliest available date of ART 
initiation in that clinic.   For all patients enrolled in the clinic ART register, 
longitudinal data of their time in care will be gathered.  In order to minimise the 
effect of survivorship bias on estimates of outcome (i.e. from the inclusion only of 
patients currently in treatment), I will attempt to include the records of all patients 
who ever initiated ART, including records for deceased or patients no longer 
attending ART care who have become lost to follow-up (LTFU).   
 
Clinics will be selected in collaboration with national MoHs.  Each health clinic will 
need to meet the following criteria:  
x provides ART within the health centre (patients do not have to transfer 
elsewhere for ART care),  
x has been providing ART for a minimum of 3 years,  
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x has copies of ART registers, patient files and previously submitted 
monitoring reports for a minimum of 3 years, and,  
x to the best of ability, is a non-research clinic (so that patient outcomes are 
not influenced by additional resources from research studies).    
 
Health centres will be selected to reflect the distribution of high, medium and low 
patient-volume burden sites in each country, to account for potential differences in 
compiling indicators between small and large clinics.  For example, based on the 
proportion of high, medium and low patient-volume burden health centres providing 
ART in Malawi, 4%, 8% and 87% of study health centres will be selected from high, 
medium and low burden health centres in Malawi, respectively [333].  The health 
centres will provide a mix of health centres in urban, peri-urban and rural areas, 
being funded through the MoH or the MoH in collaboration with external funders, 
and capturing patient data through paper-based and electronic systems.   
 
Across the countries selected for the study, the number of clinics which will be 
included will provide a balance between having a high number across which the 
predictive performance of programmatic monitoring indicators can be assessed and 
a realistic number from which data from patient files can be gathered.  It is 
recognised that large numbers of patient files will add to data-collection burden and 
may potentially impact data-cleaning accuracy.  Table 7.1 provides scenarios for 
different number of sites selected per country and the resulting different number of 
patient files.  These scenarios are based on data from Malawi in 2012 [333].  For 
example, in the  scenario  where  100  sites  are  selected  in  Malawi  (15%  of  Malawi’s 
661 sites), this will mean indicator performance can be assessed in 100 health 
centres, and I will be able to conduct survival analyses on data from around   
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Table 7.1 Scenarios for the number of patient files available for data-collection, 
by different numbers of health centres, based on Malawi 2012 
Health centres by size Number of health centres (country total=661 
sites) 
 25 (4% of 
total sites) 
50 (8% of 
total sites) 
100 (15% of 
total sites) 
200 (30% of 
total sites) 
High burden     
 Number of sites (4%) 1 2 4 8 
 Number of patient files 
(based on >5,000 
cumulative/site) 
>5,000 >10,000 >20,000 >40,000 
Medium burden     
  Number of sites (8%) 2 4 8 16 
  Number of patient files 
(based on 2 -5,000 
cumulative/site) 
4,000 – 
10,000 
8,000 – 
20,000 
16,000 – 
40,000 
32,000 – 
80,000 
Low burden     
 Number of sites (87%) 22 44 87 174 
 Number of patient files 
(based on <2,000 
cumulative/site) 
<44,000 <88,000 <174,000 <348,000 
Total patient files 53,000 – 
59,000 
106,000 -
118,000 
210,000-
234,000 
420,000 -
468,000 
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210,000 – 234,000 patient files in Malawi.  The number of clinics in the remaining 
countries will be determined once the total number of ART providing clinics, their 
break down by high, medium or low patient-volume burden, and the cumulative 
number of patients ever initiated has been established, and consent from the 
individual national MoH has been obtained.   
 
7.3.3 Survival indicators: data collection 
For included patients, all previously-recorded patient-level clinical data will be 
gathered.  These data are currently recorded in ART registers and individual patient 
longitudinal treatment cards.  As a minimum, the following data will be gathered 
from ART registers: 
 
Demographics unique identification number, sex, date of birth, age at 
initiation of ART 
Clinical    date of ART initiation, CD4 percentage/CD4 count or  
 WHO stage at initiation of ART, date last seen in ART 
clinic, and, if available, reason for dropping out of care 
(e.g. death, transferring-out, becoming lost to follow-
up) 
 
Additional information (as collected in current MoH patient treatment cards) will be 
gathered from patients who remain in care for at least one follow-up appointment.  
As I demonstrated in Chapter 6, the data collected in patient treatment cards are 
different in each country.  I will gather the following data, which were commonly 
collected in the four countries examined in Chapter 6:  
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dates seen in clinic, WHO stage at appointment or CD4 count if available, 
ART regimen, regimen switch or substitution, ART interruption, ART 
adherence, diagnosis of opportunistic infections at appointment, 
hospitalisations, and important clinical events (e.g. new WHO stage IV 
events including TB, Kaposi Sarcoma).   
 
Only data that are currently recorded in ART registers or patient treatment cards 
will be collected. No new data items will be sought from individual patient 
notebooks.  However, because LTFU rates are likely to be high in some sites, field 
staff will be recruited to ascertain the vital status of patients LTFU.   
 
In addition to patient-level data, for each clinic, I will gather ART-programme 
monitoring data previously reported to the MoH in the cross-sectional and quarterly 
reports.  I will collect the indicator data that were routinely compiled in the reports 
for the 3-year period prior to the beginning of the study.  As a minimum, this will 
include the indicators which are recommended by the MoH, WHO, 
UNAIDS/UNGASS, PEPFAR or the GFATM and which are used in Malawi (Table 7.2) 
[301, 305, 308, 316, 335].   Additional indicator data reported to national MoH will 
be gathered respectively for each included country.  
 
7.3.4 HIV drug resistance indicators: study population 
In the prospective component of this study examining the WHO EWI of HIVDR, all 
adult and adolescent patients newly initiating ART in selected treatment 
programmes in LMIC will be invited to participate.  Patients transferring-in, having 
initiated ART earlier elsewhere, will not be eligible for inclusion.   
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Table 7.2 Indicators measuring the outcome of patients treated within ART 
programmes, recommended by PEPFAR, the GFATM, the WHO, UNGASS or 
national MoH and collected in Malawi 
Indicators  
x Proportion still alive and known to be on treatment 6, 12, 24 etc. months 
after initiation of ART 
x Proportion on first-line regimen after 6, 12, 24 etc. months from initiation on 
ART 
x Proportion whose plasma RNA viral load is <1000 copies/ml after 12 months 
of first-line ART 
x Median CD4 cell count and/or CD4 percentage increase, or lowering of WHO 
clinical staging, at 6, 12, 24 etc. months compared to baseline 
x Proportion with ART toxicities and proportion with ART switch due to 
toxicities or drug failure 
x Proportion with severe pain and symptoms who report their symptoms were 
controlled 
x Proportion  whose  functional  status  is  ‘working’  at  6, 12, 24 etc. months 
x Proportion with AIDS defining event(s) following treatment initiation 
x Proportion of all deaths attributable to HIV 
x Proportion with severe malnutrition receiving food supplementation 
x Proportion demonstrating >90% adherence by self-reported/pill count 
x Proportion picking up appropriate prescribed regimen and/or attending all 
clinic appointments on time 
x Proportion who received ART for entire time period (e.g. 6 out of 6 months) 
x Proportion whose regimen was stopped, modified or incompletely dispensed 
due to ART stock-outs during a time period 
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Sample size calculations were based on available literature from Senegal, Côte 
d’Ivoire  and  Uganda, and a systematic review of HIVDR in sub-Saharan Africa.  This 
literature suggests that HIV drug resistance will develop among 10 – 47% of 
patients who remain in care at 12 months, with the Lamivudine-associated M184V 
mutation the most commonly seen mutation [24, 73, 336, 337].  In this study, I 
have assumed HIVDR of around 30% (the mid-point estimate between 10 - 47%).  
Table 7.3 depicts the precision which would be given according to different sample 
size scenarios, which can be used to determine study budget.  For example, 
recruiting 1,000 patients will enable the detection of resistance at 12 months in 
30% of those who initiated ART with a 95% confidence interval between 27% and 
33%, whereas recruiting 5,000 patients will enable the detection of resistance 
among 30% of those who initiated ART with a 95% confidence interval between 
29% and 31%.   
 
The number of patients to be recruited from any country, and from any one clinic 
within that will be relative to the total number of patients initiating ART in the 
country and in individual clinics.  For example, Malawi newly initiated around 
100,000 patients onto ART in 2012 (4 x 24,168 patients initiated during 4th quarter), 
whereas the Ukraine newly initiated just under 5,000 patients during 2011 [333] 
[338].  Further, in Malawi, I calculated that an average of >625, 250 – 625, and 
<250 patients initiate ART per year in high, medium and low burden sites, 
respectively [333].  Countries with higher numbers of patients initiating ART will 
recruit respectively higher number of patients to the resistance study, while high 
patient-volume burden clinics will recruit at least three times as many patients as 
low burden clinics.  Patients will be invited to participate by consecutive sampling 
until the required sample size is reached.   
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Table 7.3 Study precision (Confidence Interval, CI) given by different sample size 
scenarios for the Resistance study, assuming 90% power and resistance at 12 
months is detected in 10%, 30% and 47% of original sample size 
Sample size 500 1000 1500 2000 3000 5000 10000 
10%  
    Lower CI  
 
7.9% 
 
8.5% 
 
8.8% 
 
8.9% 
 
9.1% 
 
9.3% 
 
9.5% 
    Upper CI 12.5% 11.7% 11.4% 11.1% 10.9% 10.7% 10.5% 
30%  
    Lower CI  
 
26.6% 
 
27.6%  
 
28.1% 
 
28.3% 
 
28.6% 
 
28.9% 
 
29.2%  
    Upper CI 33.6% 32.5% 32.0% 31.7% 31.4% 31.1% 30.8% 
47%  
    Lower CI  
 
43.2% 
 
44.4% 
 
44.9% 
 
45.1% 
 
45.5% 
 
45.8% 
 
46.2% 
    Upper CI 50.8% 50.0% 49.2% 48.9% 48.5% 48.2% 47.8% 
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As the size of clinics and workload burden on staff may influence how the HIVDR 
EWI are computed, the study will recruit patients initiating ART from a variety of 
health clinics using the same methods for site selection as described in the survival 
indicators component.  This will enable an assessment of the performance of the 
drug resistance indicators in various settings.  The overall number of included clinics 
will provide a mix of high, medium and low patient-volume burden clinics, from 
rural, peri-urban and urban settings.  The specific clinics will be selected in 
collaboration with the MoH and each clinic will meet the following criteria:  
x has provided ART for a minimum of 12 months (WHO criteria for use of 
HIVDR EWI),  
x is able to recruit the required sample size, and  
x is geographically close to the location of where virology tests will take place 
for ease of transport logistics for stored blood samples.  
 
7.3.5 Resistance indicators: data collection 
For all study participants, at ART initiation, a spot of blood will be taken by finger 
prick and stored as Dried Blood Spots (DBS).  For study participants who remain in 
care 12 and 24 months after ART initiation, a further DBS will be extracted.  The 
DBS samples will be used to measure the presence of transmitted drug resistance at 
baseline and acquired resistance 12 and 24 months after initiation of ART.   The 
DBS will be collected on filter papers (Guthrie cards), and provide a good alternative 
substrate for plasma for resistance testing.  This is useful as transporting and 
maintaining the temperature of plasma samples in the warm African environment 
can be challenging.  Although DBS must be stored at -20° C to prevent degradation 
of RNA, once dried they are considered non-infectious and can be transported at 
ambient temperature up to a number of days and then stored [339] [340].  The 
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technique of DBS for measuring drug resistance has been shown both in the UK and 
LMIC to be appropriate [340, 341].    
 
Viral load quantification will be done on all 12 month DBS samples and, if viral load 
exceeds 1,000 copies/ml, genotypic resistance testing will be undertaken.  If 
evidence of resistance is present at 12 months, genotypic testing will be undertaken 
on the  participant’s  stored baseline sample.  This will allow an assessment of 
whether the patient presented with resistance before treatment initiation, or 
developed resistance after ART initiation.  Viral load testing will also be done on the 
24 month DBS samples of all patients remaining in care.  If viral load exceeds 1000 
copies/ml, resistance testing will be undertaken on the 24 month sample.    
 
In addition, a sub-sample of all the DBS samples taken at ART initiation will be 
tested for resistance.  This is because participants who initiate ART with TDR may 
be less responsive to treatment, either dying or dropping out of care before 12 
months, which would lead to a bias in available samples for testing at 12 and 24 
months and could result in an underestimate of TDR at ART initiation.  The samples 
for TDR testing will be sequentially selected, based on the size of the sub-sample.  
Sample size scenarios are presented in Table 7.4.  These scenarios are based on 
evidence from the DART trial, which was conducted in routine ART clinics in Uganda 
and Zimbabwe, and which estimated the presence of TDR in around 10% of those 
initiating ART [342].  For example, a sub-sample of 1,000 DBS (20% of a 
hypothetical 5,000 patients in the resistance study) would enable the detection of 
TDR among 10% of patients at ART initiation with 90% power, with a 95% 
confidence interval between 8.5% - 11.7%, whereas a sub-sample of 2,500 DBS 
(50% of a hypothetical 5,000 patients at ART initiation) would enable the detection  
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Table 7.4 Precision (Confidence Interval, CI) given by different sample size 
scenarios for the Transmitted Drug Resistance sub-sample, assuming 90% power 
and TDR is detected in 10% of ART initiators, based on a hypothetical 5,000 
patients in the resistance study 
Percent of samples 
at ART initiation 
10%  20% 30% 50% 
Sub-sample size 500 1000 1500 2,500 
Lower CI  7.9% 8.5%  8.8% 9.0% 
Upper CI 12.5% 11.7% 11.4% 11.0% 
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of TDR among 10% of patients at ART initiation with 90% power, with a confidence 
interval between 9.0% - 11.0%.    
 
The number of viral load and resistance tests to be carried out will be based on the 
number of study participants, an estimate of attrition and the number of 
participants expected to remain in care at 12 and 24 months, and an estimate of the 
proportion with detectable viral load and the proportion with resistance at each 
time-point.  Twelve months after the initiation of ART, attrition is assumed to be 
20% and 23% by 24 months, based on the findings from my literature review, 
presented in Chapter 2.  The proportion with detectable viral load at 12 and 24 
months is expected to be 33% and 35% respectively, of those remaining in care, 
based on the systematic review of African studies [74].   Resistance is estimated to 
be 30% at 12 months.  
 
Figure 7.1 provides the example scenario if 5,000 patients are recruited to the 
study.  For example, 1,000 DBS samples will be tested for TDR (20% of all ART 
initiators).  No further testing will be conducted on samples found to harbour TDR.  
After allowing for attrition, it is anticipated that 4000 patients will remain in care at 
12 months.  Viral load testing will be conducted on the 12 month DBS sample of 
these 4000 patients.  Of these, it is anticipated that 1320 will have detectable viral 
load.  Resistance tests will be conducted on these samples.  It is estimated that 
1200 participants will have resistance at 12 months.  For these participants, 
resistance tests will be conducted on their baseline DBS samples.   At 24 months, it 
is anticipated that 3850 participants will remain in care.  Viral load tests will be 
conducted on the DBS samples from all 3850 participants at 24 months.  Of these, 
1348 are expected to have detectable viral load, on whom resistance tests will be  
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Figure 7.1 Flowchart depicting number of viral load and resistance tests to be 
conducted for a given sample size of 5000 patients 
 ART initiation 
Patients to be recruited n=5000 
 
ART initiation 
Sample (assuming 20% of those 
initiating ART) for transmitted 
drug resistance n=1000 
 
12 months after initiation 
Expected number still in care (attrition 
estimated at 20% from initiation) & 
number of viral load tests  
n=4000 
 
24 months after initiation 
Expected number still in care 
(attrition estimated at 23% 
since initiation) & number of 
viral load tests  
n=3850 
 
12 months after initiation 
Expected number with detectable viral 
load (estimated at 33% of those in 
care) & number of resistance tests 
n=1320 
 
12 months after initiation 
Expected number with resistance 
(estimated at 30% of those in care) & 
number of ART initiation samples for 
resistance testing 
n=1200 
 
24 months after initiation 
Expected number with 
detectable viral load (estimated 
at 35% of those in care) & 
number of resistance tests 
n=1348 
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conducted. 
 
Clinic-level data on all resistance study participants in Uganda will be gathered from 
patient treatment cards.   The resistance component of the study will evaluate the 
WHO EWI HIVDR, as shown in Table 7.5.  Therefore, data from monthly and 
quarterly indicator reports that are routinely compiled throughout the 24 month 
study period will also be collated.   
 
7.4 Analysis plan: survival and resistance components 
I will estimate long-term survival and the probability of developing HIVDR.  I will 
compare the derived survival and resistance estimates with reported information on 
survival and resistance indicators.  The survival and resistance components are 
described separately.  
 
7.4.1 Estimating long-term survival 
I will use Kaplan-Meier and Cox proportional hazards models to estimate long-term 
survival of the treated population, accounting for factors at baseline known to 
influence survival (e.g. immune status and age).  I will include all retrospective 
data, regardless of subsequent outcome (e.g. whether a patient has died, become 
lost to follow-up or is still attending the clinic), in order to minimise the risk of 
survivorship bias in estimating survival (i.e. including only those who lived long 
enough to reach a certain time period).  I will assess the available data for 
completeness by comparing the data on those who register to initiate ART with the 
data available from the full patient files.  If this highlights the preferential inclusion 
of currently alive patients (e.g. if a site has records only for those currently under  
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Table 7.5 WHO Early Warning Indicators of HIV drug resistance 
WHO Early Warning Indicator of HIV drug resistance 
x Proportion still alive and known to be on treatment 6, 12, 24 etc. months 
after initiation of antiretroviral therapy 
x Proportion on first-line regimen after 6, 12, 24 etc. months from initiation on 
ART 
x Proportion whose plasma RNA viral load is <1000 copies/ml after 12 months 
of first-line ART 
x Proportion demonstrating >90% adherence by self-reported/pill count  
x Proportion picking up appropriate prescribed regimen and/or attending all 
clinic appointments on time  
x Proportion whose regimen was stopped, modified or incompletely dispensed 
due to ARV stock-outs during a time period  
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follow-up), I will use appropriate statistical methods in the analyses, which allow for 
left-truncation  of  data  by  “late  entry”  into  the  risk  set  [343, 344]. 
 
For sensitivity analyses, I will collect information on how complete the active 
ascertainment of vital status was by the study staff,  so  that  the  appropriate  “right-
censoring”  strategies  can  be  used  in  analyses [344].  Where field workers have not 
been able to trace patients LTFU and information on patients vital status remains 
unknown, I will impute estimates of mortality among patients LTFU, based on 
strategies published in literature to deal with informative censoring [319].  This will 
be done in two ways.  Firstly, I will assume mortality among patients LTFU is 40%, 
based on the combined estimate from a published literature review (scenario A); 
secondly, I will assume there is an inverse relationship between the rate of LTFU 
and mortality among those LTFU, as observed in the literature review (scenario B).  
In scenario B, I will use, for example, the following associations, as observed in the 
review: if LTFU is 5%, I will use an estimate of mortality among LTFU of 60% and if 
LTFU is 45% I will use an estimate of mortality among LTFU of 20%.   
 
Data from patients who transferred-in having initiated ART elsewhere will not be 
used in the overall survival estimates as their date of ART initiation may be 
uncertain.   
 
7.4.2 Estimating HIV drug resistance 
All nucleotide sequences, generated electronically, will be interpreted using the 
Stanford programmes HIVdb (for treated patients) and Calibrated Population 
Resistance programme (for the baseline samples of untreated patients, primary 
drug resistance) [345].  The study will use a new algorithm for surveillance of 
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transmitted HIV drug resistance, in conjunction with the WHO HIV Drug Resistance 
Surveillance Network distinguishing between mutations emerging on therapy, such 
as those identified in the widely used IAS-USA algorithms, with those associated 
with transmission [345].  This will enable the study to avoid mis-allocating 
“baseline”  resistance, which developed before entering ART treatment programmes 
due to prior antiretroviral experience, from transmitted resistance.  It appears that 
resistance due to either transmission or prior therapy can be distinguished by the 
nature, and number of mutations (unpublished data from the DART trial). The DART 
trial identified 10% baseline resistance, comprising a range of mutations inferring 
prior exposure to therapy [342].  
 
7.4.3 Comparing derived versus reported information: survival and 
resistance components 
I will compare derived versus reported information on all indicators by using the 
patient-level data to compute currently collected indicators.  These derived data will 
be compared with the data recorded in quarterly indicator reports submitted over 
the three years prior to the commencement of the study.  This will enable an 
assessment of how accurately the reported data reflect actual patient data.  
Furthermore, this comparison will help highlight whether feasible, simpler, non-
computational methods of reporting indicators are adequate in the absence of 
computerised technology.  
 
7.4.4 Assessing correlation between indicators and outcome 
I will assess the ability of the indicators to predict longer-term outcome, in terms of 
survival and HIVDR.   
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i) Assessing Correlation: for each indicator, the Pearson correlation 
coefficient will be estimated, assessing the linear dependence of each 
indicator against survival. For example, for  the  indicator  ‘proportion  
of the population with > 90% adherence’,  a clinic may report that 
80% of the population have > 90% adherence.  The survival 
analyses may, however, estimate that 70% of the population 
survives to 24 months.  The Pearson correlation coefficient will be 
used to describe how positively or negatively correlated the indicator 
‘proportion with > 90%  adherence’  is  with  the  gold-standard of long-
term survival.  Similarly, the linear dependence of the WHO HIVDR 
EWI will be assessed against the gold-standard of presence of drug 
resistance at 12 months.  
ii) Estimating sensitivity and specificity of indicators:  sensitivity and 
specificity tables will be constructed for each indicator with type I 
and II errors for each.  For example, for the indicator ‘proportion 
with  >  90%  adherence  to  ART’, each individual will be classified as a 
success (if they are > 90% adherent) or failure (if they are ≤90% 
adherent) and compared to the gold standard of being alive at 24 
months.  The sensitivity and specificity analyses will allow the 
calculation and assessment of each  indicator’s  positive  predictive  
value, e.g. the proportion that the indicator correctly deems to be 
alive at 24 months post ART initiation.  Receiver Operating 
Characteristic (ROC) curves will be used to guide overall indicator 
performance by assessing  the  most  suitable  “cut-off”  points  for  an  
indicator. For example, ROC curves will be used to estimate what 
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proportion of patients with > 90% adherence, and at which time 
points, best correspond with 24-month survival.   
 
The analyses will use as the estimate for overall survival, that derived when using  
scenario B to estimate mortality among patients LTFU.  I will stratify the 
retrospective analyses by calendar period, as the inclusion of retrospective data is 
likely to introduce a calendar-time effect (i.e. an improvement in programme 
performance over time).   
 
Data from patients who transferred-in having initiated ART elsewhere during an 
earlier reporting quarter will be included in the comparisons of how accurately the 
compiled indicators reflect the data from ART registers.  This is because the 
denominator used for survival indicators in cohort reports is based on the number of 
patients enrolling in the ART register in a given month or quarter (e.g. January – 
March), and they do not distinguish between new initiators and patients 
transferring-in for care.  
 
If it transpires that research is being conducted in any of the included clinics, any 
data provided by the research site will be used as comparators when assessing the 
correlation between indicators and survival/resistance.  For example, I will evaluate 
if indicators in research sites are significantly better at predicting survival than 
indicators compiled in sites without additional research resources.  This will enable 
an assessment of whether the ability of the indicator to predict outcome is 
dependent on the quality of the data available to the individual compiling the 
monitoring report. 
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7.4.5 Assessing indicators in paediatric populations 
By including a large number of clinics with paediatric populations, and by extracting 
individual level data on patient age, the study will evaluate the ability of currently 
reported indicators to assess outcome in the paediatric populations.  All indicators 
will be evaluated for children who are less than 15 years old when initiating therapy.  
Additional potential indicators will be evaluated, assessed through the ROC curves, 
suitable for paediatric patients such as use of height and weight measures, if 
recorded in patient files, given  that  malnutrition  is  known  to  predict  a  child’s  
prognosis [35].  This study will also examine a potential indicator relating to the 
presence of anaemia, using data on mean haemoglobin levels (if available), as these 
data have been shown to predict survival in observational studies [339]. 
 
7.4.6 Estimating risk of mortality and morbidity over time 
From the prospective data, the study will enable an assessment of mortality risk 
over time.  Although mortality rates are expected to decrease steeply following 
therapy initiation, the subsequent rate is unlikely to be as rapid while the patient is 
maintained on first-line therapy. Currently, however, the frequency of scheduled 
clinic visits is fairly uniform, whether therapy has just been initiated (when 
appointments tend to be monthly) or the patient has been stable for 2 years or 
more (when appointments may be 2 – 3 months apart).  The risk of death and 
morbidity over time following therapy initiation will be estimated using Poisson 
regression by using number of events and corresponding person-years at risk. 
These data will be helpful in determining the optimal frequency of follow-up of 
treated individuals and can inform the decision on the optimal time points on which 
indicators should be based.  For example, if the rate of death is 3 times as high in 
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the first 12 months as the second 12 months, it would be advisable to have more 
frequent monitoring in the first 12 months. 
7.5 Logistic and budgetary considerations 
Resistance tests will be carried out locally, where WHO approved laboratories exist.  
Where local laboratory facilities are not WHO approved, the DBS samples will be 
sent to UCL, London.  Testing on these samples will be done by UCL staff, working 
in tandem with local staff, to provide capacity building.  Routinely-collected paper-
based data from ART registers, patient treatment cards and monitoring reports will 
be entered onto an electronic data-base.  Currently, data-scanning technology exists 
in Malawi to undertake scanning of data from ART programmes with paper-based 
record systems, through the NGO BAOBAB Health [346].  This study will use similar 
methods.  To do this, a member of staff will travel to clinics, scan the paper-based 
data and upload them, using the electronic ART programme data-base at the 
Lighthouse Trust, Malawi as the basis for data-collection.  Each country in the study 
will be responsible for a data-base housed in a link institution (e.g. Lighthouse Trust 
Malawi, MRC UVRI Uganda).  The data will be extracted from each country’s  
database and a dataset will be pooled centrally at the MRC CTU, cleaned, queried 
and archived in London.  The pooled dataset in London will contain no information 
that could lead to the identification of ART patients.  Ethical clearance will be sought 
for this study from the appropriate local and international science and ethics 
committees.   
 
The budget for this study will need to take into account the following: staffing costs 
in each country (nurses for blood draws, a part-time laboratory technician  to 
conduct the virology and resistance tests, a local study coordinator to scan and 
collate the patient and programme data, field-tracers to ascertain the outcomes of 
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patients who become LTFU), and an epidemiologist based in London to liaise with 
the teams responsible for the scanning equipment and electronic data-bases, for 
analyses and to oversee the study;  travel costs to ensure the electronic data-bases 
meet the study requirements and to oversee the data-collection; and funds for the 
laboratory tests.  The selected sample size for the retrospective and prospective 
components will determine the final costs. 
 
After an initial period of ethical applications, site selection, protocol writing, staff 
training and pilot visits to sites to ensure retrospective data are available, the data 
collection for the retrospective component is expected to take around 2 months per 
site, based on my experience from the CTX study, including patient tracing, with 
smaller sites requiring less time and larger sites more.  An 18-month period is 
estimated for the retrospective data-collection for the survival indicators.    
Depending on the target sample-size and number of clinics involved, recruitment to 
the HIVDR prospective study is expected to take 6 months.   The extraction of DBS 
at initiation, 12 and 24 months and the prospective data-collection is expected to 
take 30 months.  Figure 7.2 shows a Gantt chart depicting a time-line for this study.  
The study is expected to take 5 years from ethical approval applications to the 
dissemination of study findings.  
 
7.6 Discussion  
ART programme monitoring indicators and the WHO EWI HIVDR have never been 
evaluated programmatically and the importance of this work has been recognised 
by representatives from key stakeholders in ART care (WHO, UNAIDS, UNGASS, 
PEPFAR, GFATM, DfID).  Furthermore, by using retrospective data available in most 
clinics, which should include data from 2004, follow-up information will be available  
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Figure 7.2 Gantt chart depicting a 5-year time-line from ethical approval applications through to results dissemination 
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up to nearly 10 years post initiation of ART.  This will enable the estimation of up to 
10-year survival of patients on ART.  Such a long-term estimate of patients on ART 
in routine care settings in LMIC has never been reported.  However, by relying on 
routinely-collected ART programme data, this study has some limitations.   
 
Firstly, data completeness of ART registers and patient files may vary between 
health centres.  However, by using routinely-collected data, this study will show 
how well reported indicators reflect the data that are used by staff in health centres 
for patient and programme management, and how well, according to these data, 
the indicators reflect the health of patients in care.    
 
Secondly, ascertainment of vital status of the patient population will be dependent 
on the ability of each clinic to ascertain vital status for their patients who have 
become LTFU. This can lead to lower survival estimates at clinics able to ascertain 
that patients no longer seen at the clinic have, in fact, died.  LTFU status is unlikely 
to be random.  Data from Malawi recently showed that 65% of patients lost to 
follow-up had actually died or stopped ART and 90% of patients who transfer out 
have in fact, transferred in elsewhere and show good survival outcomes, and a 
recent systematic review reported deaths among patients LTFU ranging from 12 – 
87% [319, 320, 347].  The employment of patient tracers to establish the status of 
patients no longer in care will minimise the number of patients for whom this 
information is unknown.  Where this information is not retrieved by the patient 
tracers, the use of different scenarios for the vital status of patients LTFU, along 
with appropriate statistical techniques to account for right censoring will provide a 
range of estimates for unknown outcomes.  
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Thirdly, accounting for patients transferring in for care who previously initiated ART 
elsewhere but who do not inform staff is challenging.  The estimates of TDR at ART 
initiation should provide an understanding of what proportion of ART initiators have 
had prior drug exposure and have transferred-in unofficially. 
 
Finally, while all efforts will be made to include only non-research health clinics, I 
recognise that given the multiple stakeholders involved in ART delivery, many health 
centres in Africa have been involved in research.  This is particularly true for large 
health centres, making it difficult to know if differences from smaller health centres 
are due to size or engagement in research.  The inclusion of sites involved in 
research will allow me to compare the performance of clinics against optimal ones. 
 
 
This study will further our knowledge regarding which data reported by sites are 
actually useful in assessing the performance of a treatment programme.  The study 
will provide the evidence-base through which indicators can be refined, enabling 
decisions to be made on which indicators should be selected to monitor HIV 
programmes.  Refining indicators will reduce the reporting burden on clinics as 
indicators with poor performance are dropped, and, with fewer data to collect, 
should encourage better accuracy of reported indicators.  With continuous 
interactions throughout the duration of this study with the representatives from the 
WHO, UNAIDS, UNGASS, PEPFAR, the GFATM and national MoH, it is intended that 
the results will feed into national and international recommendations for indicators 
used to monitor the health of the treated population.  This work will ensure that 
indicators capture the construct they purport to measure enabling fair programme 
comparisons to be made and facilitating donor reporting standardisation.  Refined 
indicators can be used to predict longer-term outcome of the patients in care 
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enabling managers to respond to predictors of failure early.  This work is key to 
effective monitoring of programmes. 
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 Conclusion Chapter 8
 
This chapter synthesises the findings addressing the research aims of this thesis, to 
provide an improved understanding of key aspects of the treatment and health of 
patients accessing HIV-care programmes in LMIC and to evaluate the ways in which 
these aspects are measured, as follows: 
 
x one in five and nearly one in four patients are no longer in care 12 and 24 
months after ART initiation, respectively.  Retention of the treated 
population over the longer-term is even lower.  Furthermore, little published 
literature reports after 24 months making understanding longer-term 
outcomes of treated populations challenging.  Given that ART has been 
scaled-up in LMIC since 2004, there is a need for more data on longer-term 
outcomes on ART. 
x national MoHs collect data in cohort reports on the proportion of patients in 
care for longer periods than the initial 12 months, meaning data are 
available over the longer-term.  Publishing such data would inform 
stakeholders about the longer-term health of patients on ART.    
x published literature on the outcomes of treated populations are heavily 
weighted towards literature from sub-Saharan Africa and understanding the 
outcomes of treated populations in other geographical areas is challenging.  
As the number of patients accessing care programmes in LMIC geographical 
regions outside of sub-Saharan Africa continues to grow, publishing on the 
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outcomes of patients treated in these ART programmes will provide a wider 
understanding of the health of treated populations.     
x just over half (47/83) the studies in the literature review reported on 
retention in care, while only 33 reported on reasons for attrition from care, 
32 on immunological outcomes, 16 on virological outcomes and fewer still on 
other clinical outcomes (including AIDS-defining illnesses such as 
Tuberculosis, IRIS or hospitalisations), highlighting the uncertainty around 
how best to report on the health of treated populations. 
x capturing and addressing reasons for attrition from care is essential if 
improvements in retention are to be made.  The accuracy of such data when 
produced from paper-based systems must, however, be considered. 
 
x the probability of CPT initiation after HIV diagnosis was low in Uganda and 
Tanzania and the proportion of time interrupting CPT was high, 5 years after 
international recommendations for the routine use of CPT were published. 
x monitoring tools used to assess access to CPT are inadequate as reporting 
numbers diagnosed and numbers initiating CPT leads to assumptions that it 
is the same individuals starting CPT in the reporting period as were 
diagnosed.  Furthermore, there is no reporting on access to CPT while in 
care.  
x capturing data on the number of days-worth of CPT tablets prescribed for an 
appointment interval, the number of days-worth CPT is short by if it is 
prescribed with a shortfall, the number of days by which a patient attends 
an appointment late, and the number of occasions when CPT is dispensed 
from pharmacy with a shortfall will highlight the magnitude of supply-chain 
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or patient-led problems.  Revised CPT monitoring reports are needed to 
reflect these data. 
 
x 7% of patients in Uganda were diagnosed with a CMD and 11% with GPD.   
x being able to identify patients at risk of these disorders is vital, yet 
identifying risk factors from routinely-collected data is currently not possible.  
x the validity of K10 and CESD was extremely poor against M.I.N.I. diagnoses 
and these commonly-used screening tools vastly overestimate the 
prevalence of mental health disorders.  For patients in HIV care in LMIC, 
where financial and staffing resources are scarce and the scope for mental 
health interventions is limited, the use of invalid mental health assessments 
risks targeting scarce resources incorrectly.   
x new screening tools for common mental disorders that can be used in LMIC 
are needed as the use of the K-10 and CES-D in Ugandan HIV outpatient 
clinics cannot be recommended based on findings from this thesis.  More 
research is needed to identify appropriate tools which can be used within 
busy HIV care clinics in LMIC.   
 
 
x wide variations exist in the tools and indicators used by MoHs in Malawi, 
Uganda, the Ukraine and Tanzania, highlighting a lack of consensus on how 
best to monitor the health of the treated population.  Furthermore, the 
internal, external, content and construct validity of indicators is questionable 
and has never been evaluated. 
x  ART programme monitoring indicators need to be evaluated scientifically in 
order to identify how best to monitor the health of the treated population. 
 300 
 
Following on from the limitations discussed in each chapter, I would add a number 
of recommendations from the experience I derived from this work, as these may be 
of benefit to others undertaking similar work in the future. 
 
While the main literature review in chapter 2 was never intended to be a systematic 
review or meta-analysis, the inclusion of other search engines (e.g. Embase, Global 
Health) would have allowed for a wider selection of studies to be included.  
Moreover, in a similar way to the data I included from cohorts reporting to UNAIDS, 
the inclusion of data from cohorts reporting to the GFATM and PEPFAR would have 
provided additional data not subject to the potential biases of including only 
information from cohorts published in peer-reviewed journals.  Finally, an evaluation 
of the quality of studies before deciding on their inclusion would have minimised the 
influence of cohorts with a weak study design on summary estimates. 
 
The Cotrimoxazole study described in chapters 3 and 4 was challenging as it used 
retrospective data which resulted in many missing data, particularly on the date of 
CPT initiation in the pre-ART register.  There were also many missing data in patient 
files relating to the number of pills prescribed or the number of days-worth of pills 
prescribed to patients.  A prospective study may have allowed for better data 
capture on these key outcome measures.   
 
The mental health study described in chapter 5 which was undertaken in 2 clinics in 
Uganda would have benefitted from the inclusion of more clinics. The interviews 
would have benefited from being reversed (having the screening tool assessments 
before the diagnostic interview) in order to minimise any bias on the part of 
participants.  It would have been interesting to examine the results derived for the 
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AUROC against a clinically-relevant value rather than choosing values which 
maximised sensitivity and specificity.   
 
The comparison of MoH indicators described in chapter 6 could have benefited from 
being undertaken across a wider range of countries, particularly outside of sub-
Saharan Africa, for example in Asia, Latin America and more in Eastern Europe.  
This would have allowed a comparison with the priorities of the Ministry of Health in 
countries experiencing challenges associated with HIV care different to those 
experienced in sub-Saharan Africa.   
 
The study described in chapter 7 may benefit from the inclusion of a third 
component, examining indicators which predict viral suppression among patients in 
care, given the clinical importance of controlled viraemia for patients in care.   A 
further expansion to this study design would have been the inclusion of ART 
programmes in areas of civil conflict where the burden of refugees and internally 
displaced persons is vast.  This would allow the examination of which indicators are 
most appropriate to monitor the health of patients accessing ART programmes in 
areas where ensuring the regular supply of medications and retaining patients in 
care is particularly challenging [348, 349].   
 
8.1 Dissemination plans and recommendations for future research 
I plan to disseminate the results of the Cotrimoxazole and mental health studies to  
representatives from the MoH, who approved the work in their countries.   
Thereafter, I hope to publish the following manuscripts: 
x A review of the long-term health of populations treated in ART programmes 
in LMIC 
 302 
 
x Access to and ongoing use of CPT after HIV diagnosis and associated factors 
in Uganda and Tanzania 
x Validity of measurement tools used to diagnose mental disorders among 
HIV-infected patients in Uganda 
I have previously published the results of the comparison of national monitoring 
data and continue to liaise with the representatives from the MoH involved in this 
work as I attempt to secure funding for the proposed indicators validation study.    
 
This topic is multifaceted and to generate achievable policy changes there is a need 
for further assessments at the local level.  Future research in the following areas 
can facilitate the attainment of better overall care and monitoring of the health of 
patients in HIV care: 
 
1. It is important to monitor the welfare of HIV-positive individuals not yet on 
ART, particularly relating to access to and retention on CPT.  Studies are 
needed to quantify the role of CTX stock-outs and late-appointment 
attendance on poor outcome.  
2. It is important to identify the most appropriate mental health screening tools 
which can be used quickly by HIV health care workers.  A multi-country 
study is needed in which more evidence can be generated to assess whether 
any data routinely collected in HIV care can be used to identify at-risk 
patients, and in which appropriate screening tools can be identified.  
3. It is important to assess currently used monitoring indicators scientifically.  A 
study (as recommended in Chapter 7 of this thesis) is needed to evaluate 
the validity and predictive value of currently collected ART programme 
monitoring indicators. 
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8.2 Conclusion 
With international recommendations to raise CD4 thresholds to 500 cells/mm³ for 
the initiation of ART and the move towards the use of ART for the prevention of HIV 
transmission, HIV care is now entering an era of further expanded access to ART 
[350].  It is worth noting that while current evidence suggests that a combination of 
ART and CPT is better than ART alone in the prevention of mortality and morbidity 
in children, the role of CPT may become less relevant as ART is initiated earlier in 
the course of disease [240].  With the new recommendations, as the number of 
patients accessing ART will increase, so too will the challenges for clinic staff 
responsible for the health of patients in their care.  Primarily, retaining ever-
increasing numbers of patients in care with suppressed viraemia will become all the 
more important.  This is likely to be particularly challenging as patients who are less 
sick at ART initiation may be less adherent to appointments and to ART regimens, 
increasing the risk of onward viral transmission and the development of drug 
resistance.  Identifying indicators which best capture retention in care and which 
can reliably predict HIVDR, as proposed in chapter 7, will be crucial.  The provision 
of ART to larger numbers of patients will result in increased and prolonged exposure 
to ART and an associated need to monitor toxicities and transmitted and acquired 
drug resistance [350].  Additionally, the provision of ART to pregnant and 
breastfeeding mothers will increase the need to monitor pregnancy-related 
toxicities, birth defects, the growth of new-borns and possible developmental delays 
in infants exposed to ARV drugs [350].  These additional monitoring activities will 
add to the reporting burden on clinic staff and resources will need to be put in place 
to ensure that accurate data on all aspects of HIV care are captured, to address the 
validity issues identified in chapter 6.  The study proposed in chapter 7, to identify 
only the most relevant monitoring indicators, becomes all the more relevant, the 
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results of which should ensure the burden on clinic staff of reporting requirements is 
minimal.   
 
In spite of the significant achievements in scaling-up access to ART in LMIC, in 
practice, this has only offered part of a solution to the long-term management of 
patients in HIV care.  Many areas of health are not being sufficiently addressed, 
examples of which are given here: the prevention of opportunistic infections and the 
identification of common mental disorders which are known to affect adherence to 
care.  Furthermore, the benefits of initiating patients on ART may be short-lived, if 
retention in care is not ensured.  Moreover, evidence is needed for ART programme 
monitoring indicators, to assess which, if any, reflect the health of the populations 
in care.  This is important if health care staff time is to be used efficiently and 
effectively and if HIV care programmes are to be better evaluated.   
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